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Abstract	
	
Traumatic	haemorrhagic	shock	(THS)	is	the	most	frequent	cause	of	preventable	
death	after	severe	injury.	Shock	is	characterised	by	inadequate	provision	of	oxygen	and	
substrates	to	tissues	in	relation	to	their	requirements,	and	it	is	within	the	microcirculation	
that	this	process	is	regulated.	Investigation	of	the	microcirculation	is	therefore	key	to	
understanding	the	pathological	processes	following	THS.		
In	Part	I,	some	mechanisms	of	microcirculatory	dysfunction	following	trauma	are	
presented.	Endotheliopathy	of	trauma	is	associated	with	poor	microcirculatory	flow,	and	
occurs	within	minutes	of	injury.	It	is	also	associated	with	higher	levels	of	circulating	cell-free	
DNA	(cfDNA),	supporting	the	hypothesis	that	cfDNA	is	an	aetiological	factor	in	this	
pathological	response.	Both	endotheliopathy	and	elevated	cfDNA	and	are	related	to	poor	
clinical	outcomes.	
In	Part	II,	clinical	implications	of	microcirculatory	monitoring	are	discussed	for	
patients	in	the	early	phase	following	THS.	It	is	safe	and	feasible	to	monitor	the	
microcirculation	following	THS,	and	a	novel	point-of-care	grading	system	has	performed	
well,	suggesting	that	targeted	fluid	resuscitation	towards	microcirculatory	flow	after	THS	
may	be	possible.	The	optimal	fluid	strategy	in	this	context	is	unknown,	but	physical	
properties	(e.g.	oncotic	potential	and	viscosity)	as	well	as	endothelial	restorative	properties	
appear	to	be	as	important	as	oxygen-carrying	capacity.	Potential	therapeutic	interventions	
aimed	at	microcirculatory	and	endothelial	resuscitation	open	intriguing	possibilities	for	
improving	outcomes	after	THS.		
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1.1.	 Background	
	
The	microcirculation	is	a	vast	and	complex	network	of	capillaries	and	their	connecting	
arterioles	and	venules.	Although	the	heart	and	large	vessels	are	responsible	for	the	
pressurised	transport	of	blood	throughout	the	circulation,	it	is	at	this	junction	of	the	arterial	
and	venous	systems	where	the	specialised	tasks	required	for	the	diffusion	of	substances	to	
and	from	tissues	occur,	in	micro-vessels	with	an	approximate	diameter	of	5–10	μm1.	Arising	
from	the	embryonic	mesoderm,	the	microcirculation	has	been	described	as	an	‘organ’2,	with	
an	approximate	mass	of	110g	and	a	surface	area	of	350m2.	Although	only	around	5%	of	the	
circulating	volume	is	in	the	microcirculation	at	any	one	time3,	4,	it	is	an	essential	part	of	the	
circulatory	system	for	survival	of	tissues	because	it	is	where	gas,	nutrient	and	metabolic	
product	diffusion	happens.	Since	diffusion	is	the	main	means	by	which	movement	of	such	
substances	occur,	most	metabolically	active	cells	in	the	body	are	no	more	than	100	µm	
away	from	a	micro-vessel4.	The	exact	density	and	concentration	of	micro-vessels	in	a	given	
region	depends	on	the	metabolic	demands	of	the	surrounding	tissues.	
Microcirculatory	behaviour	has	received	recent	attention	due	to	its	apparent	
significance	during	the	shocked	state	in	sepsis5-7,	cardiogenic	shock8,	9,	following	major	
surgery10,	11,	and	more	recently	in	traumatic	haemorrhagic	shock12.	There	is	some	evidence	
that	microcirculatory	flow	does	not	necessarily	always	follow	macro-circulatory	
haemodynamics13,	and	attention	directed	specifically	towards	the	microcirculation	may	be	
warranted	when	treating	patients	with	shock	and	critical	illness14.	Both	flow	reduction	and	
heterogeneity	of	flow	between	regions	are	likely	to	be	of	clinical	significance	during	shock15,	
16.	Since	perfusion	in	the	microcirculation	is	a	product	of	the	characteristics	of	the	vessels	
(tone,	patency)	and	the	intraluminal	contents	(pressure	and	rheology),	It	is	likely	that	
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microcirculatory	flow	is	related	to	the	behaviour	and	state	of	the	endothelial	lining.		
Understanding	the	functional	anatomy	of	the	endothelial	layer	within	the	microcirculation	is	
necessary	for	a	fuller	understanding	of	the	mechanisms	and	behaviour	during	both	the	
healthy	and	shocked	states.	
	
1.2.	 Functional	anatomy	of	the	microcirculation		
1.2.1.	 Structure	of	the	microcirculation	
Although	arterioles	and	venules	have	the	muscle	and	connective	tissue	layers	that	
characterise	the	rest	of	the	circulation,	the	capillaries	in	between	do	not.	Instead	they	
consist	of	only	the	single	celled	inner	(tunica	intima)	layer.	Although	oxygen	exchange	can	
also	occur	across	endothelial	layers	of	the	arterioles	and	venules,	the	majority	occurs	at	
these	capillaries.	The	endothelial	layers	of	micro-vessels	are	heterogeneous	depending	on	
their	location	and	function,	and	are	divided	into	(a)	continuous;	(b)	fenestrated;	or	(c)	
discontinuous	(Figure	1.1).	
	
1.2.1.1.		Continuous	micro-vessels	(Figure	1a)		
	 These	have	a	basement	membrane	with	tight	junctions	between	endothelial	
cells	without	exposed	‘windows’	between	them.	Due	to	these	structural	constraints	
they	are	the	least	permeable	micro-vessels	and	only	allow	the	passage	of	water	and	
other	molecules	that	are	less	than	3nm	in	radius,	with	larger	molecules	only	
admitted	to	pass	through	the	endothelial	layer	by	selective	transport17.	Such	
continuous	micro-vessels	are	found	in	the	skin,	muscle,	cardiac,	respiratory,	and	
central	nervous	systems.		
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1.2.1.2.		Fenestrated	micro-vessels	(Figure	1b)		
	 These	are	characterised	by	small	full	thickness	pore-like	gaps	in	the	
endothelial	layer	(approximately	70nm	in	diameter)18,	which	allow	a	higher	
permeability	of	larger	molecules	during	filtration,	secretion	and	absorption.	These	
micro-vessels	are	mainly	found	in	the	endocrine	and	exocrine	glands,	choroid	plexus,	
renal	system	and	intestinal	mucosa1.		
	
	
	
Figure	1.1.	Illustration	of	the	different	types	of	microcirculatory	vessels.		
A:	Continuous	(e.g.	skin,	muscle,	respiratory	system)	
B:	Fenestrated	(e.g.	endocrine	and	exocrine	glands)	
C:	Discontinuous	(e.g.	liver,	spleen)			
	
	
Original	illustration	by	Andrew	Dakin,	Medical	Illustration	Department,	Queen	Elizabeth	Hospital	
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1.2.1.3.		Discontinuous	micro-vessels	(Figure	1c)		
	 These	have	large	fenestrations	(approximately	100	–	200	nm	in	diameter)18	
as	well	as	gaps	between	cells,	and	allow	high	permeability	for	exchange	of	particles,	
filtering,	and	haematopoiesis.	Such	vessels	are	found	in	organs	with	sinusoids	such	
as	bone	marrow,	liver	and	spleen.	
	
Although	these	three	types	of	endothelial	surfaces	are	distinct	from	each	other,	
endothelial	cells	are	heterogeneous,	dynamic,	and	can	change	in	nature	depending	on	cell	
signalling	pathways.	For	example,	vascular	endothelial	growth	factor	(VEGF)	is	able	to	
modify	micro-vessels	from	continuous	to	fenestrated19;	conversely,	lack	of	VEGF	can	cause	
reduction	in	fenestrations20.		
	
1.2.2.	 Endothelial	interface	
The	endothelial	layer	components	include	the	endothelial	cells,	their	basal	lamina	
and	the	endothelial	glycocalyx	that	lines	the	luminal	surface.	Interactions	between	the	
endothelium	and	circulating	cells	(such	as	leukocytes,	platelets	and	red	cells)	occurs	at	the	
endothelial	surface	via	specialised	trans-membrane	cell	adhesion	molecules	such	as	those	in	
the	cadherin,	immunoglobulin,	integrin	and	selectin	protein	families21.		These	molecules	
have	a	complex	role	in	the	interactions	between	the	endothelium,	inflammatory,	and	
coagulation	components22.		
	
1.2.2.1.		Endothelial	cells			
	 The	lining	of	the	all	blood	vessels	consists	of	a	single-cell	layer	of	flattened	
endothelial	cells	resting	against	the	basal	lamina,	each	approximately	3µm	thick	
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around	the	nucleus,	but	tapering	on	either	side	towards	the	periphery	of	the	cell23.	
These	endothelial	cells	arise	from	the	embryonic	mesoderm	by	differentiation	of	
haemangioblasts	and	angioblasts24.	Each	cell	is	joined	to	surrounding	cells	by	
adhesional	junctions1.	In	the	rest	of	the	circulation,	the	thickness	of	muscle	and	
connective	tissue	vary	depending	on	the	location,	function	and	size,	but	the	
endothelial	lining	is	always	present.	At	the	smallest	vessels	of	the	microcirculation	it	
is	the	only	the	layer	of	endothelial	cells	and	basal	lamina	that	remain,	as	well	as	
some	interspersed	pericyte	cells	that	wrap	themselves	around	the	micro-vessels25.		
Endothelial	cells	are	dynamic,	and	there	is	experimental	evidence	that	they	
are	aligned	in	the	direction	of	blood	flow,	and	when	the	flow	direction	changes	the	
cells	also	change	their	alignment26.	Endothelial	cells	regulate	the	growth	of	new	
micro-vessels	in	tissues	due	to	increased	demand	for	oxygen	in	relation	to	its	
provision.	When	tissues	lack	oxygen	there	is	an	increase	in	the	amount	of	active	
hypoxia-inducible	factor	1	(HIF-1)	within	the	affected	cells.	The	increased	
concentration	of	active	HIF-1	induces	gene	transcription	of	vascular	endothelial	
growth	factor	(VEGF).	The	VEGF	(and	other	more	non-specific	growth	factors)	acts	on	
endothelial	cells,	causing	them	to	migrate	through	the	basal	lamina	and	proliferate	
and	move	towards	the	HIF-1	signal—in	effect,	‘sprouting’	a	new	branch	in	the	micro-
vessel.	These	cells	form	new	micro-vessels	and	increase	the	amount	of	available	
oxygen	in	their	new	territories.	Further	proliferation	is	stopped	when	the	HIF-1	and	
VEGF	concentrations	are	restored	to	normal.	Angiopoetin-1	also	stimulates	
endothelial	remodelling	and	cell	migration	via	Tie2	receptors	on	the	endothelial	cell	
membrane27.		
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1.2.2.2.	Endothelial	glycocalyx			
	 The	endothelial	glycocalyx	is	a	dynamic	mesh	of	molecules	that	form	an	
exclusion	zone	between	circulating	cells	and	the	luminal	surface	of	the	endothelium,	
with	a	thickness	of	approximately	2-3µm	in	small	arteries28	(Figure	1.2).	The	complex	
network	of	molecules	includes	some	that	are	trans-membrane,	acting	as	anchors	for	
the	glycocalyx	to	adhere	to	the	endothelium	(including	proteoglycans	and	
glycoproteins),	as	well	as	some	soluble	molecules	that	remain	within	the	layer	
(including	soluble	glycosaminoglycans	and	proteoglycans)	(Figure	1.3).	The	anchoring	
proteoglycans	of	the	glycocalyx	consist	of	core	proteins	with	their	linked	
glycosaminoglycan	chains;	the	main	core	proteins	are	syndecan	(4	subtypes),	and	
glypican	(6	subtypes),	and	the	main	glycosaminoglycan	chains	are	heparan	sulfate,	
chondroitin	sulfate,	keratan	sulfate,	dermatan	sulfate,	and	hyaluronic	acid29.		
	
Figure	1.2.	Schematic	diagram	of	a	micro-vessel	to	illustrate	the	relationship	between	(A)	
endothelial	cells,	(B)	the	endothelial	glycocalyx	and	the	circulating	contents	(C)	
	
Original	illustration	by	Andrew	Dakin,	Medical	Illustration	Department,	Queen	Elizabeth	Hospital	
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Figure	1.3.	Schematic	diagram	of	the	endothelial	glycocalyx,	demonstrating	some	of	the	
individual	components	of	the	layer.	
Original	illustration	by	the	author.	
	
	
The	molecules	that	form	the	glycocalyx	are	derived	from	both	circulating	
plasma	components	as	well	as	the	endothelial	cells	themselves,	and	there	is	a	
dynamic	equilibrium	between	the	soluble	components	and	the	circulation.	The	
composition	and	thickness	of	the	glycocalyx	is	affected	by	enzymatic	action,	shear	
forces,	and	contents	of	the	circulation,	so	that	its	exact	geometry	and	boundaries	are	
not	static,	but	instead	represent	a	constantly	shedding	and	re-assembling	matrix	of	
diverse	components29.		
The	endothelial	glycocalyx	has	an	important	role	in	the	mediation	of	vascular	
permeability,	which	may	be	determined	by	the	structure,	size,	and	charge	of	
molecules	within	its	layer30.	Interactions	between	circulating	cells	and	the	
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endothelium,	as	well	as	modulation	of	local	rheology	of	the	circulation	are	also	
influenced	by	the	glycocalyx29.	The	delicate	equilibrium	within	the	glycocalyx	may	be	
lost	by	disruption	to	the	normal	haemostasis,	leading	to	shedding	without	associated	
re-modelling,	which	may	occur	during	critical	illness,	increasing	vascular	
permeability31.	The	endothelial	glycocalyx	is	shed	following	haemorrhagic	shock,	and	
restoration	of	this	layer	may	be	dependent	on	the	type	of	fluid	resuscitation,	which	
will	be	discussed	in	Chapter	7.	The	importance	of	the	stability	and	equilibrium	of	the	
endothelial	glycocalyx	has	received	recent	attention	in	the	study	of	both	traumatic32	
and	septic33	shock,	and	this	will	be	discussed	in	greater	detail	in	the	subsequent	
chapters	in	humans	(Chapters	2	–	4),	and	animal	models	(Chapter	7).		
	
1.2.2.3.		Pericytes		
	 Pericytes	are	a	heterogeneous	group	of	cells	that	wrap	themselves	around	
the	endothelial	layer,	embedded	within	the	basement	membrane.		Although	their	
number	and	function	varies	throughout	the	microcirculation,	their	role	is	generally	in	
the	maintenance	of	homeostasis.	They	have	an	important	role	during	angiogenesis34.	
They	have	regionally	specific	roles,	such	as	forming	part	of	the	blood-brain	barrier	in	
the	central	nervous	system,	the	blood-retinal	barrier	at	the	retina,	and	form	an	
important	part	of	the	glomerular	filtration	system35.	They	may	even	have	a	region-
dependent	immune-regulatory	role36.		
	
1.2.3.	 Innervation	and	regulation	
The	arterial	inflow	and	venular	outflow	of	the	microcirculation	are	regulated	through	
sympathetic	innervation	of	the	circular	smooth	muscle.	Arterioles	are	the	main	site	to	
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determine	vascular	resistance.	The	single	cell-lined	capillaries	do	not	have	a	muscular	layer,	
and	therefore	are	not	subject	to	neurological	innervation.	Instead	they	have	their	own	
regulatory	mechanisms	based	on	the	shear	stress	of	blood	flow	past	the	cellular	surface.	
Endothelial	cells	modify	their	thickness	and	micro-vessel	diameter	based	on	localised	
signalling	pathways	and	cell-cell	interactions	rather	than	neurological	innervation37.	
Circulating	blood	components	may	also	influence	the	behaviour	of	the	endothelial	cells.	For	
example,	red	blood	cells	release	adenosine	triphosphate	(ATP)	and	nitric	oxide	(NO)	in	the	
presence	of	hypoxia,	causing	localised	vasodilatation38,	39.		
	
1.2.4.	 Flow	dynamics	
For	a	Newtonian	fluid,	flow	through	a	passive	tubular	structure	is	ordinarily	defined	
according	to	the	Hagen–Pouiselle	equation:	𝑸 = 𝝅𝒓𝟒𝚫𝑷𝟖𝝁𝑳 	
In	this	model,	the	most	important	physical	features	are	the	pressure	gradient	(DP),	and	the	
radius	of	the	tube	(r).	Small	changes	in	radius	may	have	a	large	impact	on	flow.	However,	
the	passage	of	blood	through	the	microcirculation	is	not	quite	as	simple,	since	the	micro-
vessels	are	not	passive,	and	blood	is	a	non-Newtonian	fluid,	flowing	through	a	branching	
vascular	system40.	Endothelial	cells	may	swell,	and	the	contents	within	the	circulation	vary	
in	time	and	space.	Additional	factors	such	as	the	viscosity	and	shear	stress	(the	force	on	the	
endothelium	parallel	to	its	surface)	affect	flow	when	there	is	interaction	between	blood	and	
the	endothelial	surface.	The	magnitude	of	viscosity	depends	in	a	non-linear	fashion	on	the	
haematocrit	(volume	fraction	of	red	blood	cells),	and	is	proportional	to	the	suspending	
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phase,	plasma	viscosity41,42.	The	apparent	viscosity	of	the	blood	decreases	markedly	in	
micro-vessels	with	diameter	<100µm	due	to	the	Fahraeus	effect,	whereby	haematocrit	
decreases	from	the	systemic	values	due	to	phase	separation	and	central	flow	of	the	red	
cells;	a	minimum	viscosity	occurs	in	capillaries	with	diameter	~7µm	where	the	red	cells	are	
aligned	in	a	single	column43.	However,	plasma	viscosity	continues	to	influence	flow	
resistance	regardless	of	haematocrit,	and	within	the	microcirculation	the	plasma	viscosity	
may	be	particularly	influential	given	the	reduction	in	local	haematocrit.	In	addition,	the	
endothelial	cells	and	the	endothelial	glycocalyx	interact	with	circulating	components,	adding	
an	additional	‘active’	factor	of	influences	in	flow	resistance44.	Flow	dynamics	within	the	
microcirculation	are	therefore	not	only	determined	by	physical	factors	(pressure,	velocity,	
and	diameter),	but	also	by	the	characteristics	of	the	circulation	and	vascular	endothelium,	
and	their	influence	on	plasma	viscosity	and	shear	stress.		
	
1.2.5.	 Regional	variation	in	microcirculatory	form	and	function	
There	are	regional	variations	in	the	anatomy	of	the	microcirculation	in	order	to	
facilitate	organ-specific	functions.	The	most	significant	of	these	regional	variations	occur	
within	major	organs	such	as	the	lungs,	heart,	brain,	gut	and	liver.		
	
1.2.5.1.	Lungs		
	 Endothelial	cells	in	the	respiratory	microcirculation	are	continuous.	The	
unique	configuration	of	surrounding	microcirculatory	networks	to	pulmonary	alveoli	
facilitate	the	efficient	interface	between	respiratory	air	at	the	alveolar	epithelium	
and	the	circulation	at	the	vascular	endothelium.	At	this	site	oxygen	diffuses	into	the	
micro-vessels	and	carbon	dioxide	diffuses	out	of	the	vessels.	The	relatively	high	
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surface	area	of	respiratory	microcirculation	in	close	proximity	to	airways	allows	for	
the	additional	functions	of	humidification	and	thermoregulation.	These	endothelial	
cells	also	have	unique	secretory	functions,	including	the	production	of	angiotensin-
converting	enzyme,	ADPase	and	prostacyclins,	and	leukocyte-adhesion	molecules	in	
higher	concentrations	that	the	rest	of	the	circulation45.		
	
1.2.5.2.		Heart	
	 Since	the	heart	is	a	very	metabolically	active	organ,	its	microcirculation	is	
formed	of	a	high	concentration	of	continuous	endothelial	cells.	There	are	many	more	
endothelial	than	cardiomyocyte	cells	within	the	cardiac	tissue45,46,	and	there	is	at	
least	one	micro-vessel	adjacent	to	every	cardiomyocyte.	Their	interaction	is	essential	
for	the	control	of	rhythmicity,	contractility	and	growth.	The	release	of	vasoactive	and	
bioactive	molecules	causes	vasoconstriction	and	dilatation,	as	well	as	controlling	
coagulation,	growth	and	inflammatory	factors46.	The	relationship	between	
endothelial	cells	and	cardiomyocytes	is	also	essential	for	the	development	and	repair	
of	the	heart47.		Signalling	is	especially	efficient	due	to	small	distances	between	these	
cells	and	large	contact	surface	area.		
	
1.2.5.3.		Brain	
	 The	microcirculation	in	the	brain	is	part	of	the	blood-brain	barrier,	with	tight	
junctions	and	adherens	junctions	between	continuous	endothelial	cells,	and	
surrounding	pericytes	and	astrocytes	that	all	help	to	reduce	the	permeability	of	the	
junction	to	larger	molecules.	The	micro-vessels	surrounding	the	choroid	plexus	are	
fenestrated,	allowing	the	passage	of	larger	molecules.	Since	the	brain	is	a	highly	
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metabolically	active	organ,	the	endothelial	cells	of	its	microcirculation	have	
specialised	glucose	transporters	on	both	apical	and	basal	sides.	There	is	some	
evidence	to	suggest	that	pericytes	also	regulate	the	microcirculatory	flow48.	
	
1.2.5.4.	Alimentary	canal		
	 The	gut	has	a	rich	blood	supply	in	order	to	provide	for	its	metabolic	
requirements,	as	well	as	for	its	absorptive	function.	The	microcirculation	is	
fenestrated,	and	is	densest	at	the	site	of	the	villi	where	the	majority	of	absorption	
occurs,	at	the	base	of	which	there	is	diffuse	arterio-venous	shunting.	Micro-vessels	
at	the	villi	are	in	such	close	proximity	that	they	allow	for	exchange	of	substances	
between	themselves	and	the	villi	but	also	between	each	other.		
	
1.2.5.5.		Liver	
	 The	liver	has	microcirculatory	vessels	arising	from	both	the	hepatic	artery,	
vein,	and	portal	vein.	These	micro-vessels	intermingle	at	the	site	of	the	hepatic	
sinusoids,	which	themselves	consist	of	fenestrated	and	discontinuous	endothelium	
without	a	basement	membrane,	in	a	radiating	pattern	that	forms	individual	lobules.	
The	sinusoids	control	the	dynamic	exchange	between	the	microcirculation	and	the	
hepatocytes	by	modulating	their	size	and	shape	due	to	factors	such	as	flow	or	
pressure.	As	well	as	the	arterio-portal	anastomosis	and	the	vasa	vasorum	of	the	
portal	vein,	there	are	two	additional	microcirculatory	connections	between	the	
arterial	and	venous	supply.	These	are	the	terminal	arteriosus	twigs	(between	hepatic	
arterioles	and	sinusoids)	and	the	peribiliary	plexus	(between	hepatic	arterioles	and	
portal	venules	around	the	bile	ducts)49.		
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1.3.	 Definitions		
1.3.1.	 Trauma	
This	thesis	discusses	some	of	the	mechanisms	of	microcirculatory	dysfunction	
following	trauma	and	haemorrhagic	shock,	and	their	clinical	implications.	For	the	purposes	
of	the	rest	of	the	thesis,	“trauma”	is	defined	as	the	presence	of	an	injury	that	causes	direct	
damage	to	tissues,	either	by	penetrating	or	blunt	mechanisms.	The	trauma	patients	
included	in	Chapters	2	–	5	have	all	triggered	the	hospital’s	“trauma	alert”	according	to	the	
pre-hospital	Major	Trauma	Triage	Tool	that	takes	in	to	account	the	patients’	vital	signs	and	
anatomical	injuries.	These	patients	have	been	assessed	by	pre-hospital	personnel	as	having	
a	Glasgow	Coma	Scale	≤13,	systolic	blood	pressure	(SBP)	<90mmHg,	or	respiratory	rate	
either	<10	or	>29	breaths	per	minute	after	being	injured.	Further	anatomical	considerations	
that	may	trigger	such	a	“trauma	alert”	include	penetrating	injuries	to	the	neck,	head,	torso,	
or	proximal	extremities,	any	chest	deformities,	the	presence	of	2	or	more	fractures,	crushed	
or	deformed	extremities,	proximal	limb	amputations,	and	pelvic	or	skull	fractures.					
	
1.3.2.	 Shock	
“Shock”	is	defined	as	an	inadequate	perfusion	of	tissues	relative	to	their	
requirements.	In	a	clinical	context,	this	is	usually	judged	using	clinical	surrogate	markers,	
such	as	SBP	or	mean	arterial	pressure	(MAP),	as	well	as	arterial	blood	gas	parameters	such	
as	base	excess,	lactate,	and	pO2.	“Haemorrhagic	shock”	is	defined	as	the	inadequate	
perfusion	of	tissues	due	to	the	loss	of	blood	and	subsequent	hypovolaemic	shock.	In	
Chapters	2,	4,	and	5,	patients	are	defined	as	having	haemorrhagic	shock	if	they	require	
blood	product	transfusion	to	restore	tissue	perfusion,	have	a	plasma	lactate	>2mmol/l,	and	
require	transfer	to	the	Intensive	Care	Unit	for	organ	support.	In	Chapter	7,	haemorrhagic	
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shock	is	defined	for	a	number	of	different	preclinical	(animal)	studies,	and	is	expressed	in	
terms	of	more	precise	volumes	or	percentages	of	blood	lost,	or	according	to	measured	
pressures,	and	will	be	described	in	detail	in	that	Chapter.		
	
1.3.3.	 Microcirculatory	dysfunction		
	 The	definition	of	“microcirculatory	dysfunction”	used	in	this	thesis	is	the	abnormal	
reduction	in	density	of	microcirculatory	vessels,	reduction	in	the	flow	of	red	cells	through	
those	micro-vessels,	reduction	in	the	proportion	of	vessels	that	are	perfused,	and	an	
increase	in	heterogeneity	of	flow	between	vessels.	These	will	be	physically	quantified	using	
validated	criteria	in	Chapters	2,	5,	and	6,	by	using	hand-held	video-microscopy,	as	described	
later	in	this	chapter.	Pre-clinical	studies	using	animal	models	have	quantified	
microcirculatory	dysfunction	using	other	parameters	such	as	red	blood	cell	velocity,	vessel	
diameter,	functional	capillary	density,	and	shear	rate,	which	are	all	reduced	after	
haemorrhagic	shock	(as	will	be	discussed	in	Chapter	7).		
	
1.3.4.	 Endotheliopathy	of	trauma	
	 “Endotheliopathy	of	trauma”	will	be	defined	as	the	activation	and	injury	of	the	
endothelial	cells	and	shedding	of	the	endothelial	glycocalyx	following	trauma.	This	will	be	
described	in	Chapters	2	–	4	according	to	the	presence	of	circulating	biomarkers	of	
endothelial	injury	(thrombomodulin)	or	glycocalyx	shedding	(syndecan-1)	significantly	
higher	than	the	range	that	is	present	amongst	healthy	controls	with	the	same	demographic	
characteristics.	These	will	be	discussed	later	in	this	chapter.	In	Chapter	7,	electron	
microscopic	examination	has	been	used	for	direct	measurement	of	glycocalyx	thickness	for	
animal	models	of	haemorrhagic	shock.			
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1.4.		Measuring	microcirculatory	dysfunction		
1.4.1.	 Video-microscopy	techniques	
Intra-vital	microscopy	has	been	used	for	the	visualisation	of	the	microcirculation	in	
pre-clinical	studies	of	shock	at	various	anatomical	locations	including	the	conjunctiva50,	
pancreas51,	intestines	and	renal52,	hepatic53,	and	muscle54	tissues.	The	dorsal	skin	fold	
preparation	has	been	a	way	of	examining	the	microcirculation	in	awake	hamsters55,56.	
Electron	microscopy	has	been	performed	on	histological	samples	from	experimental	studies	
to	examine	the	microcirculation57.	Other	technologies	such	as	laser	speckle	contrast	
imaging58	and	laser	Doppler	technologies59	have	also	been	used	to	visualise	the	
microcirculation	in	pre-clinical	studies.	These	imaging	techniques	all	measure	the	physical	
parameters	relating	to	the	anatomical	flow	and	density	of	the	microcirculation	rather	than	
the	physiological	or	metabolic	parameters	such	as	pO2,	lactate	or	base	excess.				
	 In	human	studies,	techniques	to	visualise	the	microcirculation	cannot	usually	depend	
on	surgical	implantation,	but	must	instead	utilise	non-invasive	or	less-invasive	technologies.	
Sublingual	video-microscopy	has	been	used	in	large	animal	models60-62,	and	has	been	
translated	into	clinical	research	due	to	its	appealing	non-invasive	and	easily	accessible	
modality.	The	sublingual	mucosa	is	supplied	by	the	sublingual	artery,	which	arises	from	the	
lingual	artery,	a	branch	of	the	external	carotid	artery	within	the	carotid	triangle.	This	
suggests	that	the	sublingual	microcirculation	may	correspond	to	that	within	the	central	
microcirculation,	although	there	is	currently	no	clinical	evidence	to	confirm	this.	However,	
there	is	some	evidence	that	sublingual	microcirculatory	flow	reflects	the	flow	in	the	
splanchnic	circulation,	since	the	magnitude	and	time	course	of	changes	within	the	
sublingual	microcirculatory	flow	have	been	reported	to	reflect	the	same	alterations	within	
the	gut63.	These	factors	suggest	that	the	sublingual	microcirculation	has	an	appealing	
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combination	of	anatomical	suitability	and	accessibility	for	determining	overall	
microcirculatory	flow	dynamics.		
Earlier	clinical	investigations	utilised	sublingual	orthogonal	polarisation	spectral	dark-
field	technology,	and	this	was	soon	followed	by	the	side-stream	dark	field	(SDF)	and	incident	
dark	field	camera	(IDF)	technology64.	In	Chapters	2,	5,	and	6	of	this	thesis,	I	will	describe	the	
utilisation	of	an	IDF	device	in	the	visualisation	of	human	microcirculation	of	patients	
following	traumatic	haemorrhagic	shock	in	greater	detail.	In	Chapter	7,	I	will	describe	the	
wider	breadth	of	techniques	used	in	animal	experiments.		
	
1.4.2.	 Endothelial	biomarkers	
In	addition	to	the	physical	flow	in	microcirculatory	vessels,	information	about	the	
state	of	the	endothelium	may	be	derived	from	the	detection	of	circulating	biomarkers.	The	
general	concept	is	that	higher	levels	of	biomarkers	indicate	pathological	changes	such	as	
injury,	damage	or	inappropriate	activation	of	the	endothelium.	Molecules	such	as	syndecan-
1,	thrombomodulin,	sVE-cadherin,	sE-selectin,	Angiopoietin-2,	soluble	endothelial	protein	C	
receptor,	and	histone-complexed	DNA	fragments	have	all	been	proposed	as	markers	of	
endothelial	damage65-67.	In	Chapters	2	and	3	of	this	thesis	I	will	present	syndecan-1	as	a	
biomarker	of	endothelial	glycocalyx	shedding,	and	thrombomodulin	as	a	biomarker	of	
endothelial	cell	injury.	Syndecan-1	is	one	of	the	anchoring	transmembrane	proteoglycans	of	
the	glycocalyx,	and	thrombomodulin	is	a	glycoprotein	expressed	on	the	endothelial	surface.	
These	will	be	described	in	more	detail	in	the	relevant	chapters.	Although	not	currently	used	
within	clinical	practice,	these	biomarkers	have	potential	prognostic	value,	since	they	may	
predict	clinical	outcomes;	for	example,	increased	concentrations	of	these	biomarkers	within	
the	circulation	following	trauma	may	be	associated	with	coagulopathy	and	mortality65,	68-71.	
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Restoration	of	abnormal	levels	of	biomarkers	back	to	baseline	has	also	been	used	to	
indicate	a	relative	restoration	of	the	endothelium	following	a	given	therapy	in	some	
experimental	studies57,	72.		
	
1.5.	 Aims,	hypotheses,	and	research	questions	
1.5.1.	 Aims	
The	aims	of	this	thesis	are:	(a)	to	investigate	the	mechanisms	of	early	
microcirculatory	dysfunction	following	traumatic	haemorrhagic	shock;	and	(b)	to	investigate	
the	ways	in	which	this	microcirculatory	dysfunction	might	be	detected	during	the	early	
emergency	resuscitation	of	these	patients,	and	how	these	data	might	be	utilised.	In	order	to	
achieve	these	aims,	this	thesis	will	address	12	research	questions	that	are	derived	from	8	
hypotheses,	as	listed	in	Table	1.1.		
	
	
	 	
Chapter	1	 	 Introduction	to	the	microcirculation	
	 20	
Table	1.1.		 Hypotheses	and	research	questions		
	 Hypothesis	 Research	Question	 Chapter	
1	 Microcirculatory	flow	is	affected	by	the	
integrity	of	its	endothelial	lining		
Are	poorer	microcirculatory	flow	dynamics	
associated	with	elevated	biomarkers	of	
endotheliopathy?	
2	
2	 Endotheliopathy	occurs	very	soon	after	
injury,	and	is	encountered	during	the	
on-scene	or	pre-hospital	period	
How	soon	after	injury	are	biomarkers	of	
endotheliopathy	elevated?	
3	
3	 Early	endotheliopathy	and	failure	to	
restore	the	endothelium	are	both	
associated	with	subsequent	organ	
failure	
Is	early	endothelial	biomarker	elevation	
associated	with	multiple	organ	dysfunction	
syndrome?	
	
Is	the	restoration	of	endothelial	biomarker	
levels	to	“normal	range”	associated	with	
better	outcomes	than	persistently	raised	
levels?			
3	
4	 Tranexamic	acid	acts	to	restore	the	
endothelium	following	trauma	
Are	biomarkers	of	endotheliopathy	different	
for	patients	receiving	pre-hospital	tranexamic	
acid	to	those	who	did	not,	following	trauma?	
3	
5	 The	release	of	cell-free	DNA	into	the	
circulation	after	injury	may	be	
associated	with	endotheliopathy,	and	
poorer	outcomes	
Are	biomarkers	of	endotheliopathy	correlated	
with	levels	of	cell-free	DNA?	
	
Are	higher	levels	of	cell-free	DNA	associated	
with	poorer	clinical	outcomes?	
4	
6	 Microcirculatory	flow	parameters	can	
be	measured	early	following	injury,	
even	for	profoundly	unwell	trauma	
patients	
Is	sublingual	microcirculatory	video-
microscopy	both	safe	and	feasible	in	the	
Emergency	Department	for	trauma	patients?		
5	
7	 Trained	professionals	can	assess	the	
microcirculation	at	the	bedside	with	as	
much	accuracy	as	lengthy	offline	
computer	analysis		
Can	a	microcirculatory	score	be	assigned	to	
patients	based	on	a	visual	inspection	only?	
	
Can	this	novel	scoring	system	be	taught	to	
healthcare	professionals?	
	
Does	this	scoring	system	correspond	well	to	
traditional	offline	computer	analysis?	
6	
8	 Whole	blood	is	the	optimal	fluid	for	the	
restoration	of	the	microcirculation	
following	haemorrhagic	shock	
Which	type	of	fluid	is	able	to	restore	
microcirculatory	flow	with	the	greatest	
efficacy	in	pre-clinical	studies	of	haemorrhagic	
shock?	
7	
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traumatic	hemorrhagic	shock.	J	Trauma	Acute	Care	Surg.	2018;84(1):81–88	
	 	
Chapter	2	 	 Microcirculatory	flow	and	endotheliopathy	
	 29	
2.1.		 Introduction	
There	has	been	considerable	interest	in	the	endotheliopathy	of	trauma,	since	it	is	
associated	with	increased	vascular	permeability1,	is	an	independent	predictor	of	mortality2,	
and	may	be	a	key	determinant	in	the	development	of	inflammation	and	coagulopathy3.	
Endotheliopathy	of	trauma	is	distinct	from	normal	physiological	activation	of	the	
endothelium,	since	the	endothelium	is	not	only	activated,	but	also	becomes	physically	
damaged,	with	shedding	of	the	glycocalyx	and	disruption	of	tight	junctions,	with	resultant	
capillary	leakage4.	In	particular,	endothelial	glycocalyx	shedding	may	have	a	role	in	
microcirculatory	dysfunction	due	to	its	essential	role	in	the	integrity	and	function	of	the	
oxygen	exchange	surface	of	all	micro-vessels5,	6.	Endotheliopathy	of	trauma	is	associated	
with	sympathoadrenal	activation7,	8,	and	may	be	induced	by	the	action	of	damage-
associated	molecular	patterns	(DAMPs)	that	are	released	into	the	circulation	following	
tissue	injury9,	10,	as	well	as	raised	levels	of	pro-inflammatory	cytokines	responsible	for	
disruption	of	endothelial	integrity11.	Aside	from	the	inflammatory	and	coagulopathic	
consequences	of	endotheliopathy,	there	may	also	be	derangements	in	flow	dynamics	within	
the	micro-vessels	so	that	oxygen	perfusion	is	inadequate,	leading	to	hypoxia	and	acidosis.	
Prior	to	the	current	study,	the	relationship	between	endotheliopathy	and	microcirculatory	
flow	dynamics	following	traumatic	haemorrhagic	shock	(THS)	has	yet	to	be	investigated.			
Away	from	the	patient,	enzyme-linked	immunosorbent	assays	(ELISA)	can	be	
performed	for	surrogate	markers	of	endotheliopathy,	such	as	thrombomodulin	(CD141)	and	
syndecan-1	(CD138).	Thrombomodulin	is	a	transmembrane	glycoprotein	in	endothelial	cells	
that	acts	as	a	cofactor	during	activation	of	Protein	C	by	thrombin7,	12.	It	is	not	normally	
secreted	by	endothelial	cells,	but	is	present	in	the	circulation	due	to	endothelial	cell	
damage13.	This	makes	it	a	useful	biomarker	of	endothelial	injury,	and	has	been	used	in	this	
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role	for	patients	following	sepsis7,	14,	myocardial	infarction15,	cardiac	arrest16,	and	trauma2,	8,	
17.	Syndecan-1	is	a	transmembrane	heparan	sulfate	proteoglycan	whose	extracellular	
domain	forms	part	of	the	endothelial	glycocalyx.	It	has	been	used	as	a	biomarker	for	
glycocalyx	shedding	for	patients	following	trauma2,	11,	18.		
At	the	bedside,	non-invasive	video-microscopy	can	be	used	to	visualise	the	flow	of	
red	blood	cells	in	the	sublingual	microcirculation.	The	latest	Incident	Dark	Field	(IDF)	
technology	allows	for	the	acquisition	of	high	definition	views	of	the	flow	and	perfusion	of	
these	micro-vessels	whose	primary	function	is	oxygen	and	substrate	exchange.	This	
technique	has	been	used	to	examine	the	response	of	the	microcirculation	to	critical	illness,	
sepsis	and	shock19.	More	recently,	investigators	have	demonstrated	a	prognostic	value	in	
this	technology	for	haemorrhagic	trauma20,	in	particular	in	the	detection	of	loss	of	
haemodynamic	coherence21.	There	have	been	no	clinical	studies	that	have	tested	whether	
glycocalyx	shedding	and	endothelial	cell	damage	are	associated	with	poorer	flow	dynamics	
in	the	microcirculation.		
The	aim	of	the	current	study	was	to	test	whether	endotheliopathy	following	
traumatic	haemorrhagic	shock	was	associated	with	physical	changes	in	the	flow,	density	and	
perfusion	of	vessels	in	the	microcirculation,	from	initial	resuscitation	to	stabilisation	in	the	
Intensive	Care	Unit	(ICU).	It	was	hypothesised	that	there	would	be	an	association	between	
endotheliopathy	and	poor	flow	dynamics	of	the	microcirculation	(Hypothesis	1;	Table	1.1).		
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2.2.	 Methods	
2.2.1.	 Study	design	
A	prospective	longitudinal	observational	study	was	conducted	in	order	to	compare	
flow	dynamic	parameters	of	the	microcirculation	with	serum	markers	of	endothelial	damage	
and	glycocalyx	shedding.	All	data	are	from	a	single	site	in	the	MICROSHOCK	study22.		This	
study	had	been	granted	prior	ethical	approval	(Research	Ethics	Committee	reference:	
14/YH/0078;	Yorkshire	and	the	Humber	Leeds	West),	and	a	protocol	was	published	in	
advance22.		
	
2.2.2.	 Patient	selection	
Patients	who	were	potentially	eligible	for	inclusion	at	a	single	Major	Trauma	Centre	
(University	Hospitals	Birmingham,	UK)	were	identified	through	the	screening	of	trauma	
team	activations.	Trauma	patients	were	eligible	for	inclusion	if	they	required	blood	
products,	had	been	intubated,	required	admission	to	ICU,	and	had	a	point-of-care	lactate	of	
greater	than	2mmol/l.	They	were	enrolled	into	the	study	either	in	the	Emergency	
Department	(ED)	or	ICU	depending	on	suitability	for	study	observations.	Patients	were	
excluded	if	they	were	under	the	age	of	16,	prisoners,	or	had	extensive	facial	injuries	that	
would	make	access	to	the	sublingual	area	problematic.	Patients	that	were	expected	to	die	
due	to	the	extensive	nature	of	their	injuries,	and	were	being	treated	palliatively,	were	also	
excluded.	Selection	bias	was	minimised	by	ensuring	that	there	were	no	significant	
differences	between	patients	enrolled	in	the	study	and	those	that	were	eligible	but	not	
included.		
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2.2.3.	 Capacity	and	consent	
All	patients	were	expected	to	lack	capacity	to	consent	for	study	participation	at	the	
time	of	study	enrolment	due	to	the	nature	of	their	injuries,	and	a	requirement	for	
recruitment	as	soon	as	possible	after	arrival	in	the	hospital.	Study	subjects	were	therefore	
enrolled	under	the	guidance	of	the	Mental	Health	Act	2005	and	the	Declaration	of	Helsinki.	
Approval	for	subjects	to	participate	in	this	study	was	obtained	from	the	physician	in	charge	
of	the	care	of	the	patient	(designated	as	the	“Professional	Consultee”),	who	was	not	a	study	
investigator.	If	appropriate,	agreement	for	study	participation	could	also	be	requested	after	
discussion	with	a	member	of	the	patient’s	family,	or	a	close	friend	(designated	as	a	
“Personal	Consultee”).	Ultimately,	if	the	patient	regained	capacity	after	data	had	already	
been	obtained,	the	study	was	discussed	with	them	and	they	were	asked	for	consent	for	all	
data	to	be	retained.	If	they	did	not	regain	capacity,	then	the	previous	permissions	from	their	
Professional	or	Personal	Consultee	remained	extant.							
	
2.2.4.	 Data	collection	
Patient	demographics	(age,	gender),	injury	details	(including	mechanism	and	
timings),	physiological	parameters	(heart	rate	and	systolic	blood	pressure),	and	Glasgow	
Coma	Scale	(GCS)	were	recorded	prospectively,	and	then	corroborated	using	a	combination	
of	electronic	and	paper	medical	records.	The	most	recent	point-of-care	lactate	reading	to	
each	time	point	was	also	recorded,	as	well	as	the	number	and	type	of	blood	products	and	
volumes	of	crystalloids	used	during	the	study	period.	Injury	Severity	Scores	(ISS)	were	
obtained	from	the	Trauma	Audit	and	Research	Network,	a	central	validated	resource	in	the	
UK.	Outcomes	recorded	for	patients	included	ICU-free	and	hospital-free	days	(calculated	by	
recording	the	number	of	days	that	the	patient	was	present	in	ICU	and	hospital	respectively	
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during	a	period	of	30	days),	mortality	within	30	days,	and	Sequential	Organ	Failure	
Assessment	(SOFA)	scores	at	days	3,	6,	and	10.		
	
2.2.5.	 Sublingual	video-microscopy	
A	single	operator	(D.N.N.)	conducted	IDF	video-microscopy	in	order	to	acquire	non-
invasive	video	clips	of	the	sublingual	microcirculation	(Cytocam,	Braedius	Medical	B.V.,	
Huizen,	The	Netherlands).	Briefly,	the	camera	was	placed	gently	under	the	tongue	until	a	
clear	view	of	the	mucosal	microcirculation	was	acquired,	without	blood	or	saliva	artefact,	
with	minimal	pressure,	and	optimal	focus	and	illumination	according	to	consensus	quality	
requirements	for	this	technology23.	Multiple	clips	of	100	frames	each	were	recorded	and	
stored	on	a	computer	for	analysis.	At	least	5	good	quality	clips	were	recorded	at	each	time	
point	in	order	to	facilitate	optimal	analysis24.		
	
2.2.6.	 Microcirculatory	analysis	
Videos	that	had	been	acquired	by	IDF	video-microscopy	were	exported	for	analysis	
and	were	individually	graded	for	quality	according	to	the	most	commonly	reported	domains	
(illumination,	focus,	content,	duration,	pressure,	and	stability)25.	Of	the	highest	quality	clips,	
3-5	from	each	patient	time	point	were	kept	for	analysis.	These	clips	were	allocated	random	
numbers	to	ensure	that	their	analysis	was	blinded	to	patient,	time	point,	and	clinical	status.	
Semi-automated	analysis	was	undertaken	for	each	clip	using	dedicated	computer	software	
(Automated	Vascular	Analysis	V.3.2,	Microvision	Medical,	The	Netherlands).	All	videos	were	
then	un-blinded,	and	the	time	points	assigned	average	values	for	total	vessel	density	(TVD,	
mm/mm2),	perfused	vessel	density	(PVD,	mm/mm2),	proportion	of	perfused	vessels	(PPV,	
%),	microcirculatory	flow	index	(MFI),	and	microcirculatory	heterogeneity	index	(MHI)	
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according	to	consensus	guidelines	for	reporting	sublingual	microcirculation24.	In	addition,	
point-of-care	microcirculation	(POEM)	scores	(a	composite	score	for	flow	and	
heterogeneity)26	were	allocated	for	each	time	point.	The	methodology	for	the	allocation	of	
POEM	scores	will	be	described	in	greater	detail	in	Chapter	6	of	this	thesis.	In	summary,	flow	
is	defined	as	“normal”,	“impaired”,	or	“critical”	for	a	video	clip	if	<25%,	25–50%,	or	>50%	of	
the	vessels	in	the	visual	field	respectively	are	sluggish	or	stopped.	In	addition,	heterogeneity	
is	either	“present”	or	“absent”	if	>5	or	<5	vessel	segments	have	different	flow	to	the	
remainder.	This	is	repeated	4	times,	and	an	algorithm	calculates	the	overall	score	based	on	
the	majority	of	responses.	A	score	is	allocated	from	1	(worst)	to	5	(best).			
	
2.2.7.	 Serum	sampling	
At	the	same	time	point	at	which	video-microscopy	was	performed,	a	6	ml	sample	of	
peripheral	blood	was	taken	from	an	available	venous	access	point.	After	a	30-minute	
incubation	at	room	temperature,	samples	were	centrifuged	at	1,620	x	g	for	10	minutes	at	
4oC,	after	which	aliquots	of	serum	were	stored	in	cryotubes	at	-80oC.	Serum	samples	were	
collected	and	stored	in	the	same	manner	for	17	healthy	volunteers,	matched	for	age	and	sex	
to	the	patient	cohort.	
	
2.2.8.	 Enzyme-linked	immunosorbent	assays	
Commercially	available	ELISAs	were	used	according	to	their	relevant	protocols	for	
the	quantitative	measurement	of	serum	concentrations	of	syndecan-1	and	
thrombomodulin.	Syndecan-1	(CD	138;	Abcam;	product	code	ab46506,	Cambridge,	MA)	was	
used	as	a	surrogate	marker	of	glycocalyx	shedding,	because	it	is	an	anchoring	proteoglycan	
within	the	endothelial	glycocalyx,	and	its	presence	within	the	circulation	suggests	
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breakdown	of	the	normal	architecture	of	the	glycocalyx.	Thrombomodulin	(CD	141;	Abcam;	
product	code	ab46508,	Cambridge,	MA)	was	used	as	a	surrogate	marker	of	endothelial	cell	
damage,	since	it	is	soluble	and	present	within	the	circulation	following	direct	injury	to	
endothelial	cells13.	Although	glycocalyx	shedding	and	endothelial	cell	injury	are	unlikely	to	
be	mutually	exclusive,	these	biomarkers	have	been	reported	in	these	terms	in	previous	
investigations	of	endotheliopathy5-8.	For	the	thrombomodulin	assay,	the	intra-	and	inter-
assay	coefficients	of	variation	were	reported	as	3.9%	and	9.8%	by	the	manufacturer.	For	the	
syndecan-1	assay,	these	were	6.2%	and	10.2%	respectively.		
For	each	ELISA,	a	96-well	plate	was	used,	containing	wells	that	had	been	coated	with	
monoclonal	antibodies	by	the	manufacturer	for	the	biomarker	of	interest.		Standards	were	
prepared	according	to	the	manufacturer’s	protocol,	by	serial	dilution	using	the	standard	
diluent	buffer.	For	the	thrombomodulin	ELISA,	the	standard	concentrations	were	20ng/ml,	
10ng/ml,	5ng/ml,	2.5ng/ml,	1.25ng/ml,	and	0.625ng/ml.	For	the	syndecan-1	ELISA,	the	
standard	concentrations	were	256ng/ml,	128ng/ml,	64ng/ml,	32ng/ml,	16ng/ml,	and	
8ng/ml.	These	were	prepared	in	duplicate.	Blank	controls	were	used	for	all	ELISAs.	Control	
solutions	were	provided	by	the	manufacturer.		
For	the	assays,	100µl	was	added	to	wells	for	each	standard,	blank	controls,	control	
solutions,	and	patient	samples.	Then	50µl	of	1X	Biotinylated	anti-syndecan-1	or	anti-
thrombomodulin	was	added	to	all	wells	for	the	syndecan-1	and	thrombomodulin	assays	
respectively.	The	plates	were	then	covered	and	incubated	for	1	hour	at	room	temperature	
(18-25oC).	After	this	period,	the	plates	were	washed	three	times	according	to	the	
manufacturer’s	protocol,	using	300µl	of	1X	Wash	Buffer.	Then	100µl	of	Streptavidin-HRP	
solution	was	added	to	all	wells,	and	the	plates	were	incubated	again	for	30	minutes.	After	
this	period,	the	plates	were	washed	in	the	same	manner	as	previously,	and	then	100µl	of	
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Chromogen	TMB	substrate	solution	was	added	to	each	well.	After	incubation	in	the	dark	for	
15	minutes,	100µl	of	Stop	Reagent	was	added	to	each	well.	Plates	were	then	immediately	
taken	to	the	spectrophotometer,	where	readings	were	taken	at	450nm	as	the	primary	
wavelength,	and	620nm	as	a	reference.		
The	absorbance	was	calculated	for	each	well	by	subtracting	the	optical	density	of	the	
average	of	blank	controls.	The	standard	curve	was	then	calculated	using	the	mean	
absorbance	for	each	duplicate	standard	concentration,	and	a	graph	plotted	with	standard	
concentration	on	the	x-axis	and	absorbance	on	the	y-axis	(Figure	2.1).	The	concentration	of	
syndecan-1	or	thrombomodulin	in	each	sample	well	was	then	interpolated	from	the	
standard	curve.	This	was	performed	using	GraphPad	Prism	version	7.0	(GraphPad	Software,	
California,	USA).	The	concentrations	of	the	control	wells	were	checked	against	the	expected	
concentrations	in	order	to	ensure	that	the	assay	had	been	performed	correctly.		
	
	
Figure	2.1.		 Example	of	a	standard	curve	derived	from	thrombomodulin	concentration	
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2.2.9.	 Data	analysis	
Continuous	data	were	tested	for	normality	using	the	Shapiro-Wilk	test.	Normal	data	
are	presented	as	mean	and	standard	deviation	(SD),	and	non-normal	data	are	presented	as	
median	and	interquartile	range	(IQR).	Spearman's	rank	correlation	coefficient	was	used	to	
determine	the	correlation	between	thrombomodulin	and	syndecan-1	concentrations	for	all	
patients,	as	well	as	the	correlation	between	each	of	the	biomarker	concentrations	and	flow	
dynamics	with	lactate.	Patient	time	points	were	calculated	from	time	of	injury,	and	were	
divided	into	three	groups:	(i)	<10	hours;	(ii)	10	–	30	hours;	and	(iii)	30	–	50	hours	since	injury.		
It	is	well	established	in	previous	studies	of	microcirculatory	flow	dynamics	that	
healthy	volunteers	score	near-maximum	values	of	the	traditional	parameters	of	choice	
(such	as	PPV	close	to	100%,	MFI	equal	to	or	close	to	3.0,	and	heterogeneity	near	to	0)27-29.	
Comparison	of	flow	dynamics	between	healthy	controls	and	critically	unwell	patients	is	
therefore	unlikely	to	yield	surprising	or	meaningful	results.	Of	greater	interest	would	be	the	
difference	between	patients	within	the	critically	unwell	cohort.	In	order	to	test	the	
association	of	flow	dynamics	and	endothelial	cell	damage	and	glycocalyx	shedding	amongst	
the	injured	cohort	in	the	current	study,	flow	dynamic	parameters	were	dichotomised	above	
and	below	the	average	value	at	each	time	point	(the	median	for	non-normal	data	and	the	
mean	for	normal	data)	in	a	manner	similar	to	that	previously	reported	for	microcirculatory	
parameters30.	The	“worse”	group	were	considered	to	have	poor	microcirculatory	flow	
dynamics.	Concentrations	of	syndecan-1	and	thrombomodulin	were	compared	between	
these	“above”	and	“below”	average	groups.	Multiple	pairwise	comparisons	of	biomarkers	
between	patients	and	healthy	controls	were	made	using	Dunn’s	multiple	comparisons	tests.	
Comparison	of	flow	dynamics	between	time	points	was	made	using	the	Skillings-Mack	test	
for	repeated	measures	of	non-normal	data	that	allows	for	some	missing	values.	A	p-value	of	
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<	0.05	was	considered	statistically	significant.	Box	and	whisker	graphs	are	presented	
according	to	the	Tukey	method,	with	horizontal	bars	as	the	median	value,	boxes	as	the	
interquartile	range,	and	the	upper	and	lower	whiskers	being	1.5	times	the	interquartile	
range	above	and	below	the	75th	and	25th	percentile	respectively.		
	
2.3.	 Results	
2.3.1.	 Patient	characteristics	
Analysis	was	performed	for	155	sublingual	video-microscopy	clips	that	corresponded	
to	39	time	points	from	17	trauma	patients.	Six	patients	had	data	from	all	three	time	points,	
10	had	data	from	two	time	points,	and	one	patient	died	after	the	first	time	point.	Patient	
characteristics	are	shown	in	Table	2.1.	
	
2.3.2.	 Endothelial	cell	damage	and	glycocalyx	shedding	
When	pairs	of	thrombomodulin	and	syndecan-1	concentrations	for	all	healthy	
controls	and	patients	were	compared,	there	was	a	significant	correlation	between	them	(r	=	
0.634;	p	<	0.001)	(Figure	2.2),	indicating	an	association	between	glycocalyx	shedding	and	
endothelial	cell	damage.		
	
2.3.3.	 Endotheliopathy,	flow	disruption	and	perfusion		
Thrombomodulin	and	syndecan-1	were	both	significantly	correlated	with	lactate	
concentrations	(Figure	2.3)	(r	=	0.331;	p	<	0.05;	and	r	=	0.440;	p	<	0.01	respectively),	
suggesting	that	endotheliopathy	is	associated	with	perfusion	mismatch.	When	flow	
dynamics	were	compared	to	lactate	concentrations,	there	were	significant	correlations	with	
PVD	(r	=	-0.416;	p	<	0.01);	PPV	(r	=	-0.440;	p	<	0.01);	MFI	(r	=	-0.464;	p	<	0.01);	MHI	(r	=	
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0.363;	p	<	0.05);	and	POEM	score	(r	=	-0.440;	p	<	0.01).	There	was	no	significant	correlation	
with	TVD	(r	=	-0.312;	p	=	0.053).		
	
Table	2.1.		 Study	patient	characteristics	
	
Patient	characteristic	 All	
Age,	years	 35	(25–52)	
Sex,	male:female	 16:1	
Mechanism	of	injury	 	
									Road	traffic	accident	 10	(59)	
									Stabbing	 4	(24)	
									Fall	 2	(11)	
									Crush	 1	(6)	
Injury	Severity	Score	 27	(23–34)	
Physiological	parameters	on	arrival		 	
									Heart	rate,	min-1	 108	(98–118)		
									Systolic	blood	pressure,	mmHg	 91	(61–108)	
									Glasgow	Coma	Scale	 9	(3–14)		
									Plasma	lactate,	mmol/l	 6.0	(3.6–10.2)		
Blood	products	required	in	ED	 	
									Packed	red	cells,	units	 3	(2–4)		
									Fresh	frozen	plasma,	units	 2	(0–4)		
Crystalloid	fluid,	ml	 	
									Injury	to	T1	 1000	(500	–	1475)	
									Between	T1	and	T2	 3000	(2000	–	4000)	
									Between	T2	and	T3	 3000	(1250	–	4000)	
Outcomes	 	
									ICU-free	days	 11	(0–19)	
									Hospital-free	days	 0	(0–5)		
									SOFA	score,	day	3	 6	(8	–	9)		
									SOFA	score,	day	6	 4	(3	–	6)		
									SOFA	score,	day	10	 3	(3	–	4)		
									30	day	mortality	 3	(18)	
Summary	data	are	presented	as	median	and	interquartile	range	in	parentheses;	categorical	data	are	
reported	as	N	(%).	ICU-	and	Hospital-free	days	are	calculated	for	a	30-day	period.		
ED:	Emergency	Department;	ICU:	Intensive	Care	Unit;	SOFA:	Sequential	Organ	Failure	Assessment	
T1:	first	time	point	(<10h);	T2:	second	time	point	(10-30h);	T3:	third	time	point	(30-50h)	
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Figure	2.2.		 The	relationship	between	thrombomodulin	and	syndecan-1	concentrations	
for	all	patients	and	healthy	controls.	
	
	
	
	
Figure	2.3.	 The	relationship	between	(a)	thrombomodulin	and	(b)	syndecan-1	
concentrations	and	lactate	for	all	patients.		
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2.3.4.	 Glycocalyx	shedding	and	endothelial	cell	damage	over	time	
Figure	2.4	illustrates	the	concentrations	of	syndecan-1	and	thrombomodulin	for	all	
patients	over	time.	When	syndecan-1	concentrations	were	compared	with	healthy	controls	
(30	(IQR	20	–	44)	ng/ml),	they	were	significantly	higher	at	the	10h	(63	(IQR	41	–	296)	ng/ml),	
10-30h	(61	(IQR	38	–	109)	ng/ml)	and	30-50h	(51	(IQR	34	–	90)	ng/ml)	time	points.	In	
contrast,	there	were	no	significant	differences	between	thrombomodulin	concentrations	for	
healthy	controls	(2.9	(IQR	2.2	–	3.4)	ng/ml)	and	patients	at	the	<10h	(3.7	(IQR	2.8	–	4.7)	
ng/mL),	10-30h	(3.9	(IQR	3.4	–	4.5)	ng/ml),	or	30-50h	(2.9	(IQR	2.4	–	6.0)	ng/ml)	time	points.				
	
	
	
Figure	2.4.	 Concentrations	of	(a)	syndecan-1	and	(b)	thrombomodulin	over	the	study	
time	points	for	all	patients	compared	to	healthy	controls	(HCs).		
*p	<	0.05;	**p	<	0.01	vs.	HCs	using	Dunn’s	multiple	comparisons	test		
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2.3.5.	 Flow	parameters	improve	over	time	
Flow	dynamics	for	all	three	time	points	are	illustrated	in	Figure	2.5.	There	was	a	
significant	improvement	over	time	for	measures	of	flow	(MFI;	p	<	0.001),	perfusion	(PPV;	p	<	
0.001),	heterogeneity	(MHI;	p	<	0.001),	and	combined	flow	and	heterogeneity	(POEM	score;	
p	<	0.01).	There	were	no	significant	differences	over	time	for	measures	of	total	or	perfused	
vessel	density	(TVD	(p	=	0.276)	and	PVD	(p	=	0.389)	respectively).		
	
Figure	2.5.	 Flow	dynamics	for	all	patients	over	time,	including	(a)	Microcirculatory	Flow	Index;	
(b)	Proportion	of	Perfused	Vessels;	(c)	Microcirculatory	Heterogeneity	Index;	and	(d)	Point-of-
Care	Microcirculation	score.			
**p	<	0.01;	***p	<	0.001	using	the	Skillings-Mack	test	
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2.3.6.	 Glycocalyx	shedding	and	flow	dynamics	
Figure	2.6	illustrates	the	concentrations	of	syndecan-1	at	each	time	point	relative	to	
flow	dynamic	parameters.	Higher	heterogeneity	of	flow	(MHI),	as	well	as	worse	perfusion	
(PPV)	and	flow	(MFI)	were	associated	with	glycocalyx	shedding	at	all	three	time	points.	The	
most	significant	differences	were	observed	within	10h	of	injury;	at	this	time	point,	
syndecan-1	concentrations	were	significantly	higher	than	healthy	controls	(30	(IQR	20	–	44)	
ng/ml)	when	there	was	worse	TVD	(78	(IQR	63	–	417)	ng/ml);	PVD	(156	(IQR	63	–	590)	
ng/ml);	PPV	(249	(IQR	64	–	578)	ng/ml);	MFI	(249	(IQR	64	–	578)	ng/ml);	MHI	(45	(IQR	38	–	
68)	ng/ml);	and	POEM	scores	(108	(IQR	44	–	462)	ng/ml)	(all	p	<	0.01).	Below	average	TVD	
and	PVD	were	associated	with	glycocalyx	shedding	at	<10h	and	10-30h	(all	p	<	0.05),	but	not	
at	the	30-50h	time	points.	
	
2.3.7.	 Endothelial	cell	damage	and	flow	dynamics		
Figure	2.7	illustrates	the	concentration	of	thrombomodulin	at	each	time	point	
relative	to	flow	dynamic	parameters.	In	contrast	with	syndecan-1,	thrombomodulin	was	
only	raised	within	10	hours	of	injury	when	compared	to	healthy	controls	(2.9	(IQR	2.2	–	3.4)	
ng/ml)	for	worse	PPV	(4.1	(IQR	3.4	–	6.2)	ng/ml)	and	MFI	(4.1	(IQR	3.4	–	6.2)	ng/ml)	(both	p	
<	0.05).	Below	average	density	(TVD)	and	functional	density	(PVD)	were	associated	with	
endothelial	damage	only	at	the	10-30h	time	point	(3.7	(IQR	3.3	–	3.9)	ng/ml	and	3.7	(IQR	3.3	
–	3.9)	ng/ml	respectively),	but	not	at	the	<10h	or	30-50h	time	points.	No	associations	were	
found	between	endothelial	cell	damage	and	heterogeneity	of	flow	(MHI)	or	POEM	scores	(p	
values	all	non-significant).	
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Figure	2.6.		Concentrations	of	syndecan-1	at	each	time	point,	dichotomised	to	“above”	
and	“below”	the	average	values	of	(a)	Microcirculatory	Heterogeneity	Index;	(b)	
Proportion	of	Perfused	Vessels;	and	(c)	Point-of-Care	Microcirculation	score;	and	(d)	
Microcirculatory	Flow	Index	compared	to	healthy	controls	(HCs).	
*p	<	0.05,	**p	<	0.01;	***p	<	0.001	vs.	HCs	using	Dunn’s	multiple	comparisons	test		
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Figure	2.7.	 Concentrations	of	thrombomodulin	at	each	time	point,	dichotomised	to	
“above”	and	“below”	the	average	values	of	(a)	Total	Vessel	Density;	(b)	Perfused	Vessel	
Density;	(c)	Proportion	of	Perfused	Vessels;	and	(d)	Microcirculatory	Flow	Index	compared	
to	healthy	controls	(HCs).	
*p	<	0.05	vs.	HCs	using	Dunn’s	multiple	comparisons	test		
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2.4.	 Discussion	
The	main	finding	from	this	study	is	that	there	is	an	association	between	
endotheliopathy	and	impaired	microcirculatory	perfusion	following	traumatic	haemorrhagic	
shock,	the	effects	of	which	were	most	striking	within	10	hours	of	injury.	The	correlation	
between	plasma	lactate	readings	and	both	endothelial	biomarkers	and	microcirculatory	
flow	dynamics	may	suggest	a	concurrent	oxygen	perfusion	deficit	associated	with	
endotheliopathy	and	microcirculatory	flow	disruption,	although	these	correlations	were	not	
strong.	Deterioration	in	flow	may	represent	one	of	the	mechanisms	of	microcirculatory	
dysfunction	attributable	to	endotheliopathy,	and	poor	flow	dynamics	following	shock	may	
be	responsible	for	worsening	endotheliopathy.	Although	the	current	study	does	not	
attribute	causality,	it	is	likely	that	poor	flow,	glycocalyx	shedding	and	endothelial	cell	
disruption	are	mutually	detrimental,	and	together	may	contribute	to	derangement	in	
oxygen	exchange,	inflammatory	dysregulation	and	coagulopathy	following	trauma	and	
haemorrhagic	shock.	In	terms	of	the	exact	sequence	of	events,	further	investigations	are	
required	to	determine	whether	it	is	the	endotheliopathy	that	causes	flow	disruption	due	to	
alterations	in	vessel	diameter,	viscosity,	and	shear	forces,	or	whether	it	is	reduced	flow	that	
causes	endotheliopathy,	perhaps	due	to	tissue	ischaemia	and	sympathoadrenal	
activation7,8.		
Other	investigators	have	reported	an	association	between	injury	severity,	
catecholamine-driven	sympathoadrenal	response,	hypocoagulability,	and	raised	levels	of	
syndecan-1	and	thrombomodulin	as	markers	of	glycocalyx	shedding	and	endothelial	cell	
injury2,	31.	Trauma-induced	coagulopathy	has	been	observed	in	patients	with	glycocalyx	
shedding,	and	it	has	been	postulated	that	endogenous	auto-heparinisation	may	be	
responsible	for	this32,	as	well	as	the	generation	of	thrombin	and	activation	of	protein	C33.	
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The	term	“shock-induced	endotheliopathy”	(SHINE)	has	been	used	to	describe	the	same	
phenotype	observed	in	several	different	critical	illnesses	characterised	by	shock4.	These	
observed	effects	of	endotheliopathy	may	be	considered	in	the	context	of	the	
microcirculatory	flow	disruption	observed	in	the	current	study,	which	are	likely	to	
exacerbate	the	pathologic	process	by	reducing	the	efficient	flow	of	red	cells	and	oxygen	
delivery	to	tissues.			
It	is	notable	that	most	of	the	flow	parameters	showed	dramatic	improvement	over	
the	three	time	points	(Figure	2.5),	and	yet	the	glycocalyx	does	not	appear	to	have	been	
restored	to	normality	according	to	the	levels	of	syndecan-1	(Figure	2.4).	Although	the	
median	levels	of	syndecan-1	improved	over	time,	they	were	still	raised	above	that	of	
healthy	controls,	a	finding	in	keeping	with	a	previous	study11.	Restoration	of	flow	
parameters	may	be	a	reflection	of	a	pressure-based	resuscitation	strategy	and	goal-directed	
therapy	aimed	at	restoring	oxygen	perfusion	and	reducing	acidosis,	rather	than	any	therapy	
deliberately	targeted	at	repairing	the	endothelium.	The	exact	consequences	of	incomplete	
endothelial	restoration	are	unknown,	but	it	seems	likely	that	any	inflammatory	and	
coagulopathic	processes	caused	by	the	injured	endothelium	would	continue	to	have	an	
effect	on	subsequent	clinical	progression	until	the	endothelium	was	returned	to	its	normal	
state.	Furthermore,	it	is	unknown	what	degree	of	“useful”	endothelial	activation	following	
trauma	there	may	be.	It	is	a	possibility	that	there	is	a	level	of	endothelial	activation	that	
might	cause	levels	of	syndecan-1	and	thrombomodulin	to	increase	significantly	above	those	
of	healthy	controls,	but	still	not	be	pathological.	Others	have	recently	proposed	threshold	
values	for	syndecan-1	above	which	there	was	a	significant	association	with	mortality34,	but	
further	investigations	of	the	precise	role	of	endothelial	activation	following	trauma	are	
justified.			
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The	flow	parameters	observed	in	this	study	included	those	used	for	research	but	also	
a	point-of-care	tool	that	may	be	used	at	the	bedside	(which	will	be	described	in	greater	
detail	in	Chapter	6)26.	Other	investigators	have	also	proposed	bedside	utilisation	of	more	
traditional	research	parameters35,	36.	Sublingual	video-microscopy	is	safe	to	be	performed	
for	patients	following	injury,	even	in	the	ED	for	haemodynamically	unstable	patients	(as	will	
be	discussed	in	greater	detail	in	Chapter	5)37.	If	conducted	in	real	time,	these	parameters	
may	be	able	to	aid	in	the	identification	of	patients	likely	to	suffer	from	ongoing	
consequences	of	endotheliopathy	by	directly	visualising	the	dynamic	changes	from	initial	
resuscitation	through	to	ICU.	Since	endotheliopathy	may	predict	poor	patient	outcome2,	14,	
this	information	is	of	potential	value	in	the	clinical	context.		
A	recent	experimental	swine	model	of	trauma	and	haemorrhagic	shock	showed	that	
even	with	identical	injury	and	haemorrhage,	there	was	a	wide	variation	in	microcirculatory	
dysfunction	between	animals	from	the	outset30,	confirming	the	findings	of	an	earlier	small	
animal	model38.	The	level	of	microcirculatory	dysfunction	was	not	predictable	based	on	
injury-specific	details,	but	instead	may	be	subject	to	genetic	susceptibility.	The	same	may	
also	be	true	for	injured	humans;	for	example,	age	is	associated	with	a	different	biomarker	
profile	related	to	circulating	inflammatory	and	sympathoadrenal	mediators39.	Diagnostic	
techniques	may	be	desirable	if	they	can	distinguish	between	patients	at	risk	of	
endotheliopathy	and	those	who	are	not.	In	the	current	study	there	was	a	wide	variation	in	
biomarker	levels	and	flow	dynamics	parameters,	with	some	overlap	in	values	between	
healthy	volunteers	and	injured	patients.	Furthermore,	although	statistically	significant,	the	
correlations	between	the	lactate	and	the	study	parameters	of	interest	are	not	perfect.	In	
addition,	there	may	be	time	lag	effects	between	these	events.	These	are	findings	that	might	
be	anticipated	in	a	trauma	population	due	to	the	heterogeneity	of	injury	patterns	and	
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severity	along	with	differences	in	genetic	susceptibility	between	patients.	Biomarkers	and	
flow	dynamics	alone	may	not	be	sensitive	or	specific	enough	to	determine	clinical	decisions	
during	resuscitation,	but	may	have	a	role	in	the	overall	assessment	of	patients	in	the	context	
of	their	other	physiological	and	biochemical	parameters.	This	may	be	especially	relevant	if	
endothelial	and	microcirculatory	behaviour	is	subject	to	genetic	variation	between	
individuals	in	the	presence	of	the	same	injury	patterns.					
The	current	management	strategy	for	traumatic	haemorrhagic	shock	involves	an	
early	damage	control	resuscitation	(DCR)	phase	that	begins	during	the	pre-hospital	
evacuation	of	the	casualty,	followed	by	fluid	resuscitation	with	empirical	ratios	of	packed	
red	cells,	plasma,	and	platelets.	Following	empirical	resuscitation,	a	more	bespoke,	
individualised	approach	to	ongoing	resuscitation	is	favourable,	using	additional	diagnostic	
modalities	such	as	thromboelastography40.	Currently	there	is	no	point-of-care	test	for	
endotheliopathy	of	trauma,	but	it	appears	that	sublingual	video-microscopy	has	the	
potential	to	provide	rapid	point-of-care	information	relating	to	this	important	pathology	
during	individualised	resuscitation.	Previous	investigators	have	described	a	restoration	of	
the	endothelial	glycocalyx	with	plasma-based	fluid	resuscitation41-44,	and	the	ideal	
resuscitation	fluid	for	restoring	microcirculatory	flow	dynamics	should	act	to	restore	the	
endothelial	glycocalyx	(as	will	be	described	in	greater	detail	in	Chapter	7)45.	Whether	
additional	microcirculatory	data	might	direct	fluid	resuscitation	towards	a	plasma-based	
strategy	in	the	clinical	situation	is	yet	to	be	determined,	and	further	clinical	investigation	of	
this	is	warranted.		
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2.4.1.	 Limitations	
This	study	included	a	relatively	small	number	of	patients,	with	all	of	the	associated	
statistical	limits.	Analysis	was	performed	on	an	individual	time	point	(rather	than	individual	
patient)	level	in	order	to	increase	the	number	of	data	points	to	address	our	research	
question.	The	patients	included	in	the	current	study	were	profoundly	unwell,	with	high	
injury	severity	scores	and	poor	physiological	parameters	on	admission.	The	data	from	the	
current	study	may	not	necessarily	be	translatable	for	patients	with	less	severe	injuries	and	
physiological	burden.	Sublingual	video-microscopy	is	not	currently	in	widespread	clinical	
use,	and	the	utility	of	these	data	in	the	clinical	context	are	yet	to	be	examined	in	prospective	
clinical	trials.		
All	patients	in	this	cohort	received	crystalloid	fluids	during	their	pre-hospital	and	in-
hospital	resuscitation,	and	it	is	not	known	to	what	extent	these	may	have	affected	the	
microcirculatory	flow.	It	is	also	unknown	whether	the	delivery	of	crystalloid	fluids	may	have	
an	influence	on	the	concentrations	of	biomarkers	(such	as	a	dilutional	affect).	For	example,	
it	is	not	known	whether	a	reduction	in	biomarker	level	to	normal	might	be	due	to	
haemodilution	or	a	genuine	restoration	of	the	endothelium.	Further	investigations	of	
microcirculatory	flow	in	relation	to	the	volumes	and	types	of	fluids	in	a	larger	number	of	
patients	would	be	warranted.						
	
2.5.	 Conclusion	
There	is	an	association	between	endotheliopathy	(including	endothelial	cell	damage	
and	glycocalyx	shedding)	and	alterations	in	flow,	density,	functional	density,	proportion	of	
perfused	vessels,	and	micro-vessel	heterogeneity.	This	microcirculatory	dysfunction	may	
explain	in	part	some	of	the	mechanisms	of	the	oxygen	perfusion	deficit	that	is	attributable	
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to	endotheliopathy.	The	clinical	utility	of	these	flow	parameters	at	the	bedside	is	yet	to	be	
elucidated.				
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3.1.	 Introduction	
In	the	previous	chapter,	we	discussed	the	relationship	between	endotheliopathy	of	
trauma	and	microcirculatory	flow	disruption.	These	pathological	processes	are	associated	
with	each	other,	and	were	most	profound	at	the	earliest	time	points.	It	would	therefore	be	
of	some	value	to	describe	the	time	course	over	which	these	processes	might	occur	following	
injury,	whether	they	affect	patient	outcomes,	and	whether	there	is	a	treatment	that	might	
be	given	to	mitigate	them.	This	chapter	will	address	these	questions.				
Trauma	induced	coagulopathy	(TIC)	has	been	observed	in	injured	patients	on	arrival	
in	hospital1,	and	within	the	pre-hospital	environment2,	3,	suggesting	that	it	may	occur	soon	
after	injury.	Abnormal	inflammatory	function	following	trauma	has	also	been	observed	on	
admission	to	hospital4,	and	we	have	recently	reported	that	this	occurs	within	the	first	hour	
following	injury5.	Activation	of	the	interconnected	inflammatory	and	coagulation	pathways	
are	influenced	by	a	“genomic	storm”	that	occurs	following	injury,	mimicking	the	response	to	
critical	inflammatory	stress6.	This	may	include	the	disruption	of	the	endothelial	barrier,	
which	has	been	proposed	as	a	unifying	mechanism	for	these	processes	following	trauma7.	
There	have	been	no	investigations	of	this	specific	process	in	the	pre-hospital	setting.	Data	
regarding	the	timing	and	nature	of	endotheliopathy	following	injury	and	before	arrival	in	
hospital	may	facilitate	a	greater	understanding	of	the	mechanisms	of	coagulopathy	and	
inflammatory	disorder	following	trauma.		
The	endothelial	layer	consists	of	endothelial	cells,	their	basal	lamina	and	the	
endothelial	glycocalyx	that	lines	the	luminal	surface.	Endothelial	injury	and	glycocalyx	
shedding	may	occur	following	trauma	as	a	consequence	of	its	exposure	to	circulating	
damage-associated	molecular	patterns	(DAMPs)8,	neutrophil	extracellular	traps9,	
sympathoadrenal	activation10,	hypovolaemia11,	and	ischemia12.		In	injured	patients,	soluble	
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thrombomodulin	and	syndecan-1	have	been	used	as	surrogate	markers	of	endothelial	cell	
injury	and	glycocalyx	shedding	respectively10,	13,	as	described	in	the	previous	chapter.	These	
biomarkers	have	been	observed	in	abnormal	concentrations	in	blood	samples	acquired	from	
patients	at	hospital	admission13,	but	it	is	unknown	exactly	when	endotheliopathy	occurs	
following	a	traumatic	insult.	If	endothelial	activation	and	microcirculatory	dysfunction	are	to	
be	confirmed	as	a	unifying	mechanism	for	the	pathological	inflammatory	processes	
following	trauma7,	then	it	would	be	expected	that	endotheliopathy	precedes,	or	
concurrently	occurs,	with	coagulopathic	and	inflammatory	changes	following	injury.	We	
sought	to	investigate	endotheliopathy	of	trauma	(EoT)	within	a	cohort	of	trauma	patients	
that	we	recently	observed	to	have	early	inflammatory	and	immune	cell	dysregulation5.				
A	recent	in	vitro	study	of	the	EoT	demonstrated	that	when	injured	human	umbilical	
vein	endothelial	cells	were	exposed	to	tranexamic	acid	(TXA),	concentrations	of	both	
thrombomodulin	and	syndecan-1	(used	as	markers	of	endotheliopathy)	were	reduced	
significantly	more	than	for	those	cells	without	TXA14.	This	study	generated	the	hypothesis	
that	TXA	may	play	some	role	in	the	amelioration	of	the	EoT,	but	this	has	not	been	tested	in	
the	clinical	setting.		
The	current	study	measured	biomarkers	of	endothelial	cell	injury	(thrombomodulin)	
and	glycocalyx	shedding	(syndecan-1)	as	surrogate	markers	of	EoT.	The	aim	of	the	study	was	
to	provide	an	estimation	of	the	time	of	onset	of	EoT	post-injury,	and	to	investigate	whether	
the	evolution	of	EoT	between	the	scene	of	injury	and	hospital	admission	is	associated	with	
subsequent	organ	failure.	Furthermore,	since	these	two	time	points	represent	“before”	and	
“after”	treatment	with	TXA,	we	tested	the	hypothesis	that	TXA	might	reduce	biomarkers	of	
EoT	as	has	been	reported	in	vitro14.		
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It	was	hypothesised	that	there	would	be	an	early	rise	in	biomarkers	of	EoT	following	
trauma,	which	would	be	associated	with	poorer	outcomes,	and	that	patients	who	received	
TXA	would	have	a	greater	decrease	in	biomarker	levels	than	those	who	did	not	receive	TXA	
(Hypotheses	2–4;	Table	1.1).		
	
	
3.2.	 Methods	
	
3.2.1.	 Study	design	and	setting	
A	prospective	longitudinal	observational	study	was	undertaken	using	a	pre-hospital	
design	described	previously5;	trauma	patients	were	enrolled	during	pre-hospital	evacuation,	
as	soon	after	injury	as	possible	by	paramedic	personnel	across	a	large	UK	major	trauma	
network.	After	being	conveyed	to	the	regional	Major	(Level	1)	Trauma	Centre	(University	
Hospitals	Birmingham	NHS	Foundation	Trust),	study	participants	were	followed	up	by	
embedded	trauma	research	personnel.	The	current	study	includes	patients	from	the	Brain	
Biomarkers	After	Trauma	Study	(BBATS);	Research	Ethics	Committee	(REC)	approval	was	
granted	prior	to	the	start	of	the	study	(REC	5,	Wales,	Ref.	13/WA/0399).	This	study	is	
reported	according	to	the	STROBE	guidance	for	observational	studies.	Patients	were	
enrolled	from	May	2014	to	February	2017.		
Pre-hospital	blood	products	were	not	available	in	this	trauma	network	during	the	
study	period.	Pre-hospital	TXA	delivery	was	given	according	to	a	specific	protocol	that	
included	injured	patients	with	any	of	the	following:	systolic	blood	pressure	<90	mmHg;	
heart	rate	>100	bpm;	risk	of	significant	haemorrhage;	or	who	required	intravenous	fluid	
therapy.	Patients	were	not	given	TXA	if	more	than	3	hours	had	passed	since	injury,	if	they	
had	an	isolated	head	injury,	a	known	history	of	convulsions,	or	hypersensitivity	to	TXA.						
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3.2.2.	 Study	participants	
Trauma	patients	with	the	likelihood	of	an	Injury	Severity	Score	(ISS)	of	8	or	higher	
were	eligible	for	inclusion,	regardless	of	type	of	injury.	Since	ISS	is	not	usually	calculated	
until	after	the	patient	has	left	hospital,	specific	training	was	delivered	to	the	pre-hospital	
practitioners	within	the	study	region	before	the	start	of	the	study,	so	that	prediction	of	
likely	ISS	could	be	made	as	appropriate.	Patients	were	excluded	if	they	were	pregnant,	
prisoners,	or	under	the	age	of	16.	Patients	could	only	be	enrolled	if	there	was	a	peripheral	
venous	sample	of	blood	taken	within	60	minutes	from	time	of	injury.	All	eligible	patients	
were	screened	by	dedicated	research	staff	on	arrival	in	ED	to	minimise	the	risk	of	selection	
bias.	For	the	purposes	of	the	current	study,	patients	with	isolated	traumatic	brain	injury	
were	excluded.	Time	of	injury	was	defined	as	the	“call	time”	(i.e.	the	time	that	an	
emergency	call	was	received	by	the	ambulance	control	room).	
	
3.2.3.	 Capacity	and	consent	
Due	to	the	injuries	sustained	and	requirement	for	swift	emergency	evacuation,	it	
was	considered	that	patients	would	not	have	capacity	to	consent.	The	REC-approved	
protocol	was	undertaken	according	to	the	World	Medical	Association	Declaration	of	
Helsinki,	and	the	Mental	Capacity	Act	2005.	As	described	in	Chapter	2,	a	Professional	
Consultee	may	agree	to	patient	enrolment,	as	well	as	a	close	relative	or	friend	(Personal	
Consultee).	Once	the	patient	regained	capacity,	they	were	approached	in	order	to	gain	
consent	for	the	retention	of	data	already	obtained,	and	for	continued	follow	up.	If	a	patient	
did	not	regain	capacity,	the	permission	from	their	Professional	or	Personal	Consultee	to	
participate	in	the	study	remained	extant.		
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3.2.4.	 Blood	sampling	and	storage	
Peripheral	blood	samples	were	taken	during	the	pre-hospital	evacuation	of	all	
patients	within	60	minutes	of	injury.	The	timing	of	this	sample	was	meticulously	recorded	in	
contemporaneous	records	by	pre-hospital	personnel	(designated	as	the	“pre-hospital”	time	
point).	A	further	peripheral	blood	sample	was	taken	between	4	and	12	hours	after	injury	
(designated	the	“in-hospital”	time	point).	Blood	samples	were	collected	into	BD	Vacutainers	
(Becton	Dickinson,	Oxford,	UK)	containing	z-serum	clotting	activator.	Following	a	30-minute	
incubation	at	room	temperature,	samples	were	centrifuged	at	4oC	for	10	minutes	at	1,620	x	
g.	Aliquots	were	stored	at	-80oC	until	analysed.	Serum	samples	were	acquired	and	stored	for	
19	“healthy	control”	(HC)	volunteers,	who	were	matched	as	a	group	for	sex	and	age	to	the	
study	cohort.	All	HCs	had	declared	themselves	to	be	in	good	health,	and	not	currently	under	
any	medical	investigations	or	treatment,	and	had	no	chronic	diseases.			
	
3.2.5.	 Enzyme-linked	immunosorbent	assays	
Commercially	available	ELISAs	were	used	to	measure	concentrations	of	syndecan-1	
(CD	138)	(Abcam,	ab46506,	Cambridge,	MA)	and	thrombomodulin	(CD	141)	(Abcam,	
ab46508,	Cambridge,	MA)	in	the	serum	samples	(as	described	in	detail	in	Chapter	2).	
Analysis	was	undertaken	in	accordance	with	the	relevant	protocols,	including	the	use	of	
control	and	blank	wells	in	order	to	validate	the	results.		
	
3.2.6.	 Data	collection	
Data	were	recorded	prospectively	for	all	patients,	and	then	confirmed	using	
electronic	and	paper	records.	Data	included	patient	demographics	(age,	gender),	and	
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mechanism	of	injury.	Injury	severity	scores	(ISS)	were	acquired	from	the	centralised	UK	
Trauma	Audit	and	Research	Network	after	discharge	from	hospital.	Physiological	
parameters	in	the	pre-hospital	period	included	systolic	blood	pressure	(SBP),	heart	rate	
(HR),	and	respiratory	rate.	Those	in	ED	included	lowest	SBP	and	associated	HR,	and	Glasgow	
Coma	Scale.	Plasma	lactate	and	base	deficit	in	ED	were	also	recorded.	Timings	of	blood	
samples	were	collected	contemporaneously	by	pre-hospital	practitioners.	Delivery	of	TXA	
between	the	first	and	second	time	points	was	recorded	in	order	to	dichotomise	patients	
into	those	who	had	received	TXA	and	those	who	had	not.		
	
3.2.7.	 Outcomes	
The	primary	outcome	for	this	study	was	development	of	multiple	organ	dysfunction	
syndrome	(MODS),	defined	as	a	sequential	organ	failure	assessment	(SOFA)	score	of	6	or	
higher	on	2	or	more	consecutive	days	during	their	admission	in	hospital	after	the	first	48h	
following	injury4,	5.	Mortality	within	90	days	was	also	recorded	for	all	patients.			
	
3.2.8.	 Data	analysis	
A	Shapiro-Wilk	test	was	used	to	determine	the	normality	of	continuous	data.	Non-
normal	data	are	presented	as	median	and	interquartile	range	(IQR).	Syndecan-1	and	
thrombomodulin	concentrations	were	considered	abnormal	if	they	were	above	the	97.5th	
percentile	of	HC	levels;	patients	were	considered	to	have	endotheliopathy	if	they	had	
abnormal	values	for	either	biomarker	(syndecan-1,	thrombomodulin,	or	both).	Correlation	
between	non-normal	continuous	variables	was	undertaken	using	Spearman’s	rank	
correlation	coefficient.	Non-normal	continuous	data	were	compared	between	groups	using	
a	Kruskal-Wallis	test,	followed	by	pairwise	comparisons	between	groups	using	Dunn’s	
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multiple	comparisons	test.	Categorical	data	were	compared	using	Fisher’s	exact	test	for	
pairwise	comparisons,	and	chi-squared	analysis	for	trends	between	groups,	and	reported	as	
n/denominator.	A	p-value	of	<	0.05	was	considered	significant.	Where	appropriate,	further	
designation	of	significance	was	made	by	indicating	when	p-values	were	<	0.01,	<	0.001	and	<	
0.0001.	
	
3.2.8.1.		Estimation	of	the	time	of	onset	of	endotheliopathy		
	 It	is	highly	unlikely	that	any	study	of	humans	will	be	able	to	determine	the	
concentrations	of	biomarkers	at	the	point	of	wounding,	and	therefore	statistical	
modelling	was	considered	the	best	opportunity	to	estimate	the	timing	of	biomarkers	
following	injury.	In	order	to	determine	the	most	likely	time	at	which	endothelial	injury	
and	glycocalyx	shedding	occur	following	injury,	the	concentrations	of	thrombomodulin	
and	syndecan-1	for	all	patients	were	plotted	against	time	from	injury.	Syndecan-1	and	
thrombomodulin	concentrations	derived	from	HCs	were	plotted	at	the	origin,	on	the	
assumption	that	trauma	patients	would	have	been	within	the	same	range	prior	to	injury.	
Analysis	was	then	performed	by	fitting	generalised	additive	models	to	the	data	using	
penalised	regression	splines	with	smoothing	parameters	selected	by	residual	maximum	
likelihood.	This	modelling	approach	accounts	for	the	distinctly	non-linear	pattern	of	the	
data	that	cannot	be	adequately	modelled	with	standard	parametric	regression	
approaches.	For	each	biomarker,	two	curves	were	plotted:	the	group	of	“abnormal”	
values	(higher	than	the	97.5th	percentile	of	HCs)	and	the	group	of	“normal”	values	which	
were	between	the	2.5th	and	97.5th	percentiles	of	HCs.	The	point	at	which	the	abnormal	
curve	crossed	the	line	of	significance	was	considered	to	be	an	estimation	for	the	point	at	
which	endotheliopathy	occurred	following	injury.		
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3.2.8.2.		Measuring	the	effects	of	TXA	
	 Patients	who	had	pre-hospital	endotheliopathy	were	dichotomised	into	those	who	
received	TXA	within	the	pre-hospital	period	(between	time	points)	and	those	that	did	
not.	Biomarkers	were	then	compared	before	and	after	treatment	in	order	to	determine	
whether	there	were	any	differences	between	the	two	groups.	
	
3.2.8.3.		Investigating	the	association	between	endotheliopathy	and	MODS		
Patients	with	both	pre-	and	in-hospital	serum	samples	were	categorised	according	to	
their	biomarkers	over	the	two	time	points:	(a)	those	with	persistent	abnormal	
biomarkers;	(b)	those	that	had	abnormal	biomarkers	that	reduced	to	normal	range;	and	
(c)	those	with	normal	biomarkers	throughout.	The	numbers	of	patients	who	developed	
MODS	were	compared	between	these	three	groups.	Furthermore,	individual	biomarkers	
were	compared	between	those	who	developed	MODS	and	those	who	did	not.		
	
3.3.	 Results	
3.3.1.	 Study	participation	
	 A	total	of	816	patients	were	screened	for	eligibility	during	the	study	period,	of	which	
107	were	potentially	eligible	patients	who	had	blood	samples	taken	within	60	minutes	of	
injury.	After	16	were	excluded	due	to	isolated	traumatic	brain	injury,	there	were	91	patients	
included.	The	median	time	of	blood	sampling	for	the	pre-hospital	time	point	was	45	(IQR	
33–55)	minutes	after	injury.	The	median	time	of	blood	sampling	for	the	second	(in-hospital)	
time	point	was	5.5h	(IQR	4.2h	–	10.5h).		
Enrolment	and	participation	at	each	stage	are	illustrated	in	a	flow	diagram	(Figure	
3.1),	with	asterisks	to	indicate	which	denominator	is	used	for	each	stage	of	data	analysis.	
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The	pre-hospital	blood	samples	were	insufficient	for	analysis	for	3	patients,	and	the	in-
hospital	blood	samples	were	insufficient	for	a	further	9	patients,	so	that	79/91	patients	had	
both	pre-	and	in-hospital	samples	suitable	for	analysis.		
	
Figure	3.1.	Flow	diagram	of	patient	enrolment	and	participation	at	each	stage	of	analysis.		
The	denominators	for	analysis	are:	*N=91	for	analysis	of	biomarkers	according	to	multiple	
organ	dysfunction	syndrome	(MODS)	and	mortality,	and	comparison	of	tranexamic	acid	
(TXA)	and	non-TXA;	**N=88	for	analysis	of	timing	of	endotheliopathy;	and	***N=79	for	
analysis	of	dynamic	changes	in	endotheliopathy	between	time	points	
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The	denominators	used	for	the	different	analyses	differ	accordingly:	
(a) Analysis	of	the	timing	of	EoT	after	injury:	N=88	(all	pre-hospital	samples)	
(b) Comparison	of	biomarkers	according	to	outcomes	(MODS	and	mortality);	and	
comparison	between	TXA	and	non-TXA:	N=91	(all	patients).		
(c) Comparison	of	patient	groups	according	to	dynamic	changes	in	endotheliopathy	
between	pre-	and	in-hospital	time	points:	N=79	(all	patients	with	both	pre-	and	in-
hospital	samples)		
	
3.3.2.	 Patient	characteristics	
The	median	age	of	all	patients	was	38	(IQR	24–55)	years,	and	78/91	were	male.	
Patient	characteristics	are	illustrated	in	Table	3.1,	with	comparison	between	patients	with	
pre-hospital	EoT	and	those	without.	There	was	a	higher	proportion	of	patients	with	blunt	
injury	in	the	pre-hospital	endotheliopathy	group	than	those	without	pre-hospital	
endotheliopathy	(60/71	versus	9/17;	p	<	0.01).	All	other	characteristics	were	not	
significantly	different	between	the	groups.	
	
3.3.3.	 Presence	of	endotheliopathy	
According	to	serum	concentrations	of	thrombomodulin	and	syndecan-1	for	HCs	and	
patients,	there	was	a	significant	difference	between	them	at	both	time	points,	for	both	
biomarkers,	as	illustrated	in	Table	3.2.	According	to	the	presence	of	abnormal	syndecan-1	or	
thrombomodulin	concentrations,	pre-hospital	and	in-hospital	endotheliopathy	were	present	
in	71/88	(81%)	and	51/82	(62%)	patients	respectively.		
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Table	3.1.	Study	participant	characteristics	according	to	presence	of	endotheliopathy	at	
the	pre-hospital	time	point	
Patient	characteristic	
All	
(N=88)	
Pre-hospital	
Endotheliopathy	
(N=71)	
No	pre-hospital	
endotheliopathy	
(N=17)	
	
	
p-value	
Age,	years	 33	(24–53)	 38	(24–56)	 25	(23	–	44)	 0.343	
Sex,	male	 75	(85)	 61	(86)	 14	(82)	 0.993	
Mechanism	of	injury	 	 	 	 	
									Blunt	 69	(78)	 60	(85)	 9	(53)	 0.008*	
									Penetrating	 19	(22)	 11	(15)	 8	(47)	 	
Injury	Severity	Score	 23	(12–36)	 24	(14–36)	 16	(9–29)	 0.267	
Pre-hospital	parameters	 	 	 	 	
									Heart	rate,	min-1		 100	(84–110)	 100	(80–118)	 99	(85–108)	 0.686	
									SBP,	mmHg	 121	(96–141)	 118	(96–140)	 127	(118–143)	 0.364	
									Respiratory	rate,	min-1	 20	(16–25)	 20	(16–25)	 18	(13–20)	 0.115	
Physiological	parameters	in	ED		 	 	 	 	
									Lowest	SBP,	mmHg	 115	(99–124)	 114	(99–124)	 119	(102–124)	 0.666	
									Heart	rate,	min-1	 88	(76–99)	 87	(75–99)	 89	(78–103)	 0.629	
									Glasgow	Coma	Scale	 13	(5–15)	 13	(4–15)	 15	(10–15)	 0.150	
									Plasma	lactate,	mmol/l	 4.1	(2.5–6.5)	 4.2	(2.7–6.7)	 3.5	(2.0–5.5)	 0.259	
									Base	deficit,	mmol/l	 -3	(-6	–	-1)	 -3	(-6	–	-1)	 -3	(-6	–	-1)	 0.438	
Summary	data	are	presented	as	median	(interquartile	range);	categorical	data	are	reported	as	N	(%)		
ED:	Emergency	Department;	SBP:	systolic	blood	pressure	
*Significant	according	to	Fisher’s	exact	test	
	
	
Table	3.2.	Serum	syndecan-1	and	thrombomodulin	concentrations	for	healthy	controls	
and	patients	according	to	time	point.		
Biomarker,	ng/ml	
Healthy	controls	
(N=19)	
Pre-hospital	
(N=88)	
In-hospital	
(N=82)	
Syndecan-1	 30	(20–44)	 59	(39	–	140)***	 53	(28	–	150)*	
Thrombomodulin	 2.9	(2.2	–	3.4)	 4.9	(3.8	–	6.4)***	 4	(3.4	–	5.1)**	
Data	are	presented	as	median	(interquartile	range),	ng/ml	
*	p	<	0.01,	**p	<	0.001,	and	***p	<	0.0001	when	compared	to	healthy	controls	using	Dunn’s	multiple	
comparisons	test		
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For	patients	with	samples	available	at	both	time	points	(N=79)	(Figure	3.1),	50/79	
(63%)	had	persistently	abnormal	biomarkers	(³1	biomarker	was	abnormal	at	both	time	
points),	18/79	(23%)	had	abnormal	biomarkers	that	returned	to	normal	(³1	biomarker	was	
abnormal	at	the	first	time	point,	but	both	were	normal	at	the	second	time	point),	and	11/79	
(14%)	had	both	biomarkers	normal	throughout;	their	characteristics	are	illustrated	in	Table	
3.3.	There	was	a	significant	difference	across	groups	for	plasma	lactate,	base	deficit,	and	
SBP	(all	p	<	0.05).	Of	all	patients	with	biomarkers	at	both	time	points,	there	were	20/79	
(25%)	who	received	blood	products	between	the	time	points.	There	was	a	significant	
difference	in	transfusion	requirement	between	these	groups	according	to	biomarker	
dynamics;	almost	all	of	those	requiring	transfusion	were	in	the	group	that	had	persistently	
abnormal	biomarkers	(p	<	0.01)	(Table	3.3).	Multivariable	analysis	to	examine	the	
association	between	blood	product	requirement	and	group	adjusted	for	ISS	could	not	be	
performed	due	to	the	low	number	of	transfusions	in	the	“abnormal-normal”	and	“normal-
normal”	groups,	which	would	risk	over-fitting	the	data.		
	
3.3.4.	 Endotheliopathy	occurs	within	minutes	of	injury	
There	was	evidence	of	glycocalyx	shedding	and	endothelial	cell	damage	within	the	
pre-hospital	(<60	min)	phase	amongst	this	cohort	of	patients.	Before	statistical	modelling,	
the	first	recorded	abnormal	syndecan-1	and	thrombomodulin	concentrations	amongst	the	
patient	cohort	were	observed	at	17	and	18	minutes	following	injury	respectively	(Figure	
3.2).		When	the	statistical	model	was	used,	glycocalyx	shedding	and	endothelial	cell	injury	
were	estimated	to	occur	at	approximately	5	and	8	minutes	following	injury	respectively	
(Figure	3.2).			
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Table	3.3.	Patient	characteristics	according	to	change	in	serum	syndecan-1	and	
thrombomodulin	concentrations	between	the	pre-hospital	and	in-hospital	time	points	
Patient	characteristic	
Abnormal-
abnormal	
(N=50)	
Abnormal-
normal	
(N=18)	
Normal-
normal	
(N=11)	
	
p-value	
Age,	years	 39	(25–63)	 36	(24–45)	 25	(23–48)	 0.417	
Sex,	male	 42	(84)	 16	(89)	 9	(82)	 0.974	
Mechanism	of	injury	 	 	 	 	
									Blunt	 39	(78)	 17	(94)	 7	(64)	 0.729	
									Penetrating	 11	(22)	 1	(6)	 4	(36)	 	
Injury	Severity	Score	 25	(15–38)	 29	(16–38)	 17	(9–29)	 0.230	
Physiological	parameters	in	ED		 	 	 	 	
									Lowest	SBP,	mmHg	 113	(95–122)	 119	(105–129)	 122	(106–134)	 0.030*	
									Heart	rate,	min-1	 87	(80–99)	 93	(81–104)	 88	(76–104)	 0.627	
									Glasgow	Coma	Scale	 13	(3–14)	 12	(6–14)	 15	(11–15)	 0.083	
									Plasma	lactate,	mmol/l	 4.8	(3.0–7.2)	 3.7	(2.5–6.4)	 2.4	(1.3–4.6)	 0.037*	
									Base	deficit,	mmol/l	 -4	(-8	–	-2)	 -3	(-6	–	-1)	 -2	(-3	–	0)	 0.023*	
Blood	product	requirement	 	 	 	 	
									All	patients	transfused	 19	(38)	 0	(0)	 1	(10)	 0.003**	
									Patients	given	RBCs	 19	(38)	 0	(0)	 1	(10)	 0.003**	
									Patients	given	FFP	 12	(24)	 0	(0)	 0	(0)	 0.017**	
Summary	data	are	presented	as	median	(interquartile	range);	categorical	data	are	reported	as	N	(%)		
ED:	Emergency	Department;	SBP:	systolic	blood	pressure;	RBC:	red	blood	cells;	FFP:	fresh	frozen	plasma	
*Significant	according	to	Kruskal-Wallis	test	
**Significant	according	to	chi-squared	test	
	
	
3.3.5.	 Endotheliopathy	is	associated	with	poor	perfusion	
When	pre-hospital	and	in-hospital	concentrations	of	syndecan-1	and	
thrombomodulin	were	compared	to	the	plasma	lactate	during	ED	resuscitation	(as	a	
surrogate	marker	of	microcirculatory	perfusion),	there	was	a	significant	correlation	with	
both	pre-hospital	and	in-hospital	syndecan-1	(Figures	3.3a	and	3.3b	respectively),	and	in-
hospital	thrombomodulin	(Figure	3.3d);	all	p	<	0.05.	However,	there	was	no	significant	
correlation	between	lactate	and	pre-hospital	thrombomodulin	concentration	(Figure	3.3c).					
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Figure	3.2.	Concentrations	of	(a)	syndecan-1	and	(b)	thrombomodulin	in	relation	to	time	
of	injury.	Healthy	controls	are	plotted	at	time	=	0	min.	Patients	are	divided	into	those	with	
elevated	concentrations	of	the	biomarker	(>97.5th	percentile	of	healthy	controls),	and	those	
with	normal	concentrations	(2.5th	–	97.5th	percentiles	of	healthy	controls).	For	each	curve	
the	central	trend	line	represents	the	average	values,	with	the	upper	and	lower	trend	lines	
representing	the	2.5th	and	97.5th	percentiles	of	observed	values.	The	vertical	interrupted	red	
line	indicates	the	time	at	which	biomarkers	are	likely	to	be	first	elevated.		
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Figure	3.3.	Concentrations	of	Syndecan-1	and	thrombomodulin	in	relation	to	lactate	
concentration	during	ED	resuscitation;	including	(a)	pre-hospital	syndecan-1;	(b)	in-
hospital	syndecan-1;	(c)	pre-hospital	thrombomodulin;	and	(d)	in-hospital	
thrombomodulin.		
Blue	dashed	lines	represent	95%	confidence	intervals.		
	
	
	
	
3.3.6.	 Endotheliopathy	is	associated	with	MODS	
Figure	3.4	illustrates	the	biomarker	levels	of	patients	according	to	whether	they	
developed	MODS.	When	patients	who	developed	MODS	were	compared	to	those	without	
MODS,	the	former	had	significantly	higher	syndecan-1	concentrations	at	the	pre-hospital	
(91	(IQR	48–184)	ng/ml	vs.	47	(IQR	33–109)	ng/ml;	p	<	0.05)	and	in-hospital	(64	(IQR	42–
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199)	ng/ml	vs.	38	(IQR	25–98)	ng/ml;	p	<	0.01)	time	points.	For	patients	with	MODS,	the	pre-	
and	in-hospital	syndecan-1	and	thrombomodulin	levels	were	both	significantly	higher	than	
those	of	HCs	(30	(IQR	19–44)	ng/ml);	both	p	<	0.0001	and	p	<	0.001	respectively.	Patients	
without	MODS	also	had	significantly	higher	syndecan-1	concentrations	in	the	pre-hospital	
samples	(p	<	0.05)	but	not	in	the	in-hospital	samples	(p	=	0.216)	(Figure	3.4a).	
	
	
Figure	3.4.	Concentrations	of	(a)	syndecan-1	and	(b)	thrombomodulin	according	to	time	
point	and	development	of	multiple	organ	dysfunction	syndrome	(MODS).		
Healthy	controls	(HC)	are	displayed	for	comparison.		
*p	<	0.05;	**p	<	0.01;	***p	<	0.001;	****p	<	0.0001	vs.	HCs	
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Patients	with	MODS	had	significantly	higher	thrombomodulin	concentrations	at	the	
pre-hospital	(5.4	(IQR	4.0–7.1)	ng/ml	vs.	4.5	(IQR	3.4–5.9)	ng/ml;	p	<	0.05)	and	in-hospital	
(4.5	(IQR	3.6–5.5)	ng/ml	vs.	3.6	(IQR	2.9–4.5)	ng/ml;	p	<	0.01)	time	points.	For	patients	with	
MODS,	the	pre-	and	in-hospital	biomarker	levels	were	both	significantly	higher	than	those	of	
HCs	(2.9	(IQR	2.2–3.5)	ng/ml);	p	<	0.0001	for	both.	Patients	without	MODS	had	significantly	
higher	thrombomodulin	concentrations	in	the	pre-hospital	samples	(p	<	0.0001)	but	not	in	
the	in-hospital	samples	(p	=	0.065)	(Figure	3.4b)	
	
3.3.7.	 Changes	in	biomarkers	are	associated	with	MODS		
For	those	patients	with	both	pre-hospital	and	in-hospital	samples	(n=79),	42/79	
patients	developed	MODS.	These	included	31/42	(74%)	who	had	persistently	abnormal	
biomarkers,	8/42	(19%)	had	abnormal	pre-hospital	biomarkers	that	normalised,	and	3/42	
(7%)	had	normal	biomarkers	at	both	time	points;	p	<	0.05.		
When	patients	were	compared	according	to	dynamic	change	in	biomarkers,	MODS	
developed	in	31/50	(62%)	in	the	group	that	had	persistently	abnormal	biomarkers,	8/18	
(44%)	in	the	group	that	had	abnormal	biomarkers	that	returned	to	normal	range,	and	3/11	
(27%)	in	the	group	that	had	normal	biomarkers	throughout;	p	<	0.05	(Figure	3.5a).	When	
syndecan-1	and	thrombomodulin	were	examined	separately,	there	was	a	similarly	
significant	trend	for	MODS	according	to	both	biomarkers;	p	<	0.05	and	p	<	0.01	respectively	
(Figure	3.6).	
There	were	12	patients	who	died.	There	was	no	significant	difference	in	mortality	
within	groups	according	to	dynamic	changes	in	biomarkers;	9/50	with	persistently	abnormal	
biomarkers,	2/18	of	those	with	abnormal	biomarkers	that	returned	to	normal	range,	and	
1/11	of	those	with	normal	biomarkers	throughout	died;	p	=	0.652	(Figure	3.5b).		
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Figure	3.5.	Presence	of	(a)	multiple	organ	dysfunction	syndrome	(MODS)	and	(b)	90-day	
mortality	amongst	patients	according	to	dynamic	changes	in	levels	of	both	syndecan-1	
and	thrombomodulin	between	pre-hospital	and	in-hospital	time	points.		
Significance	is	indicated	according	to	chi-squared	test	for	trend.	
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Figure	3.6.	Presence	of	multiple	organ	dysfunction	syndrome	(MODS)	according	to	
dynamic	changes	in	individual	biomarker	levels	(a)	syndecan-1	and	(b)	thrombomodulin	
between	pre-hospital	and	in-hospital	time	points.		
Significance	is	indicated	according	chi-squared	test	for	trend.		
	
	
	
3.3.8.	 TXA	did	not	influence	biomarkers	of	endotheliopathy		
Of	all	patients,	there	were	55/91	who	received	pre-hospital	TXA,	35/91	did	not,	and	
one	patient	was	randomised	to	either	TXA	or	placebo	as	part	of	the	CRASH-3	study15.	There	
were	38	patients	with	abnormal	pre-hospital	syndecan-1,	of	which	23/38	received	TXA.	
There	were	no	differences	in	syndecan-1	concentration	at	either	time	point	according	to	
TXA	group	(Figure	3.7a).	There	were	43	patients	with	abnormal	pre-hospital	
thrombomodulin,	of	which	25/43	received	TXA.	There	were	similarly	no	differences	in	
thrombomodulin	concentrations	at	either	time	point	according	to	TXA	group	(Figure	3.7b).			
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Figure	3.7.	Pre-hospital	and	in-hospital	levels	of	syndecan-1	and	thrombomodulin	
according	to	whether	TXA	was	given	to	the	patient	during	the	pre-hospital	period.		
Vertical	bars	represent	95%	confidence	intervals	around	the	median.		
	
	
	
3.4.	 Discussion	
The	main	finding	of	this	study	is	that	trauma-induced	endotheliopathy	occurred	
within	minutes	of	injury,	and	failure	of	abnormal	biomarkers	to	return	to	normal	was	
associated	with	a	higher	burden	of	organ	dysfunction.	MODS	was	associated	with	higher	
syndecan-1	and	thrombomodulin	at	both	pre-hospital	and	in-hospital	time	points,	but	there	
was	no	association	between	delivery	of	TXA	and	biomarker	levels.	Endotheliopathy	is	likely	
to	occur	rapidly	following	injury,	with	observed	biomarker	levels	raised	at	17	minutes	within	
the	patient	cohort,	and	statistical	modeling	of	data	predicting	that	this	occurs	very	rapidly	
within	5	–	8	minutes	of	injury.	These	data	are	in	keeping	with	the	hypothesis	that	
endotheliopathy	is	a	common	mechanism7,	16,	and	may	partly	explain	why	phenomena	such	
as	TIC	and	inflammation	have	been	recorded	in	the	pre-hospital	environment	and	on	arrival	
of	patients	in	hospital.	These	data	are	also	in	keeping	with	previous	evidence	that	high	
Chapter	3	 	 Pre-hospital	endotheliopathy	of	trauma		
	 78	
syndecan-1	is	associated	with	poorer	outcomes	amongst	trauma	patients,	even	when	taken	
very	early	after	patient	admission	to	hospital17.			
These	observations	of	early	endotheliopathy	following	injury	are	in	keeping	with	the	
current	understanding	of	the	mechanisms	of	early	coagulopathy,	since	glycocalyx	shedding	
and	endothelial	cell	injury	stimulate	the	generation	of	thrombin	and	activation	of	protein	C,	
with	subsequent	hyperfibrinolysis18.	Since	inflammatory	derangement	following	cellular	
injury	may	also	be	associated	with	subsequent	sepsis19	and	organ	failure4,	early	reversal	of	
these	interconnected	processes	has	the	potential	to	improve	outcomes.	The	patients	that	
developed	MODS	in	this	study	came	from	the	same	cohort	that	showed	inflammatory	and	
immune	cell	dysregulation	in	our	previous	detailed	study	of	immune	function,	with	raised	
levels	of	IL-6,	IL-8,	and	TNFa at	both	pre-hospital	and	in-hospital	time	points	when	
compared	to	healthy	controls5.	Together,	these	data	support	the	hypothesis	that	there	is	an	
early	and	important	relationship	between	endothelial	injury	and	altered	immune	function	
following	trauma,	and	that	these	derangements	occur	within	minutes	of	injury.	Multiple	
studies	have	reported	independent	associations	between	high	injury	severity,	high	plasma	
adrenalin	level,	and	high	circulating	syndecan-1	and	thrombomodulin	levels,	suggesting	that	
sympathoadrenal	hyper-activation	following	shock	may	be	a	key	driving	factor	in	this	
process5.		
During	the	resuscitation	of	critically	unwell	trauma	patients,	lactate	has	been	shown	
to	be	a	useful	biomarker	of	perfusion	as	a	one-off	reading	and	also	in	terms	of	progression	
between	values	(as	lactate	clearance)20.	In	a	similar	manner,	one-off	individual	biomarkers	
of	endotheliopathy	are	presented	here,	but	also	progression	of	biomarkers	during	
resuscitation,	where	the	normalisation	of	biomarkers	are	taken	as	a	surrogate	marker	of	
endothelial	restoration.	In	the	current	study,	MODS	was	associated	with	persistent	
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endotheliopathy,	and	less	common	amongst	those	with	endothelial	biomarkers	that	
returned	to	normal	range.		Restoration	of	the	injured	endothelium	may	therefore	represent	
a	meaningful	clinical	target	for	goal-directed	therapy	during	pre-hospital	evacuation.	
Deliberate	targeting	of	endothelial	integrity	is	not	currently	undertaken	in	clinical	practice.	
Plasma-based	fluid	resuscitation	represents	one	possible	treatment	of	choice	for	patients	in	
this	context,	since	both	pre-clinical21	(discussed	later	in	Chapter	7)	and	clinical22	
investigations	have	reported	restoration	of	the	endothelial	glycocalyx	after	its	delivery.	The	
current	study	was	non-randomised,	and	patients	who	had	received	plasma	were	more	likely	
to	be	in	the	group	that	had	persistently	abnormal	biomarkers.	Although	there	were	no	
significant	differences	in	ISS	between	groups,	a	greater	requirement	for	blood	product	
transfusion	in	this	group	suggests	a	higher	number	of	patients	with	haemorrhagic	trauma.	A	
similar	selection	bias	has	also	been	reported	in	observational	studies	of	pre-hospital	blood	
products,	limiting	meaningful	clinical	interpretation23.	These	data	cannot	therefore	be	used	
to	determine	the	efficacy	of	plasma-based	resuscitation	in	the	mitigation	of	
endotheliopathy	of	trauma;	further	clinical	investigations	are	required	to	test	the	hypothesis	
that	plasma	may	allow	endothelial	restoration,	especially	if	randomised	controlled	trials	of	
pre-hospital	plasma-based	fluid	resuscitation	report	improved	clinical	outcomes.			
The	need	for	pre-hospital	research	has	been	emphasised	by	the	World	Health	
Organisation24	and	the	Institute	of	Medicine	of	the	National	Academies25,	and	may	enable	
questions	to	be	addressed	that	are	not	necessarily	answered	by	pre-clinical	studies26.	
Although	the	old	concept	of	the	“golden	hour”	may	not	have	as	much	of	a	bearing	on	
outcomes	as	it	was	first	supposed27,	it	appears	to	represent	a	time	during	which	a	cascade	
of	important	pathological	processes	occur	following	injury,	very	close	to	the	point	of	
wounding.	The	data	from	this	study	have	been	obtained	within	the	pre-hospital	period,	
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within	the	first	hour	following	injury.	Rather	than	waiting	until	arrival	in	hospital	to	attempt	
to	address	pathological	processes,	there	may	be	some	justification	for	working	towards	
earlier,	and	more	bespoke,	intervention	for	critically	unwell	patients28.	Such	an	approach	
has	already	been	advocated	in	terms	of	remote	damage	control	resuscitation29,	and	the	
consideration	of	the	endothelium	and	blood	together	as	an	“organ”	during	resuscitation	
following	trauma30.							
The	derangement	of	fibrinolysis	has	been	considered	as	a	target	for	trauma	
resuscitation	in	bleeding	patients,	such	as	with	tranexamic	acid31	and	fibrinogen	
concentrate32,	but	there	are	no	clinical	therapies	directly	targeting	the	restoration	of	the	
glycocalyx	or	endothelial	integrity.	We	were	unable	to	confirm	recent	in	vitro	findings	that	
early	delivery	of	TXA	can	reduce	the	burden	of	endotheliopathy	following	injury14,	33.	This	
may	be	due	to	the	observational	study	design,	and	the	heterogeneity	in	patient	injury	
patterns	and	severity,	as	shown	by	the	large	confidence	intervals	in	the	data.	Further	
investigation	may	be	warranted	on	a	larger	scale,	with	a	more	homogenous	population,	
using	randomisation	to	reduce	the	risk	of	selection	bias.		
More	than	half	of	patients	who	did	not	reverse	their	endotheliopathy	went	on	to	
develop	multiple	organ	failure.	Although	causality	cannot	be	demonstrated	in	the	current	
study,	the	relationship	is	in	keeping	with	previous	descriptions	of	early	inflammatory	
dysfunction	and	MODS4,	5.	The	reason	that	some	patients	have	biomarkers	that	are	restored	
to	normal	range	but	others	do	not	(or	indeed	why	some	have	normal	biomarkers	
throughout)	is	unknown.	There	was	evidence	that	plasma	lactate,	base	deficit	and	SBP	were	
significantly	different	between	these	groups,	which	suggests	that	the	degree	of	shock	and	
perfusion	may	be	related	to	endothelial	integrity	–	a	finding	supported	by	the	relationship	
between	biomarkers	and	plasma	lactate	in	the	current	study.	It	is	notable	that	although	this	
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association	was	statistically	significant,	the	correlation	was	not	perfect,	suggesting	that	
there	is	a	complex	relationship	between	perfusion	and	endothelial	integrity,	with	other	
confounding	factors	in	a	heterogeneous	trauma	population.	Further	mechanistic	studies	are	
required	to	investigate	the	precise	relationships	between	the	endothelium,	perfusion,	and	
subsequent	organ	function	following	trauma.			
It	is	likely	that	there	are	some	genetic	factors	in	the	ability	of	the	endothelium	to	
respond	to	trauma	and	resuscitation,	and	early	biomarkers	may	be	one	way	of	detecting	
these	predispositions.	Other	biomarkers	in	trauma	have	been	proposed	as	prognostic	
indicators34,	but	these	are	not	commonly	used	for	trauma	triage	or	goal-directed	therapy	in	
clinical	practice.	The	utilisation	of	such	biomarkers—including	those	that	may	indicate	
endotheliopathy—remains	a	tantalising	potential	avenue	for	future	trials.	If	strategies	to	
treat	the	endothelium	are	planned	in	the	future,	it	seems	that	early	treatment	(within	the	
pre-hospital	environment)	would	be	warranted	since	the	current	study	suggests	that	early	
restoration	of	the	endothelium	(within	12	hours)	is	associated	with	lower	morbidity.		
Presence	or	absence	of	endotheliopathy	may	be	an	important	stratification	in	future	
resuscitation	and	therapeutic	intervention	clinical	trials.	
	
3.4.1.	 Limitations	
The	current	study	is	limited	by	its	number	of	patients	when	analyzing	differences	in	
relatively	rare	occurrences	such	as	mortality;	although	there	appears	to	be	a	non-survival	
trend	in	the	same	direction	as	MODS,	this	was	not	found	to	be	statistically	significant.	Not	
all	patients	had	samples	available	from	both	time	points.	These	patients	were	excluded	
during	subgroup	analysis,	which	gives	potential	risk	of	selection	bias.	The	style	of	
opportunistic	study	enrolment	during	pre-hospital	evacuation	makes	the	study	at	risk	of	
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selection	bias,	since	only	a	proportion	of	eligible	patients	were	recruited	into	the	study.	This	
risk	was	reduced	by	the	maintenance	of	a	screening	log	to	ensure	that	“missed”	patients	
were	not	significantly	different	in	demographics	and	injury	patterns	than	included	patients.		
	 The	statistical	modeling	performed	to	evaluate	the	timing	of	endotheliopathy	should	
be	considered	as	an	estimation	only,	since	it	requires	several	assumptions	that	have	the	
potential	to	be	biased;	it	was	assumed	that	patients	had	similar	biomarkers	to	HCs	prior	to	
injury,	and	that	biomarker	levels	above	the	97.5th	percentile	of	HCs	represented	the	
development	of	endotheliopathy.	These	assumptions	were	required	for	a	pragmatic	
estimation,	since	time-of-injury	sampling	is	unlikely	to	be	ethically	justifiable	or	logistically	
realised.	Furthermore,	as	mentioned	in	Chapter	2,	it	is	not	known	whether	some	of	this	
elevation	in	biomarker	concentration	represents	a	useful	inflammatory	response	to	trauma	
(i.e.	non-pathological).		
	 Dividing	patients	into	“abnormal-abnormal”,	“abnormal-normal”	and	“normal-
normal”	(as	described	in	Table	3.3)	is	likely	to	be	an	over-simplification,	and	ought	to	be	
considered	exploratory	analysis	only.	Although	on	univariate	analysis	there	did	not	appear	
to	be	a	difference	in	ISS	between	groups,	no	meaningful	multivariate	analysis	could	be	
performed	to	determine	whether	the	changes	in	biomarkers	were	indeed	related	to	injury	
burden.	Further	investigations	of	biomarkers	and	their	relationships	to	injury	and	
treatments	in	the	pre-hospital	domain	may	facilitate	a	greater	understanding	of	their	
relationships.				
	 There	were	no	pre-hospital	blood	products	available	in	the	trauma	network	in	which	
this	study	took	place,	and	patients	were	given	0.9%	saline	if	they	required	fluid	resuscitation	
during	pre-hospital	treatment	and	evacuation.	Trauma	patients	during	this	study	period	
were	given	a	medium	of	750ml	of	0.9%	saline	according	to	a	recent	large	collaborative	study	
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that	I	designed	and	facilitated35.	It	is	currently	unknown	what	influence	pre-hospital	
crystalloid	fluids	may	have	on	the	endothelium,	or	on	the	concentration	of	endothelial	
biomarkers	when	compared	to	blood	products.	Furthermore,	it	is	unknown	what	influence	
the	type	of	resuscitation	fluid	may	have	on	the	development	of	MODS,	or	the	duration	of	
shock	in	humans.	Although	these	questions	will	be	further	explored	in	Chapter	7	of	this	
thesis	for	pre-clinical	(animal)	models	of	haemorrhagic	shock,	there	are	very	limited	data	for	
humans.	These	questions	may	be	further	addressed	in	a	clinical	context	by	investigating	
biomarkers	and	outcomes	in	patients	who	have	been	randomized	to	crystalloid	fluids	or	
blood	products	in	the	pre-hospital	period,	such	as	those	patients	enrolled	in	the	RePHILL	
trial36.	
	 The	reliability	of	out-of-hospital	blood	samples	has	been	questioned	in	simulations	
of	“pre-hospital”	delay37,	which	has	the	potential	to	bias	results	based	on	time	difference	
between	sampling	and	arrival	hospital.	Since	this	was	a	pragmatic,	real-life	study,	such	a	risk	
may	exist,	but	was	kept	to	a	minimum	by	maintaining	strict	and	consistent	preparation	
techniques	as	soon	as	the	sample	was	received.	The	interquartile	range	of	times	that	the	
second	blood	samples	were	taken	was	4.2h	–	10.5h.	The	study	used	a	pragmatic	target	of	
sampling	between	4	–	12h	in	order	to	facilitate	blood	sampling	for	patients	without	
interfering	with	clinical	activities.	However,	such	a	range	in	timescales	puts	this	time	point	at	
some	risk	of	bias	due	to	variations	in	interventions	may	have	occurred	during	that	period	
between	patients.		
	
3.5.	 Conclusion	
Endothelial	cell	injury	and	glycocalyx	shedding	were	observed	within	minutes	
following	injury,	and	that	statistical	modeling	predicted	that	this	may	occur	at	
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approximately	5–8	minutes.	Failure	to	reverse	pre-hospital	endotheliopathy	is	associated	
with	poorer	clinical	outcome	in	terms	of	multiple	organ	dysfunction	syndrome.	Biomarker	
dynamics	did	not	appear	to	be	related	to	injury	severity	as	defined	by	anatomic	injuries	in	
the	ISS.	In	our	non-randomised	study,	TXA	was	not	associated	with	reduced	levels	of	
biomarkers	of	endotheliopathy.	These	findings,	together	with	other	reports	of	early	
coagulopathy	and	inflammatory	dysregulation,	suggest	that	early	interventions	aimed	at	
restoration	of	the	endothelium	may	represent	a	clinically	meaningful	target	for	
resuscitation.	The	most	appropriate	treatment	for	this	purpose	in	the	clinical	context	
remains	uncertain.				
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4.1.	 Introduction	
In	the	previous	two	chapters	we	have	seen	that	endotheliopathy	occurs	very	early	
after	injury,	and	is	associated	with	both	poor	microcirculatory	flow	and	subsequent	organ	
failure.	In	this	chapter,	further	analysis	was	performed	on	the	blood	samples	of	patients	in	
both	of	these	study	cohorts	in	order	to	determine	whether	there	was	a	relationship	
between	those	endothelial	biomarkers	and	levels	of	cell-free	deoxyribonucleic	acid	
(cfDNA)—a	potential	aetiological	factor	in	their	observed	endotheliopathy	and	
microcirculatory	dysfunction.			
cfDNA	is	defined	as	extracellular	DNA	present	within	the	circulation.	It	consists	of	a	
combination	of	nuclear	and	mitochondrial	DNA	(mtDNA)	that	enters	the	circulation	
following	cell	necrosis1,	tissue	injury,	and	the	generation	of	extracellular	traps	by	activated	
immune	cells	such	as	neutrophils2	and	monocytes3.	cfDNA	may	be	elevated	due	to	bacterial	
infection,	and	mtDNA	shares	structural	similarities	with	pathogen–associated	molecular	
patterns	(such	as	those	derived	from	bacteria).	These	fragments	may	therefore	activate	the	
innate	immune	response	following	aseptic	injury,	and	contribute	in	part	to	the	systemic	
inflammatory	response	observed	following	trauma4-7.	The	presence	of	cfDNA	may	also	give	
rise	to	hypercoagulability	by	coagulation	factor	activation,	platelet	aggregation,	and	
inhibition	of	fibrinolysis8,	9,	whilst	neutrophil	extracellular	traps	(NETs)	may	cause	further	
tissue	injury	and	endothelial	barrier	dysfunction10.	cfDNA	has	received	interest	as	a	
biomarker	following	injury	in	relation	to	mortality1,	11,	organ	failure12,	inflammation2,	and	
sepsis13.		
Syndecan-1	and	thrombomodulin	have	been	reported	as	biomarkers	of	endothelial	
cell	and	glycocalyx	injury	in	multiple	recent	studies	of	trauma14-16,	and	as	described	in	the	
previous	chapters.	The	former	is	a	transmembrane	heparan	sulfate	proteoglycan	that	forms	
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part	of	the	endothelial	glycocalyx,	and	the	latter	is	an	integral	membrane	protein	present	on	
the	surface	of	endothelial	cells	throughout	the	circulation.	Raised	levels	of	these	biomarkers	
are	associated	with	coagulopathy14,	15,	17,	18,	inflammation15,	poor	microcirculatory	flow	(as	
seen	in	Chapter	2)19,	organ	failure	(as	seen	in	Chapter	3)20,	and	mortality15-17.		
Experimental	models	have	demonstrated	that	mtDNA	directly	increases	endothelial	
permeability	through	both	neutrophil-independent	and	dependent	pathways21,	and	that	it	
may	induce	a	pro-thrombotic	phenotype	within	the	endothelium22.	These	findings	suggest	
that	there	is	likely	to	be	a	relationship	between	cfDNA	and	endotheliopathy,	and	that	each	
may	be	mutually	detrimental	to	the	other.	Indeed,	there	is	some	pre-clinical	evidence	that	
endothelial	cell	damage	by	cfDNA	is	dose-dependent23.	Other	investigators	have	reported	
an	association	between	endotheliopathy	and	elevation	of	cfDNA	levels	on	admission	to	
hospital	following	injury15,	24,	25,	but	to	our	knowledge	this	has	not	been	investigated	within	
the	pre-hospital	period	following	trauma.		
The	current	study	aimed	to	investigate	the	levels	of	cfDNA	and	biomarkers	of	
endotheliopathy	following	injury	in	a	prospective	cohort	of	trauma	patients,	and	whether	
these	biomarkers	were	associated	with	each	other	over	time,	from	the	pre-hospital	period	
to	hospital	admission.	We	also	aimed	to	investigate	whether	there	was	an	association	
between	levels	of	cfDNA	and	clinical	outcomes,	and	with	markers	of	coagulopathy.		
It	was	hypothesised	that	higher	levels	of	biomarkers	of	endotheliopathy	would	be	
associated	with	higher	levels	of	cfDNA,	that	this	would	be	true	even	within	the	first	hour	of	
injury,	and	that	there	would	be	an	association	with	markers	of	coagulopathy.	We	further	
hypothesised	that	an	increase	or	decrease	over	time	in	each	biomarker	would	be	associated	
with	the	same	directional	changes	in	the	others,	and	that	raised	cfDNA	levels	would	be	
associated	with	poorer	clinical	outcomes	(Hypothesis	5;	Table	1.1).	We	hypothesised	that	
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patients	who	received	a	blood	transfusion	or	had	surgery	would	have	increased	levels	of	
cfDNA	when	compared	to	those	who	did	not.		
	
4.2.	 Methods	
4.2.1.	 Study	design	and	setting	
The	current	study	combines	patients	from	two	prospective	longitudinal	
observational	studies	conducted	at	a	single	Major	Trauma	Centre	site	in	the	UK	(University	
Hospitals	Birmingham	NHS	Foundation	Trust,	Birmingham);	these	included	patients	from	the	
Brain	Biomarkers	after	Trauma	(BBATS)20	(REC	reference:	13/WA/0399)	(Chapter	3)	and	
MICROSHOCK19,	26	(REC	reference:	14/YH/0078)	(Chapter	2)	studies.	The	former	study	
(Cohort	A)	included	patients	with	a	predicted	ISS	>8,	regardless	of	mechanism	of	injury	or	
blood	product	requirement	between	May	2014	and	February	2017,	and	also	includes	the	
patients	with	isolated	traumatic	brain	injury	that	were	otherwise	excluded	in	Chapter	3.	The	
latter	(Cohort	B)	included	patients	with	traumatic	haemorrhagic	shock	requiring	blood	
product	transfusion,	with	a	lactate	>	2	mmol/l,	and	a	requirement	for	admission	to	Intensive	
Care	between	July	2015	and	January	2017.		
	
4.2.2.	 Capacity	and	consent	
As	described	in	the	previous	two	chapters,	all	patients	lacked	capacity	to	consent	for	
study	participation	at	the	time	of	study	enrolment,	and	enrolment	was	undertaken	
according	to	the	Mental	Health	Act	2005	and	the	Declaration	of	Helsinki.	Both	the	
MICROSHOCK	and	BBATS	studies	were	approved	to	gain	consent	to	participate	from	a	
Professional	or	Personal	Consultee.	Ultimately,	if	the	patient	regained	capacity,	they	were	
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asked	for	consent	to	remain	within	the	study,	and	for	their	previous	data	to	be	retained.	If	
they	did	not	regain	capacity,	then	previous	permissions	from	their	Professional	or	Personal	
Consultee	remained	extant.							
	
4.2.3.	 Study	time	points	
	 Patients	in	Cohort	A	all	had	blood	sampled	within	the	first	1	hour	of	injury	by	pre-
hospital	personnel	(median	time	44	(range	14–60)	minutes).	They	then	had	a	further	sample	
taken	between	4–12	hours	following	injury.	Patients	in	Cohort	B	had	blood	sampled	as	soon	
as	possible	following	admission	to	hospital,	with	a	median	time	to	sample	of	3.5	(range	1–
16)	hours.	For	the	purposes	of	the	current	study,	two	time	points	were	investigated,	as	
illustrated	in	Figure	4.1:	(i)	Pre-hospital	(<	1	hour)	(Cohort	A	only);	and	(ii)	the	first	day	of	
admission	to	hospital	(1–16h)	(Cohorts	A	and	B	combined).			
	
4.2.4.	 Blood	sampling	and	preparation	
All	patients	underwent	venepuncture	to	obtain	blood	samples	for	research	purposes	
using	BD	Vacutainers	(Becton	Dickinson,	Oxford,	UK).	For	the	current	study,	patients	had	
already	had	serum	samples	prepared	for	measurement	of	endothelial	biomarkers,	as	
described	in	Chapters	2	and	3	(collected	into	vacutainers	containing	z-serum	clotting	
activator,	and	then	centrifuged	for	10	minutes	at	1,620	x	g	after	30	minutes	at	room	
temperature).	Paired	plasma	samples	that	corresponded	to	the	same	patient	time	points	
were	prepared	for	the	measurement	of	cfDNA	levels	in	the	current	study.	For	these	
samples,	blood	had	been	collected	into	vacutainers	containing	a	1/10	volume	of	3.2%	
trisodium	citrate.	After	30	minutes	at	room	temperature,	they	were	centrifuged	twice	in	
order	to	minimise	platelet	contamination.	First,	samples	were	centrifuged	for	20	minutes	at	
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2,000	x	g,	then	the	top	two	thirds	of	fluid	were	spun	again	for	2	minutes	at	13,000	x	g.	All	
centrifugation	was	performed	at	4oC.	Only	patients	with	paired	serum	and	plasma	samples	
could	be	included	in	the	current	study	(the	former	for	endothelial	biomarkers	and	the	latter	
for	cfDNA	levels).		
	
Figure	4.1.	Flow	diagram	of	study	patients	and	samples	available	for	analysis.			
	
	
4.2.5.	 Measurement	of	endothelial	biomarkers	
The	concentrations	of	thrombomodulin	(CD	141)	and	syndecan-1	(CD	138)	in	serum	
samples	were	quantified	using	commercially	available	enzyme-linked	immunosorbent	assay	
kits	(Abcam,	Cambridge,	MA)	in	precise	accordance	with	manufacturer	instructions,	as	
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described	in	detail	in	Chapter	2.	Each	96	well	plate	included	a	standard	curve	to	interpolate	
the	concentrations	of	biomarkers,	as	well	as	blank	and	control	wells	to	validate	the	results.		
	
4.2.6.	 Measurement	of	cell-free	DNA		
In	order	to	measure	the	cfDNA	concentration	in	plasma	samples,	a	fluorometric	
assay	using	SYTOX®	Green	Dye	(Life	Technologies,	Cheshire,	UK)	was	used	as	described	
previously	13.	For	each	plate,	a	standard	curve	was	generated	using	samples	of	λ-DNA	
(Fisher	Scientific,	UK)	ranging	from	0–1000	ng/ml.	To	ensure	that	the	assay	was	reliable	
between	samples	and	assays,	the	inter-assay	and	intra-assay	coefficients	of	variation	were	
calculated;	these	were	5.3%	and	5.1%	respectively.	140	µl	of	SYTOX®	Green	Dye	(Final	
concentration	1	µM)	was	added	to	10	µl	of	plasma,	and	incubated	for	10	minutes	at	room	
temperature	in	the	dark.	All	samples	were	run	in	duplicate.	Fluorescence	was	then	
measured	using	a	BioTek	Synergy	2	fluorometric	plate	reader	(NorthStar	Scientific	Ltd,	UK).	
Calibration	was	set	at	485	nm	and	528	nm	for	excitation	and	emission	respectively.	The	
average	values	of	the	duplicate	wells	were	then	used	to	derive	cfDNA	concentrations	by	
interpolating	from	the	standard	curve.		
	
4.2.7.	 Data	collection	
Demographic	and	clinical	data	were	obtained	prospectively	for	all	patients	using	a	
combination	of	electronic	medical	records	and	bedside	medical	notes.	Data	included	age,	
sex,	comorbidities,	body	mass	index	(BMI),	smoking	and	alcohol	status,	injury	severity	score	
(ISS),	mechanism	of	injury,	lactate,	systolic	blood	pressure,	heart	rate	(HR),	international	
normalised	ratio	(INR),	partial	thromboplastin	time	(PTT)	ratio,	and	Glasgow	Coma	Scale	
(GCS).	A	Charlson	Comorbidity	Index	was	calculated	for	all	patients	based	on	the	presence	
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of	comorbidities.	Since	it	is	possible	that	blood	transfusion	might	also	increase	levels	of	
cfDNA	in	transfused	patients	due	to	the	cfDNA	within	donated	blood	products27,	patients	
who	had	been	transfused	between	time	points	were	recorded.	Similarly,	since	surgery	may	
also	increase	levels	of	cfDNA	due	to	direct	injury,	patients	who	had	surgery	between	time	
points	were	noted.		
	
4.2.8.	 Outcomes	
	 Outcomes	included	30-day	mortality,	thromboembolic	events,	as	well	as	hospital-
free	and	ICU-free	days	(calculated	as	30	minus	the	number	of	days	in	hospital	and	ICU	
respectively).			
	
4.2.9.	 Data	analysis	
Normality	of	data	was	tested	using	the	Shapiro-Wilk	test.	Continuous	data	are	
presented	as	mean	and	standard	deviation	(SD)	for	normal	data,	and	median	and	
interquartile	range	(IQR)	for	non-normal	data.	Categorical	data	are	presented	as	N	(%).	
Continuous	data	are	compared	using	t-tests	for	normal	data	and	Mann-Whitney	U	tests	for	
non-normal	data	as	appropriate.	Categorical	data	are	compared	using	Fisher’s	exact	tests.	
Correlations	have	been	tested	using	Spearman’s	rank	correlation	co-efficient.	The	
relationships	between	cfDNA	and	endothelial	biomarkers	were	examined	at	both	time	
points	using	multivariable	linear	regression	models	that	included	the	covariates	of	gender,	
age,	ISS,	GCS,	lactate,	SBP,	and	HR.	These	covariates	were	pre-specified	before	data	analysis,	
on	the	basis	of	clinical	suspicion	that	they	may	be	confounding	variables.	In	order	to	
determine	whether	levels	of	endothelial	biomarkers	followed	the	same	directional	change	
as	cfDNA	between	time	points,	a	model	was	fitted	to	examine	the	value	of	cfDNA	at	the	
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second	time	point	as	a	function	of	the	change	in	Syndecan-1	and	thrombomodulin	values,	
modified	by	other	covariates	(gender,	age,	ISS,	GCS,	lactate,	SBP,	and	HR)	and	the	value	of	
cfDNA	at	the	first	time	point.	A	p-value	of	<	0.05	was	considered	significant.	Analyses	were	
performed	using	R	version	3.2.2	(http://www.r-project.org)	and	GraphPad	Prism	version	7.0	
(GraphPad	Software,	California,	USA).		
	
4.3.	 Results	
4.3.1.	 Patient	characteristics	
There	were	122	patients	included	(105	from	Cohort	A	and	17	from	Cohort	B),	with	a	
mean	age	of	41	(SD	19)	and	median	ISS	of	25	(IQR	12–34).	A	flow	diagram	of	patients	and	
available	cfDNA	at	each	time	point	is	illustrated	in	Figure	4.1.	Five	of	the	patients	in	Cohort	A	
did	not	have	sufficient	plasma	and	serum	samples	at	the	pre-hospital	time	point	for	
comparison	between	biomarkers,	making	the	denominator	for	the	pre-hospital	time	point	
N=100.	There	were	a	further	12	patients	in	Cohort	A	that	had	insufficient	samples	for	the	
second	time	point,	making	the	denominator	for	the	in-hospital	time	point	N=110	(N=93	
from	Cohort	A,	and	N=17	from	Cohort	B).	There	were	therefore	88	patients	with	samples	
from	both	time	points	in	Cohort	A.					
The	patient	demographic	and	injury-related	details	are	shown	in	Table	4.1,	and	are	
compared	between	the	two	cohorts.	Patients	in	Cohort	B	had	worse	physiological	
parameters	for	haemodynamic	shock	and	coagulopathy	when	compared	to	Cohort	A,	with	
lower	median	SBP	(90	vs.	114;	p	=	0.0002)	and	HR	(105	vs.	87;	p	=	0.0004),	as	well	as	higher	
INR	and	PTT	ratio	(both	p	=	0.020).	Otherwise	their	demographic	and	injury	patterns	were	
not	significantly	different	between	cohorts.	Cohort	B	had	a	significantly	lower	number	of	
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ICU-free	days	than	those	in	Cohort	A	(8	vs.	22;	p	=	0.003),	but	there	were	no	significant	
differences	in	other	outcomes	between	groups.	
	
	
Table	4.1.	Patient	characteristics	according	to	patient	cohort	
Characteristic	
All	
(N=122)	
Cohort	A	
(N=105)	
Cohort	B	
(N=17)	 p-value	
Age,	mean	(SD)	 41	(19)	 41	(20)	 40	(18)	 0.816	
Male,	N	(%)	 108	(87)	 90	(86)	 16	(94)	 0.466	
BMI,	median	(IQR)	 25	(23–28)	 25	(23–28)	 25	(22–29)	 0.891	
Smoker,	N	(%)	 55	(45)	 47	(45)	 8	(47)	 >0.999	
Alcohol	intoxication,	N	(%)	 19	(16)	 19	(18)	 0	(0)	 0.071	
Co-morbidities	 	 	 	 	
								N	(%)	 26	(21)	 23	(22)	 3	(18)	 >0.999	
								CCI,	median	(range)	 0	(0–5)	 0	(0–5)	 0	(0–4)	 0.814	
ISS,	median	(IQR)	 25	(12–34)	 24	(10–36)	 27	(17–34)	 0.446	
Injury	mechanism,	N	(%)	 	 	 	 	
								Blunt	 101	(81)	 86	(82)	 13	(76)	 0.738	
								Penetrating	 23	(19)	 19	(18)	 4	(24)	 	
GCS,	median	(IQR)	 12	(4–15)	 13	(4–15)	 9	(3–14)	 0.232	
Lactate	(mmol/l),	median	(IQR)	 3.7	(2.5–6.4)	 3.5	(2.5–6.3)	 6.0	(3.6–10.2)	 0.071	
SBP	(mmHg),	median	(IQR)	 111	(97–122)	 114	(99–124)	 91	(61–108)	 0.0002*	
HR	(min-1),	median	(IQR)	 89	(79–100)	 87	(76–99)	 108	(98–118)	 0.0004*	
INR,	median	(IQR)	 1.1	(1.0–1.2)	 1.1	(1.0–1.2)	 1.2	(1.1–1.2)	 0.020*	
PTT	ratio,	median	(IQR)	 0.9	(0.8–1.0)	 0.9	(0.8–0.9)	 0.9	(0.9–1.1)	 0.020*	
Outcomes	 	 	 	 	
								Hospital-free	days,	median	(IQR)	 6	(0–20)		 8	(0–20)	 0	(0–5)	 0.097	
								ICU-free	days,	median	(IQR)		 20	(8–29)	 22	(10–29)	 8	(0–18)	 0.003*	
								Mortality,	n	(%)	 19	(16)	 16	(15)	 3	(18)	 0.728	
								PE,	n	(%)	 1	(0.8)	 1	(1.0)	 0	(0)	 >0.999	
All	continuous	data	are	presented	as	either	mean	or	median,	with	standard	deviation	or	
interquartile	range	in	parentheses	respectively,	as	indicated	(with	the	exception	that	Charlson	
Comorbidity	Index	is	shown	with	range	in	parentheses);	categorical	data	are	presented	as	N,	with	
percentage	in	parentheses.		
*Significant	according	to	Mann-Whitney	test	
BMI:	body	mass	index;	CCI:	Charlson	Comorbidity	Index;	ISS:	injury	severity	score;	GCS:	Glasgow	
Coma	Scale;	SBP:	systolic	blood	pressure;	HR:	heart	rate;	INR:	international	normalised	ratio;	PTT:	
partial	thromboplastin	time;	ICU:	Intensive	Care	Unit;	PE:	pulmonary	embolism	
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When	patients	who	received	blood	product	transfusion	were	compared	to	those	
with	no	transfusion,	they	had	a	higher	median	lactate	(6.2	mmol/l	vs.	3.2	mmol/l;	p	<	
0.0001),	lower	median	SBP	(93	mmHg	vs.	116	mmHg;	p	<	0.0001),	and	higher	median	HR	(97	
min-1	vs.	87	min-1;	p	=	0.018)	(Table	4.2).	Although	the	transfused	group	had	a	higher	median	
ISS	than	the	non-transfused	group,	this	did	not	reach	statistical	significance.	
	
Table	4.2.	Patient	characteristics	according	to	requirement	for	transfusion	
Characteristic	
All	
(N=122)	
Received	
transfusion	
(N=31)	
No	transfusion	
(N=91)	 p-value	
Age,	mean	(SD)	 41	(19)	 43	(21)	 41	(19)	 0.503	
Male,	n	(%)	 108	(87)	 27	(87)	 79	(87)	 >0.999	
ISS,	median	(IQR)	 25	(12–34)	 27	(16–43)	 23	(10–30)	 0.061	
Injury	mechanism,	n	(%)	 	 	 	 	
								Blunt	 101	(81)	 23	(74)	 76	(84)	
0.290	
								Penetrating	 23	(19)	 8	(26)	 15	(16)	
GCS,	median	(IQR)	 12	(4–15)	 10	(3–14)	 13	(4–15)	 0.133	
Lactate	(mmol/l),	median	(IQR)	 3.7	(2.5–6.4)	 6.2	(4.0–9.5)	 3.3	(2.3–5.1)	 <0.0001*	
SBP	(mmHg),	median	(IQR)	 111	(97–122)	 93	(69–109)	 116	(103–124)	 <0.0001*	
HR	(min-1),	median	(IQR)	 89	(79–100)	 97	(81–115)	 87	(76–99)	 0.018*	
All	continuous	data	are	presented	as	mean	or	median,	with	standard	deviation	or	interquartile	range	
in	parentheses	respectively;	categorical	data	are	presented	as	N,	with	percentage	in	parentheses.		
*Significant	according	to	Mann-Whitney	test	
ISS:	injury	severity	score;	GCS:	Glasgow	Coma	Scale;	SBP:	systolic	blood	pressure;	HR:	heart	rate	
	
4.3.2.	 Association	between	endothelial	biomarkers	and	cfDNA	
When	samples	were	analysed	at	each	specific	time	point	(N=100	for	pre-hospital,	
and	N=110	for	1–16h	time	points),	there	were	significant	correlations	between	cfDNA	and	
both	syndecan-1	and	thrombomodulin	at	both	time	points	(Figure	4.2).		When	Cohorts	A	
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and	B	were	individually	analysed,	there	were	similarly	significant	correlations	between	
cfDNA	concentration	and	concentrations	of	syndecan-1	and	thrombomodulin	(all	p	<	0.05).		
When	the	covariates	of	gender,	age,	GCS,	lactate,	SBP,	HR,	and	ISS	were	compared	to	all	
biomarkers	using	univariate	analyses	(Table	4.3),	pre-hospital	syndecan-1	was	significantly	
associated	with	lactate	(R2	=	0.084;	p	=	0.004)	and	SBP	(R2	=	0.040;	p	=	0.045),	and	pre-
hospital	cfDNA	was	significantly	associated	with	ISS	(R2	=	0.098;	p	=	0.002).	In-hospital	
syndecan-1	was	significantly	associated	with	lactate	(R2	=	0.198;	p	<	0.0001)	and	SBP	(R2	=	
0.100;	p	=	0.001);	in-hospital	cfDNA	was	significantly	associated	with	GCS	(R2	=	0.051;	p	=	
0.016)	and	ISS	(R2	=	0.86;	p	=	0.002);	in-hospital	thrombomodulin	was	associated	with	
lactate	(R2	=	0.094;	p	=	0.001).		
	
Table	4.3.	Univariate	analyses	of	covariates	
Covariate		
Goodness	of	Fit	
Prehospital	 	 In-hospital	
cfDNA	 SD-1	 TM	 	 cfDNA	 SD-1	 TM	
	 	 	 	 	 	 	 	
Age	
R2	 0.006	 0.036	 <0.0001	 	 <0.0001	 0.001	 0.005	
p-value	 0.432	 0.055	 0.969	 	 0.833	 0.778	 0.472	
	 	 	 	 	 	 	 	 	
GCS	
R2	 0.032	 0.011	 0.003	 	 0.051	 0.008	 0.015	
p-value	 0.069	 0.297	 0.613	 	 0.016*	 0.356	 0.197	
	 	 	 	 	 	 	 	 	
Lactate	
R2	 0.006	 0.084	 0.017	 	 0.032	 0.198	 0.094	
p-value	 0.455	 0.004*	 0.201	 	 0.064	 <0.0001*	 0.001*	
	 	 	 	 	 	 	 	 	
SBP	
R2	 0.014	 0.040	 <0.0001	 	 0.031	 0.100	 0.027	
p-value	 0.242	 0.045*	 0.905	 	 0.063	 0.001*	 0.085	
	 	 	 	 	 	 	 	 	
HR	
R2	 <0.0001	 0.003	 0.001	 	 0.018	 0.027	 <0.0001	
p-value	 0.913	 0.579	 0.806	 	 0.16	 0.082	 0.898	
	 	 	 	 	 	 	 	 	
ISS	
R2	 0.098	 0.011	 0.001	 	 0.086	 0.002	 0.029	
p-value	 0.002*	 0.314	 0.809	 	 0.002*	 0.679	 0.081	
	 	 	 	 	 	 	 	 	
cfDNA:	cell	free	DNA;	SD-1:	syndecan-1;	TM:	thrombomodulin;	GCS:	Glasgow	Coma	Scale;	SBP:	
systolic	blood	pressure;	HR:	heart	rate;	ISS:	injury	severity	score.	
*Indicates	statistically	significant	using	linear	regression	
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	 Using	multivariable	linear	regression,	the	relationships	between	cfDNA	and	both	
syndecan-1	and	thrombomodulin	were	independent	of	gender,	age,	GCS,	lactate,	SBP,	and	
HR.	However,	there	was	an	additional	significant	relationship	between	ISS	and	cfDNA.	The	
modelled	relationship	between	cfDNA	and	syndecan-1	at	increasing	ISS	values	can	be	
visualised	in	Figure	4.3.							
	
4.3.3.	 Blood	transfusion	and	surgery	 	
When	patients	were	divided	into	those	who	had	surgery	in	between	time	points	and	
those	that	did	not,	there	were	43/122	(35%)	patients	who	had	surgery.	There	were	no	
significant	differences	in	cfDNA,	syndecan-1,	or	thrombomodulin	levels	at	either	baseline	or	
at	the	second	time	point	between	those	who	had	surgery	between	time	points	and	those	
who	did	not	(Table	4.4).		
When	patients	were	divided	into	those	who	had	blood	transfusion	in	between	time	
points	and	those	who	did	not,	there	were	31/122	(25%)	who	were	transfused.	There	were	
no	significant	differences	in	cfDNA,	syndecan-1,	or	thrombomodulin	levels	between	groups	
at	baseline	(Table	4.5).	After	blood	product	transfusion	in	ED,	there	were	no	differences	in	
cfDNA	or	thrombomodulin	between	the	transfused	and	non-transfused	groups,	but	there	
was	a	significantly	higher	concentration	of	syndecan-1	amongst	the	transfused	group	(107	
ng/ml	vs.	43	ng/ml;	p	=	0.0005)	(Table	4.5).	
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Figure	4.2.	Association	between	(a)	syndecan-1	and	(b)	thrombomodulin	and	cell-free	DNA	
(cfDNA)	according	to	time	points.	P-values	are	indicated	according	to	Spearman’s	rank	
correlation	coefficient.	For	both	concentrations	of	(a)	syndecan-1	and	(b)	thrombomodulin,	
there	is	a	significant	correlation	with	concentration	of	cfDNA	at	both	time	points.	
	
	
	
	
	 	
Chapter	4	 	 Cell-free	DNA	and	endotheliopathy	
	 103	
Figure	4.3.		Relationship	between	cell-free	DNA	and	syndecan-1	at	(a)	first	(pre-hospital)	
time	point	and	(b)	second	(in-hospital)	time	point,	according	to	category	of	increasing	
injury	severity.	Solid	lines	represent	the	mean	predicted	values	(based	on	the	fitted	model),	
and	the	shaded	areas	represent	the	range	of	values	covered	by	the	95%	confidence	intervals	
associated	with	those	predicted	values.	
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Table	4.4.	Biomarker	concentrations	at	both	time	points	compared	between	patients	that	
had	surgery	between	time	points	and	those	who	did	not.	
Biomarker	
Had	surgery	
(N=43)	
No	surgery	
(N=79)	 p-value	
Pre-hospital	biomarkers,	ng/ml	 	 	 	
													cfDNA	 558	(384–956)	 817	(422–2442)	 0.132	
													Syndecan-1	 49	(35–118)	 59	(33–136)	 0.700	
													Thrombomodulin	 4.3	(3.4–6.2)		 4.7	(3.7–6.3)	 0.508	
1-16h	biomarkers,	ng/ml	 	 	 	
													cfDNA	 411	(233–1141)	 457	(368–609)	 0.231	
													Syndecan-1	 65	(37–197)	 46	(26–111)	 0.110	
													Thrombomodulin	 4.0	(3.5–5.4)	 3.7	(3.0–4.6)	 0.087	
All	summary	data	are	presented	as	median,	with	interquartile	range	in	parentheses.	
cfDNA:	cell-free	DNA	
		
	
	
Table	4.5.	Biomarker	concentrations	at	both	time	points	compared	between	patients	that	
received	a	blood	transfusion	and	those	who	did	not.	
Biomarker	
Received	transfusion	
(N=31)	
No	transfusion	
(N=91)	 p-value	
Pre-hospital	biomarkers,	ng/ml	 	 	 	
													cfDNA	 828	(379–3174)		 645	(410–1839)	 0.501	
													Syndecan-1	 109	(35–281)	 50	(34–118)	 0.095	
													Thrombomodulin	 5.7	(3.5–7.1)	 4.4	(3.6–5.9)	 0.248	
1-16h	biomarkers,	ng/ml	 	 	 	
													cfDNA	 466	(299–1790)	 433	(346–570)	 0.191	
													Syndecan-1	 107	(43–256)	 43	(25–89)	 0.0005*	
													Thrombomodulin	 4.1	(3.5–5.2)	 3.7	(2.9–4.7)	 0.073	
All	summary	data	are	presented	as	median,	with	interquartile	range	in	parentheses.	
	*Significant	according	to	Mann-Whitney	test	
cfDNA:	cell-free	DNA	
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4.3.4.	 Biomarkers	and	coagulopathy	
	 Table	4.6	shows	the	correlations	between	the	three	biomarkers	(cfDNA,	syndecan-1,	
and	thrombomodulin)	at	both	time	points,	and	both	admission	INR	and	PTT	ratios.	
Syndecan-1	levels	were	significantly	correlated	with	INR	and	PTT	ratios	at	both	the	pre-
hospital	(p	=	0.036	and	p	=	0.002	respectively)	and	in-hospital	(p	=	0.010	and	p	<	0.0001	
respectively)	time	points.	cfDNA	levels	were	only	significantly	correlated	with	INR	at	the	pre-
hospital	time	point	(with	a	borderline	significant	p-value	of	0.048),	and	with	PTT	ratio	at	the	
in-hospital	time	point	(p	=	0.028).	Thrombomodulin	was	only	significantly	correlated	with	
PTT	ratio	at	the	in-hospital	time	point	(p	=	0.001).		
	
	
Table	4.6.	Correlations	between	biomarker	concentrations	at	both	pre-hospital	(<1h)	and	
in-hospital	(1-16h)	time	points	and	admission	INR	and	PTT	ratios			
	 Correlation	with	biomarkers,	r	(95%	CI)				 	
Biomarker	 INR	 p-value	 PTT	ratio	 p-value	
Pre-hospital	biomarkers	 	 	 	 	
													cfDNA	 0.195	(0.00–0.380)	 0.048*	 0.000	(-0.218–0.220)		 0.993	
													Syndecan-1	 0.208	(0.01–0.392)	 0.036*	 0.338	(0.125–0.521)	 0.002*	
													Thrombomodulin	 0.119	(-0.084–0.311)	 0.119	 0.195	(-0.029–0.399)	 0.078	
1-16h	biomarkers	 	 	 	 	
													cfDNA	 0.054	(-0.157–0.259)	 0.607	 0.222	(0.018–0.407)	 0.028*	
													Syndecan-1	 0.243	(0.053–0.415)	 0.010*	 0.428	(0.244–0.582)	 <0.0001*	
													Thrombomodulin	 0.085	(-0.109–0.272)	 0.377	 0.328	(0.132–0.500)	 0.001*	
All	summary	data	are	presented	as	r,	with	95%	confidence	intervals	in	parentheses.	
*Significant	according	to	Spearman’s	rank	correlation	coefficient	
INR:	international	normalised	ratio;	PTT:	partial	thromboplastin	time;	cfDNA:	cell-free	DNA	
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4.3.5.	 Biomarker	levels	over	time	
For	patients	in	Cohort	A	with	cfDNA	results	for	both	time	points	(n=88),	the	
differences	in	cfDNA	concentrations	between	time	points	were	compared	to	differences	in	
concentrations	of	biomarkers	of	endotheliopathy.	When	a	model	was	fitted	to	examine	the	
value	of	cfDNA	at	the	second	time	point	as	a	function	of	the	change	in	syndecan-1	and	
thrombomodulin	levels,	increases	in	the	change	in	syndecan-1	and	thrombomodulin	
between	time	points	were	associated	with	statistically	significant	increases	in	cfDNA	levels,	
even	accounting	for	the	cfDNA	value	at	the	first	time	point.	With	all	other	covariates	held	at	
fixed	values,	a	50	ng/ml	change	in	syndecan-1	between	time	points	corresponded	to	a	15%	
increase	in	cfDNA	levels	(95%	CI	7–23%;	p	=	0.0002)	(Figure	4.4.a),	and	a	1	ng/ml	change	in	
thrombomodulin	between	time	points	corresponded	to	a	20%	increase	in	cfDNA	levels	(95%	
CI	12–29%;	p	<	0.0001)	(Figure	4.4.b).		
	
4.3.6.	 Biomarker	levels	and	outcomes	
When	cfDNA	levels	were	compared	between	those	who	died	within	30	days	and	
those	who	survived,	those	who	died	had	significantly	higher	levels	at	both	the	pre-hospital	
(1170	(IQR	538–5279)	ng/ml	vs.	617	(IQR	391–1731)	ng/ml;	borderline	p-value	of	0.049)	and	
in-hospital	(636	(IQR	410–1569)	ng/ml	vs.	432	(IQR	322–577)	ng/ml;	p	=	0.030)	time	points	
(Figure	4.5.a).	There	were	no	significant	differences	between	groups	in	terms	of	survival	for	
the	pre-hospital	or	in-hospital	levels	of	syndecan-1	(Figure	4.5.b)	or	thrombomodulin	(Figure	
4.5.c).		
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Figure	4.4.	Relationship	between	cfDNA	levels	at	the	second	time	point	and	change	in	(a)	
syndecan-1	and	(b)	thrombomodulin	concentrations	between	time	points.	Solid	lines	
represent	the	mean	predicted	values	(based	on	the	fitted	model),	and	the	shaded	areas	
represent	the	range	of	values	covered	by	the	95%	confidence	intervals	associated	with	
those	predicted	values.	
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Figure	4.5.	Comparison	at	both	time	points	according	to	30-day	mortality	for	levels	of	(a)	
cell-free	DNA;	(b)	syndecan-1;	and	(c)	thrombomodulin.		*p	<	0.05	according	to	Mann-
Whitney	U	test	
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When	hospital-free	days	and	ICU-free	days	were	compared	to	both	pre-hospital	and	
in-hospital	biomarkers,	there	were	significant	negative	correlations	between	cfDNA	and	
syndecan-1	levels	and	these	outcomes,	but	thrombomodulin	levels	did	not	have	any	
significant	correlations	(Table	4.7).	Only	one	patient	had	a	thromboembolic	event	(Table	
4.1),	therefore	no	comparisons	could	be	made	with	biomarker	levels.			
	
	
	
Table	4.7.	Correlations	between	biomarker	concentrations	at	both	pre-hospital	(<1h)	and	
in-hospital	(1-16h)	time	points	and	length	of	stay	outcomes			
	 Correlation	with	outcomes,	r	(95%	CI)				 	
Biomarker	 Hospital-free	days	 p-value	 ICU-free	days	 p-value	
Pre-hospital	biomarkers	 	 	 	 	
									cfDNA	 -0.390	(-0.546	–	-0.207)		 <0.0001*	 -0.385	(-0.542	–	-0.201)	 <0.0001*	
									Syndecan-1	 -0.217	(-0.399	–	-0.017)	 0.029*	 -0.187	(-0.373	–	0.014)	 0.060	
									Thrombomodulin	 -0.140	(-0.331	–	0.062)	 0.161	 -0.130	(-0.321	–	0.072)	 0.194	
1-16h	biomarkers	 	 	 	 	
									cfDNA	 -0.331	(-0.490	–	-0.150)		 0.0003*	 -0.334	(-0.493	–	-0.154)		 0.0003*	
									Syndecan-1	 -0.224	(-0.399	–	-0.034)	 0.018*	 -0.207	(-0.384	–	-0.016)		 0.029*	
									Thrombomodulin	 -0.165	(-0.346	–	0.028)	 0.083	 -0.178	(-0.357	–	0.015)	 0.062	
All	summary	data	are	presented	as	r,	with	95%	confidence	intervals	in	parentheses.	
*Significant	according	to	Spearman’s	rank	correlation	coefficient	
ICU:	intensive	care	unit;	cfDNA:	cell-free	DNA	
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4.4.	 Discussion	
The	main	finding	from	the	current	study	is	that	there	is	an	association	between	
circulating	levels	of	cfDNA	and	biomarkers	of	endotheliopathy	following	trauma,	
independent	of	physiological	parameters.	Neither	transfusion	nor	surgery	were	associated	
with	higher	levels	of	cfDNA.	There	were	associations	between	levels	of	cfDNA	and	clinical	
outcomes.	These	associations	were	observed	in	both	pre-hospital	(<1h)	and	in-hospital	(1-
16h)	environments,	and	changes	in	endothelial	biomarkers	had	the	same	directional	change	
as	those	of	cfDNA	between	these	time	points.	These	findings	suggest	that	the	presence	of	
cfDNA	within	the	circulation	and	endotheliopathy	of	trauma	may	be	mechanistically	linked,	
confirming	findings	of	previous	pre-clinical	10,	23,	28,	29	and	clinical	15,	24,	25	studies.	To	our	
knowledge,	our	study	is	the	first	to	report	this	association	within	the	pre-hospital	period	of	
evacuation	following	injury,	supporting	the	hypothesis	that	this	is	an	early	phenomenon,	
occurring	within	minutes,	rather	than	hours,	of	injury.	The	half-life	of	cfDNA	has	been	
reported	as	under	2	hours	30,	which	implies	that	persistently	elevated	levels	of	cfDNA	over	
subsequent	days	may	be	due	to	sustained	production	or	reduced	clearance	by	DNase.	Since	
the	half-lives	are	similarly	short	for	syndecan-1	31,	32	and	thrombomodulin	33,	our	findings	
that	the	rise	or	fall	in	cfDNA	is	associated	with	similar	patterns	in	endothelial	biomarker	
levels	suggest	that	they	may	share	a	common	pathway.			
An	observational	clinical	study	of	this	kind	cannot	demonstrate	a	causal	link	between	
endotheliopathy	and	increase	in	release	of	cfDNA,	or	whether	an	increase	in	cfDNA	from	
injured	tissues	causes	endotheliopathy,	making	pre-clinical	data	the	best	source	for	
hypotheses.	There	is	evidence	that	NETs	cause	disruption	to	the	cell-cell	contacts	between	
endothelial	cells	due	to	the	elastase-mediated	proteolysis	of	VE-cadherin	and	nuclear	
translocation	of	β-catenin29.	When	NETs	are	free	in	the	circulation,	they	may	promote	tissue	
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injury	and	oedema	34,	and	can	bind	to	endothelial	cells	and	cause	direct	injury	28.	After	
prolonged	exposure	to	NETs,	endothelial	cells	are	more	likely	to	die	than	non-exposed	cells	
or	those	only	exposed	for	a	short	period	of	time	35.	We	propose	that	the	most	likely	
sequence	of	events	is	that	cfDNA	from	cellular	injury,	surgical	intervention,	and	the	
production	of	NETs	by	circulating	activated	immune	cells	injures	the	vascular	endothelium,	
which	in	turn	releases	new	cfDNA.		
There	has	been	recent	evidence	that	in	addition	to	endogenous	sources	of	cfDNA,	
injured	patients	may	be	exposed	to	further	fragments	of	mtDNA	from	transfused	packed	
red	blood	cells,	plasma,	and	platelets,	and	that	delivery	of	these	to	patients	may	increase	
the	risk	of	transfusion-related	lung	injury	and	acute	respiratory	distress	syndrome	36,	37.	In	
the	current	study,	blood	transfusion	was	not	associated	with	higher	levels	of	cfDNA,	even	
when	the	transfusion	group	had	worse	parameters	for	perfusion	(lactate)	and	
haemodynamic	compromise	(SBP	and	HR).	The	significantly	higher	syndecan-1	levels	in	the	
transfused	group	may	represent	a	greater	amount	of	glycocalyx	shedding	amongst	the	
patients	with	haemorrhagic	shock,	a	finding	in	keeping	with	other	studies	of	the	
endothelium	following	trauma38.	Although	we	were	not	able	to	confirm	the	previous	
findings	that	transfusion	may	increase	the	amount	of	cfDNA,	these	were	a	heterogeneous	
group	of	patients,	and	non-randomised.	It	is	unknown	whether	differences	may	have	
occurred	after	our	study	time	points	(i.e.	>16	hours).			
Biomarkers	such	as	cfDNA,	syndecan-1,	and	thrombomodulin	have	not	yet	entered	
clinical	utility,	and	their	roles	within	diagnosis	and	management	of	trauma	are	still	
uncertain.	Since	the	current	study	has	shown	that	raised	levels	of	these	biomarkers	are	
associated	with	poorer	clinical	outcomes	such	as	mortality	and	length	of	stay	in	hospital	or	
ICU,	they	may	therefore	have	some	prognostic	value.	Their	potential	role	in	diagnosis	and	
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treatment	is	not	yet	known.	Best	practice	guidelines	recommend	the	use	of	goal-directed	
therapy	aimed	at	correcting	coagulopathy	using	viscoelastic	assays	such	as	rotational	
thromboelastometry	or	thromboelastography	39.	Since	cfDNA,	thrombomodulin,	and	
syndecan-1	have	all	been	shown	to	be	associated	with	coagulopathy	(both	
hypercoagulability8,	9	and	hypocoagulability	with	fibrinolysis14,	15)—a	finding	that	was	
confirmed	in	the	current	study—they	represent	possible	sources	of	further	information	to	
the	trauma	clinician	during	resuscitation	in	addition	to	viscoelastic	assays.	A	previous	
investigation	reported	better	patient	outcomes	when	there	was	a	decrease	in	cfDNA	
between	time	points	40.	In	our	study,	a	decrease	in	cfDNA	was	associated	with	a	similar	
decrease	in	both	syndecan-1	and	thrombomodulin.	The	reduction	in	these	biomarkers	
suggests	a	relative	restoration	of	the	endothelium	and	reduction	in	cell	injury	and	NET	
production,	which	may	partly	explain	any	better	clinical	outcomes	previously	observed.	
The	current	study	combines	analysis	of	blood	samples	from	two	different	cohorts	of	
trauma	patients;	Cohort	A	included	patients	who	had	any	form	of	injury	as	long	as	it	was	
likely	to	have	an	ISS	>8,	whereas	Cohort	B	included	patients	with	severe	injuries	and	the	
additional	burden	of	haemorrhagic	shock.	Despite	the	differences	in	these	cohorts,	there	
was	an	equally	compelling	relationship	between	cfDNA	and	endotheliopathy	within	each	
cohort	as	well	as	within	the	whole	group.	Furthermore,	the	association	between	syndecan-
1,	thrombomodulin,	and	cfDNA	remained	consistent	independently	of	physiological	and	
transfusion	status.	It	is	tempting	to	conclude	that	these	biomarkers	represent	a	common	
pathway.	However,	it	is	possible	that	other	confounding	variables	are	responsible	for	the	
elevation	and	decrease	in	both	cfDNA	and	endothelial	biomarkers.	For	example,	levels	of	
mtDNA	have	been	linked	to	surgical	trauma,	injury	severity	and	volume	of	intravenous	fluids	
delivered	41,	42.	The	current	study	shows	a	relationship	between	ISS	and	cfDNA.	The	precise	
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relationship	between	cfDNA	and	the	endothelium,	although	examined	in	detail	in	pre-
clinical	studies,	requires	further	analysis	in	humans.	In	particular,	attention	should	be	given	
to	causality	between	these	biomarkers,	so	that	a	full	narrative	of	trauma	from	initial	injury	
to	endotheliopathy,	coagulopathy,	and	organ	dysfunction	might	be	better	understood.				
	
4.4.1.	 Limitations	
	 The	current	study	reports	a	relatively	high	burden	of	injury	(median	ISS	of	25)	
amongst	patients,	and	therefore	the	findings	may	not	necessarily	be	translatable	to	less	
severely	injured	patients.	However,	the	range	in	ISS	and	injury	mechanisms	within	the	study	
cohorts	may	increase	the	reliability	and	translatability	of	the	main	findings.	The	number	of	
patients	is	relatively	low,	and	from	a	single	Major	Trauma	Centre	in	a	developed	trauma	
network.	Our	findings	may	benefit	from	corroboration	in	further	sites	and	other	trauma	
systems.	In	particular,	our	trauma	network	does	not	currently	deliver	pre-hospital	blood	
products,	and	it	is	unknown	what	effects	these	may	have	on	cfDNA	and	endothelial	
biomarkers	before	arrival	in	hospital.				
Although	we	report	markers	of	endotheliopathy,	the	clinical	impact	(such	as	the	
potential	for	soft	tissue	oedema	and	alterations	to	normal	fluid	balance)	was	not	examined	
in	the	current	study.	Thromboelastography	was	not	available	during	this	study.	Instead,	INR	
was	used	as	a	marker	of	acute	traumatic	coagulopathy	as	previously	described43.	Further	
clinical	investigations	of	the	impact	of	endotheliopathy	on	vascular	permeability	and	
thromboelastography	are	warranted.	
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4.5.	 Conclusion	
There	is	an	association	between	concentrations	of	cfDNA	and	markers	of	
endotheliopathy	(syndecan-1	and	thrombomodulin)	within	the	circulation	following	injury	
that	is	independent	of	physiological	parameters.	This	relationship	is	present	within	the	first	
hour	of	injury,	persists	over	time,	with	an	increase	or	decrease	in	concentration	of	one	
biomarker	being	reflected	by	a	similar	change	in	the	others.	There	is	an	association	between	
cfDNA	and	injury	severity,	and	higher	levels	of	cfDNA	are	associated	with	longer	lengths	of	
stay	and	mortality.	Although	causality	cannot	be	established,	these	findings	are	in	keeping	
with	previous	evidence	that	there	is	a	close	mechanistic	relationship	between	circulating	
DNA,	vascular	endothelial	injury,	and	poorer	clinical	outcomes.	
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5.1.	 Introduction		
In	Part	1	of	this	thesis,	we	discussed	the	relationship	between	endotheliopathy	of	
trauma	and	microcirculatory	flow	disruption,	and	that	these	pathological	processes	are	
likely	to	occur	very	early	after	injury,	and	are	associated	with	organ	failure.	Early	detection	
of	microcirculatory	failure	may	be	desirable	to	the	clinician	during	the	assessment	and	
resuscitation	of	patients,	and	may	offer	a	target	for	goal-directed	therapy.	However,	such	
utility	has	not	yet	been	realised	in	clinical	practice.	In	order	to	determine	whether	the	
clinician	might	have	access	to	microcirculatory	flow	dynamic	parameters	during	trauma	
resuscitation,	it	is	necessary	to	first	demonstrate	that	this	is	both	feasible	and	safe,	even	for	
very	unwell	patients.	Such	an	exercise	has	not	yet	been	undertaken	within	the	Emergency	
Department,	and	the	following	study	addresses	this.		
There	has	been	considerable	interest	in	the	disruption	of	the	microcirculatory	
endothelium	and	endothelial	glycocalyx	following	traumatic	haemorrhagic	shock	(THS)1,	as	
discussed	in	Part	1	of	this	thesis.	Dysfunctional	sublingual	microcirculation	following	THS	has	
been	reported	to	be	a	good	predictor	of	subsequent	organ	failure	when	measured	in	
patients	admitted	to	the	Intensive	Care	Unit	(ICU)2.	The	ability	to	maintain	microcirculatory	
perfusion	during	early	THS	has	been	shown	to	be	associated	with	more	rapid	reversal	of	the	
shock	state	during	resuscitation	in	a	large	animal	experimental	model3.	There	may	be	some	
circumstances	where	microcirculatory	flow	does	not	follow	global	haemodynamics	and	
parameters	such	as	cardiac	output	and	blood	pressure	no	longer	act	as	reliable	surrogate	
markers	for	perfusion4.	In	such	circumstances	microcirculatory	monitoring	may	offer	more	
reliable	guidance	for	resuscitation	by	adding	information	about	true	end-organ	perfusion.	
The	implications	of	bedside	point-of-care	microcirculatory	parameters	have	not	yet	been	
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realised	but	may	have	far-reaching	utility	in	both	civilian	and	military	contexts	(and	will	be	
discussed	in	the	next	chapter).		
Although	it	seems	intuitive	that	microcirculatory	readings	from	earlier	time	points	
closer	to	point	of	injury—especially	before	the	definitive	cessation	of	bleeding—may	offer	
diagnostic	and	prognostic	value	following	major	trauma,	this	has	not	yet	been	investigated.	
Some	investigators	have	performed	sublingual	microcirculatory	assessment	in	the	
Emergency	Department	(ED)	for	patients	with	sepsis5	and	acute	decompensated	heart	
failure6,	but	this	has	not	yet	been	undertaken	for	trauma	patients.	It	is	possible	that	
researchers	have	not	attempted	sublingual	video-microscopy	for	trauma	patients	in	the	ED	
because	of	the	constraints	imposed	by	clinical	urgency	and	environmental	uncertainty,	lack	
of	capacity	to	consent,	multiple	interventions,	and	rapid	transfer	of	the	patient.	Such	a	
scenario	is	also	likely	to	be	noisy	and	crowded,	with	limited	space	and	time	at	the	bedside	–	
conditions	that	may	be	even	more	hostile	in	the	deployed	military	context.	Conversely,	the	
ICU	offers	a	more	‘placid’	environment	with	a	stationary	patient,	increased	space	and	time,	
and	more	stable	physiology,	even	when	patients	are	critically	unwell.	However,	by	the	time	
of	ICU	arrival,	patients	may	have	received	multiple	resuscitative	interventions,	with	
unknown	impact	on	the	predictive	value	of	sublingual	video	microscopy.	It	is	therefore	
important	to	establish	the	feasibility	of	microcirculatory	monitoring	within	the	ED	as	a	basis	
for	studies	to	determine	its	clinical	utility.			
I	will	present	for	the	first	time	the	feasibility	of	obtaining	sublingual	video-
microscopy	video	clips	during	the	emergency	presentation	of	patients	with	THS	in	the	ED.	It	
was	hypothesised	that	non-invasive	microcirculatory	imaging	in	this	emergency	context	is	
safe,	feasible,	does	not	interfere	with	clinical	management,	and	provides	data	of	sufficient	
quality	for	meaningful	analysis	(Hypothesis	6;	Table	1.1).		
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5.2.	 Methods	
5.2.1.	 Study	design	and	setting	
A	prospective	observational	pilot	study	was	undertaken	to	assess	whether	sublingual	
video-microscopy	to	image	the	microcirculation	was	feasible	and	safe	for	both	civilian	and	
military	patients	with	THS,	and	whether	the	captured	video	clips	were	of	high	enough	
quality	for	analysis.	Both	civilian	Research	Ethics	Committee	(REC	Ref	14/YH/0078)	and	
Ministry	of	Defence	Research	Ethics	Committee	(MODREC	Ref	PPE	281/12)	approvals	were	
granted	before	the	start	of	the	study.			
	
5.2.2.	 Patient	selection	
Patients	were	enrolled	into	the	MICROSHOCK	study	(ClinicalTrials.gov	Identifier:	
NCT02111109)7.	Patients	were	eligible	for	inclusion	if	there	was	evidence	of	haemorrhagic	
shock,	and	all	of	the	following	features:	(i)	injury	mechanism	consistent	with	blood	loss;	(ii)	
the	patient	is	intubated	and	ventilated;	(iii)	plasma	lactate	concentration	>2	mmol/L;	and	
(iv)	the	patient	has	received	any	blood	products	during	initial	resuscitation.	Patient	were	
recruited	as	soon	as	possible	after	arrival	at	three	UK	Major	Trauma	Centres	(Queen	
Elizabeth	Hospital,	Birmingham;	Kings	College	Hospital	and	Royal	London	Hospital,	London).	
This	was	either	in	the	ED	or	Intensive	Care	Unit	(ICU).	The	current	study	includes	the	first	13	
civilian	patients	recruited	in	ED	and	a	further	2	deployed	soldiers	enrolled	in	the	ED	at	the	
Role	3	medical	facility	in	Camp	Bastion	during	the	Afghanistan	conflict.	
	
5.2.3.	 Sublingual	video-microscopy	
Sublingual	microcirculation	was	visualised	in	the	civilian	patients	using	incident	dark	
field	(IDF)	video-microscopy	(Cytocam,	Braedius	Medical	B.V.,	Huizen,	The	Netherlands).	
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Military	patients	were	scanned	using	a	sidestream	dark	field	(SDF)	device	(Microvision	
Medical,	Amsterdam,	The	Netherlands).	IDF	is	a	newer	technology	with	higher	resolution	
and	larger	field	of	view,	but	produces	comparable	results8.	The	devices	are	positioned	
towards	the	sublingual	mucosa	and	maneuvered	until	a	clear	image	of	the	microcirculation	
is	acquired.	Video	clips	(preferably	lasting	at	least	5	seconds	each)	are	then	recorded	and	
stored	for	offline	analysis	using	dedicated	computer	software	(Automated	Vascular	Analysis	
V.3.02,	Microvision	Medical,	The	Netherlands).	At	least	3	(but	preferably	5)	individual	video	
clips	are	required	for	data	analysis	according	to	consensus	agreement9,	but	this	does	not	
limit	the	number	of	videos	that	can	be	captured.	In	this	study	as	many	videos	as	possible	
were	recorded	to	ensure	a	sufficient	number	of	analysis	quality.	For	SDF	video	images	
continuous	video	was	taken	rather	than	short	clips;	this	was	later	spliced	into	high	quality	
segments	(each	lasting	5	seconds)	for	computer	analysis.		
	
5.2.4.	 Training	
Sublingual	video-microscopy	was	undertaken	by	dedicated	research	clinicians	and	
research	nurses	who	had	been	trained	in	the	technique	by	an	expert	user	and	the	study’s	
Chief	Investigator	(S.D.H.)	to	a	standard	suitable	for	clinical	research.	Training	was	
undertaken	paying	particular	attention	to	standard	quality	assessment	variables10,	including	
the	optimisation	of	stability,	focus	and	illumination,	as	well	as	reducing	pressure	artefact	
and	ensuring	that	the	field	of	view	contained	microcirculatory	vessels.	The	rationale	and	
details	of	these	quality	domains	have	been	described	in	detail	elsewhere11.	Since	all	patients	
in	the	MICROSHOCK	study	are	intubated,	users	are	trained	to	access	the	sublingual	area	
with	the	endotracheal	tube	in	situ.		
	
Chapter	5	 	 Emergency	microcirculatory	monitoring	
	 126	
5.2.5.	 Capacity	and	consent	
As	described	in	Part	I	of	this	thesis,	due	to	the	nature	of	the	injuries	sustained	and	
physiological	status	of	patients,	capacity	to	consent	was	absent.	The	REC-approved	consent	
process	for	enrolment	in	the	study	was	guided	by	the	Mental	Health	Act,	UK	(2005)	and	is	
explained	in	more	detail	in	the	study	protocol7	and	in	previous	chapters.	In	short,	the	
physician	in	charge	of	the	care	of	the	patient	(Professional	Consultee)	agreed	on	the	
participation	of	the	patient.	A	close	friend	or	relative	could	also	be	approached	if	
appropriate	to	act	as	a	Personal	Consultee.	Ultimately	if	the	participant	regained	capacity	
they	were	asked	for	their	permission	to	retain	data	already	collected.		
	
5.2.6.	 Data	collection	
Patient	demographics	(age,	sex)	and	injury-related	details	(mechanism	of	injury,	
injury	severity	score	(ISS))	were	recorded.	Physiological	parameters	from	the	pre-hospital	
evacuation	and	ED	included	lowest	systolic	blood	pressure	(SBP),	lowest	Glasgow	Coma	
Score	(GCS),	and	highest	lactate	(as	a	surrogate	for	perfusion).	The	number	and	type	of	
blood	products	were	recorded	as	a	measure	of	haemorrhagic	burden.	Details	regarding	
sublingual	video-microscopy	included	timings	of	video	capture,	profession	of	user,	
mechanism	of	notification	of	user,	number	of	video	clips	stored,	total	length	of	video	
capture,	and	type	of	consent	were	also	noted.	
	
5.2.7.	 Outcomes	
The	outcomes	of	interest	were:	(i)	safety	(absence	of	adverse	events	or	interference	
with	clinical	management);	(ii)	feasibility	(successful	acquisition	and	storage	of	video	clips);	
and	(iii)	the	attainment	of	videos	of	high	enough	quality	for	meaningful	data	analysis.	
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Quality	assessment	was	undertaken	according	to	a	standardised	technique	that	grades	6	
domains	for	each	video	(including	illumination,	duration,	focus,	content,	stability,	and	
pressure	artefact)10	by	a	single	assessor	(D.N.N)	who	was	blinded	to	clinical	status	of	the	
patient.	Each	domain	was	graded	as	optimal	(0	points),	suboptimal	but	still	useable	(1	
point),	or	unacceptable	and	unusable	(10	points).	If	any	video	clip	has	a	score	of	10	in	any	
domain	then	the	video	was	deemed	unusable.		
	
5.2.8.	 Minimising	potential	sources	of	bias	
All	patients	that	triggered	a	trauma	team	activation	were	screened	for	inclusion	in	
the	study,	and	a	log	was	kept	in	order	to	ensure	that	risk	of	selection	bias	was	minimised.	
The	training	of	all	video-microscopists	was	supervised	and	regularly	assessed	by	the	Chief	
Investigator	to	minimise	the	risk	of	inter-user	heterogeneity.	Quality	assessment	of	videos	
was	kept	blinded	to	clinical	status	of	the	patient,	study	site,	and	video-microscopist,	so	that	
quality	grading	was	as	unbiased	and	consistent	as	possible.			
	
5.3.	 Results	
5.3.1.	 Patient	characteristics	
There	were	15	patients	(13	civilians	and	2	military)	included	in	the	study.	The	
majority	of	patients	(12/15,	80%)	were	male;	the	median	age	was	41	(IQR	30	–	55)	years.	All	
patients	were	unconscious	and	intubated	at	time	of	study	enrolment,	and	recruited	into	the	
study	with	agreement	by	a	Nominated	Consultee.	There	were	no	cases	of	subsequent	
withdrawal	of	consent	from	the	patient	once	they	regained	capacity.		
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5.3.2.	 Injury	burden	and	physiology	
For	civilian	patients,	the	most	common	injury	mechanism	was	road	traffic	accident	
(n=7),	followed	by	crush	injury	(n=2),	fall	(n=2),	penetrating	trauma	(n=1),	and	struck	by	a	
train	(n=1).	One	military	patient	had	been	injured	in	an	improvised	explosive	device	(IED)	
blast;	the	other	had	been	crushed	by	an	armoured	vehicle.	The	median	ISS	for	all	patients	
was	26	(23	–	34).	The	median	lactate	in	ED	was	4.6	(interquartile	range	(IQR)	2.8	–	7.9)	
mmol/L.	Median	SBP	was	79	(IQR	68	–	105)	mmHg,	and	median	lowest	GCS	before	
intubation	was	9	(IQR	5	–	12).	Patients	in	this	group	received	a	median	of	4	(IQR	1.5	–	6)	
units	of	RBCs,	2	(IQR	0	–	5)	units	of	FFP,	and	0	(IQR	0	–	0.5)	units	of	platelets	within	the	first	
24	hours.	The	military	patient	injured	by	the	IED	received	32	units	of	RBCs,	31	units	of	FFP	
and	5	units	of	platelets.		
	
5.3.3.	 Video-microscopy	
The	IDF	device	was	used	for	13	civilian	patients,	and	the	SDF	device	was	used	for	the	
2	military	patients.	Figure	5.1	illustrates	a	flow	diagram	of	microcirculatory	video	
acquisition.	Video-microscopy	was	performed	by	a	doctor	for	12	patients	and	nurse	for	3	
patients.	On	all	occasions	these	healthcare	professionals	were	alerted	to	the	arrival	of	the	
patient	by	phone	call	from	the	relevant	ED.	Video-microscopy	was	performed	a	median	of	
80	(IQR	58–138)	minutes	after	arrival	of	the	patient	at	the	hospital.	Where	a	CT	was	
performed	as	part	of	trauma	management	(all	patients),	this	preceded	sublingual	video-
microscopy	in	all	instances.		
	
5.3.4.	 Safety	and	feasibility	
Video-microscopy	was	successfully	performed	and	videos	stored	for	analysis	for	all	
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patients	enrolled	in	ED.	161	video	clips	were	stored	for	analysis,	including	151	from	civilian	
patients	and	10	from	military	patients	(the	long	continuous	videos	acquired	for	the	military	
patients	were	spliced	into	5	clips	each).	The	median	time	at	the	bedside	for	video	capture	
was	6	(IQR	5	–	8)	minutes.		There	were	no	adverse	events,	and	no	incidents	reported	where	
clinical	management	was	affected	or	patient	care	interrupted.		
	
5.3.5.	 Quality	assessment	of	videos	
Of	all	videos	retained	for	analysis,	104/161	(64.6%)	were	of	suitable	quality	for	
computer	analysis.	These	videos	were	acquired	from	14	of	the	patients,	with	one	civilian	
patient	having	no	useable	data.	A	median	of	6	(IQR	5	–	10)	video	clips	per	patient	were	
eligible	for	analysis,	exceeding	the	3	–	5	clips	recommended	by	consensus	guidance9.	The	
median	quality	assessment	score	for	useable	videos	was	2	(IQR	1	–	2).	Of	the	57	video	clips	
that	were	unusable,	18	failed	quality	assessment	on	more	than	one	domain.	The	remaining	
39	video	clips	that	failed	due	to	a	single	quality	domain	included	content	(n=14),	pressure	
(n=13),	stability	(n=6),	illumination	(n=3),	focus	(n=2)	and	duration	(n=1)			
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Figure	5.1.	Flow	diagram	of	microcirculatory	video	clip	acquisition	for	computer	analysis		
N	indicates	the	number	of	study	participants	at	each	stage	
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5.4.	 Discussion	
The	main	finding	from	this	study	is	that	early	sublingual	microcirculatory	monitoring	
in	the	Emergency	Department	is	feasible	and	safe	for	patients	with	THS,	and	yields	videos	
that	can	be	used	for	analysis.	Investigation	of	patients	with	THS	can	be	performed	using	this	
technique	without	apprehension	of	interference	in	clinical	management	or	detriment	to	the	
patient.	Such	non-invasive	scanning	modalities	are	commonplace	during	trauma	
resuscitation	when	they	are	considered	to	add	valuable	information,	including	focused	
assessment	with	sonography	for	trauma	(FAST),	and	ultrasound	to	guide	fluid	therapy12.	
Associated	training	and	ongoing	validation	would	be	essential	components	if	this	technique	
were	to	be	used	in	clinical	practice.	
Patients	in	this	study	had	a	considerable	injury	burden,	with	additional	
haemodynamic	compromise	according	to	their	physiological	and	biochemical	parameters.	
Sublingual	microcirculatory	monitoring	was	still	feasible	in	this	context	within	the	very	first	
hours	of	their	arrival	in	hospital.	Although	the	clinical	utility	of	such	readings	is	yet	to	be	
realised,	it	is	possible	that	the	availability	of	additional	data	relating	to	tissue	perfusion	may	
be	of	value	in	the	resuscitation	of	such	patients.	Point-of-care	microcirculatory	monitoring	is	
not	currently	used	in	clinical	practice,	but	innovations	to	move	this	technique	from	research	
to	the	clinical	domain	have	been	proposed	by	our	group13	(as	discussed	in	the	next	chapter)	
and	others14.	If	point-of-care	microcirculatory	monitoring	is	deemed	to	be	a	useful	
resuscitation	end	point	then	it	would	be	important	to	obtain	readings	before,	during	and	
after	interventions	so	that	changes	might	be	recorded.	The	current	study	did	not	use	such	
methodology,	but	further	investigations	into	the	utility	of	this	technique	are	warranted.		
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5.4.1.	 Obstacles	and	limitations	
There	are	known	obstacles	in	the	acquisition	of	early	microcirculatory	data,	which	
were	confirmed	in	this	feasibility	study.	Patients	with	THS	are	critically	unwell,	and	their	
treatment	is	urgent	and	needs	to	progress	uninterrupted.	Transfers	to	radiology,	ICU	or	
operating	theatre	cannot	be	paused	for	data	acquisition	without	strong	justification.	
Sublingual	video-microscopy	has	potential	to	overcome	some	of	these	limitations	because	it	
is	mobile	and	can	follow	the	patient.	We	report	that	it	takes	a	matter	of	minutes	to	
undertake,	and	that	there	was	a	point	in	the	patient	pathway	in	all	cases	before	patient	
transfer	during	which	opportunistic	video-microscopy	was	suitable.	In	all	occasions	where	
cross-sectional	imaging	was	undertaken,	video-microscopy	was	performed	afterwards.	The	
study	investigators	did	not	wish	to	interfere	with	the	preparation	or	transfer	of	patients	
who	needed	urgent	imaging.	If	the	technique	is	found	to	have	clinical	utility,	then	there	may	
be	some	justification	in	obtaining	even	earlier	readings,	and	incorporating	the	technique	
into	the	resuscitative	pathway.		
	 Although	feasibility	has	been	demonstrated,	one	civilian	patient	had	no	videos	clips	
of	high	enough	quality	for	assessment.	Time	constraints	and	interference	with	video	
acquisition	may	increase	the	risk	of	such	occurrences,	and	would	require	continued	
education,	training,	and	maintenance	of	appropriate	skills	for	data	capture	in	less	than	ideal	
(and	sometimes	adverse)	circumstances.	User-dependency	is	a	common	feature	of	scanning	
modalities.	Clinical	judgment	continues	to	be	the	optimal	management	strategy	for	these	
emergency	scenarios	with	or	without	the	additional	data	that	microcirculatory	monitoring	
might	yield.	There	were	only	two	military	patients	included	in	this	study,	and	it	is	
acknowledged	that	firm	conclusions	cannot	be	made	with	these	limited	data.	Further	
validation	is	required	in	such	an	environment.				
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The	majority	of	sublingual	microcirculatory	monitoring	is	conducted	in	the	research	
domain,	and	early	bedside	point-of-care	monitoring	of	the	microcirculation	for	patients	with	
THS	has	not	been	reported.	Although	limited	by	a	small	number	of	patients,	the	current	
study	adds	to	the	growing	body	of	evidence	that	may	justify	and	facilitate	the	transition	of	
microcirculatory	monitoring	from	research	into	clinical	practice.	Restoration	of	tissue	
perfusion	by	directing	fluid	and	inotropic	resuscitation	towards	microcirculatory	targets	
appears	to	be	a	viable	technique,	but	is	yet	to	be	tested.	Some	investigators	have	proposed	
that	plasma	may	improve	microcirculatory	function	due	to	its	restorative	properties15.	
Detection	of	microcirculatory	dysfunction	may	have	a	role	in	guiding	the	choice	or	volume	
of	fluids.	Since	acquisition	of	early	microcirculatory	data	is	feasible,	it	is	timely	to	design	and	
implement	appropriate	studies	to	examine	whether	microcirculatory	goal-directed	therapy	
is	of	benefit	to	patients.		
	
	
5.5.	 References	
1.	 Chignalia	AZ,	Yetimakman	F,	Christiaans	SC,	et	al.	The	Glycocalyx	and	Trauma:	A	
Review.	Shock.	2016;45(4):338-48.	
2.	 Tachon	G,	Harrois	A,	Tanaka	S,	et	al.	Microcirculatory	alterations	in	traumatic	
hemorrhagic	shock.	Crit	Care	Med.	2014;42(6):1433-41.	
3.	 Hutchings	SD,	Naumann	DN,	Watts	S,	et	al.	Microcirculatory	perfusion	shows	wide	
inter-individual	variation	and	is	important	in	determining	shock	reversal	during	resuscitation	
in	a	porcine	experimental	model	of	complex	traumatic	hemorrhagic	shock.	Intensive	Care	
Med	Exp.	2016;4(1):17.	
4.	 Ince	C.	Hemodynamic	coherence	and	the	rationale	for	monitoring	the	
microcirculation.	Crit	Care.	2015;19(Suppl	3):S8.	
Chapter	5	 	 Emergency	microcirculatory	monitoring	
	 134	
5.	 Trzeciak	S,	Dellinger	RP,	Parrillo	JE,	et	al.	Early	microcirculatory	perfusion	
derangements	in	patients	with	severe	sepsis	and	septic	shock:	relationship	to	
hemodynamics,	oxygen	transport,	and	survival.	Ann	Emerg	Med.	2007;49(1):88-98.	
6.	 Hogan	CJ,	Ward	KR,	Franzen	DS,	et	al.	Sublingual	tissue	perfusion	improves	during	
emergency	treatment	of	acute	decompensated	heart	failure.	Am	J	Emerg	Med.	
2012;30(6):872-80.	
7.	 Hutchings	S,	Naumann	DN,	Harris	T,	et	al.	Observational	study	of	the	effects	of	
traumatic	injury,	haemorrhagic	shock	and	resuscitation	on	the	microcirculation:	a	protocol	
for	the	MICROSHOCK	study.	BMJ	Open.	2016;6(3):e010893.	
8.	 Hutchings	S,	Watts	S,	Kirkman	E.	The	Cytocam	video	microscope.	A	new	method	for	
visualising	the	microcirculation	using	Incident	Dark	Field	technology.	Clin	Hemorheol	
Microcirc.	2016;62(3):261-71.	
9.	 De	Backer	D,	Hollenberg	S,	Boerma	C,	et	al.	How	to	evaluate	the	microcirculation:	
report	of	a	round	table	conference.	Crit	Care.	2007;11(5):R101.	
10.	 Massey	MJ,	Larochelle	E,	Najarro	G,	et	al.	The	microcirculation	image	quality	score:	
development	and	preliminary	evaluation	of	a	proposed	approach	to	grading	quality	of	
image	acquisition	for	bedside	videomicroscopy.	J	Crit	Care.	2013;28(6):913-7.	
11.	 Massey	MJ,	Shapiro	NI.	A	guide	to	human	in	vivo	microcirculatory	flow	image	
analysis.	Crit	Care.	2016;20:35.	
12.	 Ferrada	P,	Evans	D,	Wolfe	L,	et	al.	Findings	of	a	randomized	controlled	trial	using	
limited	transthoracic	echocardiogram	(LTTE)	as	a	hemodynamic	monitoring	tool	in	the	
trauma	bay.	J	Trauma	Acute	Care	Surg.	2014;76(1):31-7;	discussion	7-8.	
13.	 Naumann	DN,	Mellis	C,	Husheer	SL,	et	al.	Real-time	point	of	care	microcirculatory	
assessment	of	shock:	design,	rationale	and	application	of	the	point	of	care	microcirculation	
(POEM)	tool.	Crit	Care.	2016;20(1):310.	See	also	Chapter	6	
14.	 Arnold	RC,	Parrillo	JE,	Phillip	Dellinger	R,	et	al.	Point-of-care	assessment	of	
microvascular	blood	flow	in	critically	ill	patients.	Intensive	Care	Med.	2009;35(10):1761-6.	
15.	 Tuma	M,	Canestrini	S,	Alwahab	Z,	et	al.	Trauma	and	Endothelial	Glycocalyx:	The	
Microcirculation	Helmet?	Shock.	2016;46(4):352-7.		
	
		 135	
	
	
	
	
Chapter	6	
	
	
The	microcirculation	can	be	assessed	at	the	
bedside	using	a	novel	point-of-care	
microcirculation	tool	
	
Chapter	6	 	 Point-of-care	microcirculation	
	 136	
	
	
	
	
	
	
	
The	following	chapter	is	adapted	from	the	published	article:	
	
Naumann	DN,	Mellis	C,	Husheer	SL,	Hopkins	P,	Bishop	J,	Midwinter	MJ,	Hutchings	SD.	Real-
time	point	of	care	microcirculatory	assessment	of	shock:	design,	rationale	and	application	of	
the	point	of	care	microcirculation	(POEM)	tool.	Crit	Care.	2016;20(1):310.	
	
	
	 	
Chapter	6	 	 Point-of-care	microcirculation	
	 137	
6.1.	 Introduction	
In	the	previous	chapter,	we	discussed	the	safety	and	feasibility	of	bedside	
microcirculatory	monitoring	for	unwell	patients	following	trauma.	However,	this	technology	
is	still	limited	to	use	in	research	(rather	than	clinical	practice)	because	the	videos	derived	
from	the	technique	need	to	be	analysed	at	length	by	specialist	computer	software,	and	
away	from	the	patient.	In	order	to	bring	this	technique	into	clinical	practice	at	the	bedside	
for	unwell	patients,	it	is	necessary	to	create	a	way	of	assessing	the	videos	in	real	time,	
without	the	need	for	complex	analysis	away	from	the	patient.	The	following	chapter	will	
describe	a	novel	assessment	tool	to	assess	the	microcirculation	for	exactly	this	purpose.			
Since	the	microcirculation	is	the	anatomical	location	of	oxygen	and	substrate	
exchange,	its	behaviour	during	shock	is	of	interest	to	those	involved	in	patient	resuscitation.	
The	term	“haemodynamic	coherence”	has	been	used	to	describe	a	situation	in	which	
resuscitation	aimed	at	restoring	systemic	haemodynamic	parameters	(such	as	cardiac	
output)	also	makes	a	corresponding	improvement	to	the	microcirculation1.	Some	
pathological	circumstances	such	as	sepsis	may	cause	an	imbalance	between	global	and	
microcirculatory	parameters	so	that	the	microcirculation	no	longer	corresponds	to	the	
macrocirculation	(i.e.	loss	of	haemodynamic	coherence);	in	this	circumstance	goal-directed	
resuscitation	targeted	towards	global	parameters	may	lead	to	harm1.	There	is	some	
evidence	that	when	microcirculatory	flow	is	impaired	during	circulatory	shock	it	may	not	be	
restored	even	when	blood	pressure	is	improved2.	Microcirculatory	parameters	may	also	
predict	clinical	outcomes	better	than	global	measurements	in	sepsis3	and	traumatic	
haemorrhagic	shock4.	Improvement	of	microcirculatory	parameters	during	resuscitation	
may	also	predict	better	outcomes	following	major	surgery5	and	sepsis6.		
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The	use	of	hand	held	non-invasive	sublingual	video-microscopes	(such	as	sidestream	
dark	field	(SDF)	or	incident	dark	field	(IDF)	microscopy)	has	allowed	researchers	to	study	
microcirculatory	flow	in	vivo,	both	in	experimental	models	and	in	patients,	as	discussed	in	
previous	chapters.	However,	despite	over	a	decade	of	detailed	investigations	and	
demonstrations	of	the	rationale	of	monitoring	the	microcirculation,	this	technology	and	
associated	techniques	have	still	not	advanced	from	the	research	to	clinical	domains.	A	major	
limitation	in	the	use	of	current	video-microscope	technology	is	that	analysis	depends	on	the	
capture	of	video	clips	that	require	offline	analysis.	This	takes	a	considerable	amount	of	time	
(after	the	clinical	window	of	diagnostic	utility).	Real-time	point-of-care	automated	
(computerised)	analysis	has	not	yet	been	validated	against	traditional	offline	analysis.	Even	
if	computerised	automated	analysis	were	to	yield	accurate,	validated	parameters,	their	
clinical	applicability	is	unlikely	to	be	meaningful	without	user	interpretation	and	some	form	
of	clinical	grading	system	that	might	determine	particular	therapeutic	pathways	based	on	
target	readings.	This	is	because	such	a	system	may	yield	parameters	of	unknown	clinical	
relevance.	What	is	required	in	real-life	clinical	practice	is	a	simple	grading	system	that	acts	
as	a	trigger	or	guide	for	the	delivery	of	particular	interventions.	In	the	future,	based	on	such	
algorithms,	artificial	intelligence	may	even	allow	this	process	to	be	automated.	
Here	we	describe	for	the	first	time	a	5-point	ordinal	grading	scale	of	microcirculatory	
function	based	on	a	composite	of	flow	and	heterogeneity	in	vessel	segments	viewed	by	
sublingual	video-microscopy.	The	score	is	relatively	simple	and	can	be	assigned	at	the	point-
of-care.	It	may	be	one	way	of	facilitating	goal-directed	therapy	using	microcirculatory	
parameters.	It	was	hypothesised	that	trained	professionals	could	use	this	point-of-care	tool	
as	accurately	as	offline	computer	analysis	(Hypothesis	7;	Table	1.1).		
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6.2.	 Methods		
6.2.1.	 Design	of	the	Point-of-Care	Microcirculation	grading	system	
A	schematic	diagram	(Figure	6.1)	summarises	the	stages	in	the	design	of	the	Point-
of-Care	Microcirculation	(POEM)	Score.	This	process	was	undertaken	by	two	expert	users	
(D.N.N.	and	S.D.H.),	who	have	extensive	experience	in	video-microscopy	technique	analysis.			
	
	
Figure	6.1.	Schematic	flow	diagram	of	the	stages	in	development	of	the	final	POEM	
scoring	system	
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The	scoring	system	is	based	on	the	premise	that	flow	and	heterogeneity	of	vessel	
segments	are	the	key	components	of	interest.	The	final	POEM	score	does	not	account	for	
vessel	density,	because	early	trials	of	the	scoring	system	that	incorporated	assessment	of	
density	did	not	demonstrate	its	discriminatory	utility.		
	
6.2.2.	 Assigning	a	POEM	score	
The	final	POEM	scoring	system	is	a	5-point	ordinal	scale	that	integrates	assessments	
of	both	flow	and	heterogeneity	(Table	6.1).	It	enables	a	user	to	assess	real	time	
microcirculatory	videos	obtained	during	sublingual	IDF	microscopy.	It	is	derived	from	the	
assessment	of	4	video	clips	from	the	same	patient	at	the	same	time	point	(since	a	
recommendation	of	3	–	5	video	clips	corresponds	to	the	consensus	opinion	in	traditional	
analysis7).		For	each	of	the	4	individual	video	clips,	the	user	determines	the	flow	and	
heterogeneity	as	such:		
	
6.2.2.1.		Flow	
(i)	Normal:	<25%	of	vessel	segments	in	view	are	sluggish/stopped	
(ii)	Impaired:	25	–	50%	of	vessel	segments	in	view	are	sluggish/stopped	
(iii)	Critically	impaired:	>50%	of	vessel	segments	in	view	are	sluggish/stopped		
	
6.2.2.2.		Heterogeneity	
	 Only	if	the	user	determines	that	a	clip	has	“Normal”	overall	flow	are	they	
prompted	to	also	assign	whether	heterogeneity	is	present	or	absent.	This	is	because	
during	the	pilot	phase	of	developing	the	scoring	system	(Figure	6.1)	we	found	that	
heterogeneity	was	universally	present	in	clips	with	“impaired”	and	“critically	
Chapter	6	 	 Point-of-care	microcirculation	
	 141	
impaired”	overall	flow	(i.e.	having	an	assessment	of	heterogeneity	for	such	scenarios	
did	not	make	any	difference	overall).	Heterogeneity	is	determined	for	“normal”	clips	
as	“present”	if	>5	vessel	segments	demonstrate	different	flow	to	the	remainder.	The	
threshold	for	5	vessels	segments	was	used	because	this	was	found	to	be	the	most	
discriminating	(Figure	6.1).		
	
	 Each	individual	video	clip	is	therefore	assigned	either:	“critically	impaired”,	
“impaired”,	“normal	flow	with	heterogeneity”,	or	“normal	flow	without	heterogeneity”.	The	
combination	of	4	clips	gives	the	POEM	score	(Table	6.1;	Figures	6.2	and	6.3)		
	
 
 
Table	6.1.	Point-of-care	microcirculation	(POEM)	grade	and	corresponding	definitions	
POEM	Score	 Microcirculatory	function	
5	 Normal	flow*,	with	no	heterogeneity†	
4	 Normal	flow*,	with	mild	heterogeneity††	
3	 Normal	flow*,	with	marked	heterogeneity†††	
2	 Impaired	flow**	(heterogeneity	is	also	present)	
1	 Critically	impaired	flow***	(heterogeneity	is	also	present)	
*	Less	than	25%	of	vessel	segments	in	view	are	sluggish/stopped	
**	25–50%	of	vessel	segments	in	view	are	sluggish/stopped	
***	More	than	50%	of	vessel	segments	in	view	are	sluggish/stopped		
†	0	or	1	clips	have	heterogeneity	present	
††	2	or	3	clips	have	heterogeneity	present	
†††	All	4	clips	have	heterogeneity	present	
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6.2.3.	 POEM	Score	calculation	
It	is	the	combination	of	all	4	video	clips	that	gives	overall	POEM	Score	as	per	the	
algorithm	in	Figure	6.2.	In	short,	if	two	or	more	clips	have	“critically	impaired”	flow,	then	the	
overall	POEM	score	is	1	(Critically	Impaired).	If	2	or	more	clips	have	“impaired”	flow	then	the	
overall	POEM	score	is	2	(Impaired).	If	3	or	more	clips	have	“normal”	flow	then	they	can	be	
one	of	three	different	scores:	POEM	score	3	(Normal	with	marked	heterogeneity)	if	all	4	
clips	show	heterogeneity;	POEM	score	4	if	two	or	three	clips	show	heterogeneity;	and	POEM	
Score	5	if	≤1	clip	has	heterogeneity.		
	
Figure	6.2.		Algorithm	for	overall	POEM	Score	using	the	parameters	from	4	video	clips	
	
	
	
6.2.4.	 Online	tool	
An	online	tool	(http://www.POEMscore.com)	can	be	used	to	perform	the	calculation	
for	the	POEM	Score	based	on	the	scores	for	all	4	video	clips	with	minimal	effort.	An	example	
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of	an	online	POEM	score	calculation	is	shown	in	Figure	6.3,	and	is	based	on	the	algorithm	
illustrated	in	Figure	6.2.		
	
Figure	6.3.		An	example	of	a	POEM	grade	being	assigned	using	the	online	tool.	In	this	case	
the	overall	POEM	Score	is	2,	indicating	"Impaired"	flow	
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6.2.5.	 Validation	of	the	scoring	system	by	healthcare	professionals	
A	group	of	32	healthcare	professionals	volunteered	as	study	participants	to	assess	
the	utility	of	the	POEM	score.	These	participants	were	from	two	UK	collaborating	sites	
(University	Hospitals	Birmingham	NHS	Foundation	Trust,	Birmingham,	UK,	and	King’s	College	
Hospital	NHS	Foundation	Trust,	London,	UK).	All	participants	were	current	Intensive	Care	
Unit	clinicians	or	nurses	and	had	not	previously	used	sublingual	microcirculatory	monitoring	
or	interpreted	video-microscopy	clips.		
	
6.2.5.1.			Training	
	 All	study	participants	undertook	a	standardised	60-minute	interactive	
training	session	using	18	slides	and	a	pre-selected	set	of	videos	of	varying	
microcirculatory	dysfunction	as	examples.	All	video	clips	were	obtained	from	the	
MICROSHOCK	study8,	from	patients	with	traumatic	haemorrhagic	shock	(mixed	blunt	
and	penetrating	trauma)	and	taken	on	day	0	or	1	of	their	hospital	stay.	The	aim	of	
the	training	session	was	to	teach	the	participants	how	to	assign	“normal”,	impaired”,	
or	“critically	impaired”	flow	to	individual	video	clips,	as	well	as	whether	
heterogeneity	was	“present”	or	“absent”	for	“normal”	clips.	Teaching	sessions	were	
delivered	by	subject	matter	experts	(D.N.N.	and	S.D.H.).	The	participants	were	given	
an	opportunity	to	ask	questions	and	re-look	at	some	example	videos	before	being	
asked	to	score	the	test	sequence	of	video	clips.	
	
6.2.5.2.			Testing	
	 Straight	after	the	training	session,	the	participants	were	asked	to	view	and	
score	5	video	sequences	(corresponding	to	5	different	patients),	each	of	which	
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consisted	of	4	video	clips	(20	clips	in	total).	These	videos	were	taken	from	the	
MICROSHOCK	study8,	and	had	been	recorded	using	an	IDF	video	microscope	recently	
validated	for	use	in	shock	states9	and	all	had	been	assessed	as	high	quality	according	
to	guidelines10.	The	participants	were	blinded	to	each	other’s	scores	and	the	clinical	
status	of	the	patients.	They	were	allowed	up	to	2	minutes	for	each	individual	video	
clip,	which	was	played	in	‘loop’	until	the	allocated	time	was	reached.	Once	all	4	clips	
had	been	watched	and	scored	for	a	given	sequence,	the	participants	were	not	
allowed	to	revise	their	scores.	
	
6.2.6.	 Human	versus	offline	computer	analysis	of	video	clips		
A	random	selection	of	68	individual	video	clips,	taken	at	15	time	points	from	8	
patients	that	had	been	acquired	by	sublingual	IDF	video-microscopy	during	the	
MICROSHOCK	study8	were	analysed	offline	using	Automated	Vascular	Analysis	V.3.02	
(Microvision	Medical,	The	Netherlands).	Semi-automated	analysis	was	utilised	as	described	
in	greater	detail	elsewhere8	(fully	automated	analysis	was	not	performed).	All	video	clips	
were	rated	for	quality10,	and	then	semi-quantitative	data	were	recorded	for	each	video	clip	
according	to	consensus	guidelines7.	These	included	total	vessel	density	(TVD),	perfused	
vessel	density	(PVD),	proportion	of	perfused	vessels	(PPV),	and	microcirculatory	flow	index	
(MFI)	for	individual	clips;	and	microcirculatory	heterogeneity	index	(MHI)	for	each	time	
point.	Each	individual	video	clip	was	assigned	a	random	number	at	time	of	analysis,	and	
played	in	random	order	for	an	expert	user	(S.D.H.)	to	grade	according	to	the	POEM	scoring	
tool.	Therefore	the	expert	user	was	blinded	to	both	the	computer	analysis	parameters	and	
the	clinical	status	of	the	patients.		
Using	the	assessments	from	these	individual	video	clips,	POEM	scores	were	applied	
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to	all	15	time	points	according	to	the	algorithm	in	Figure	6.2	and	web-based	tool	(Figure	
6.3).	No	time	limit	was	imposed	for	the	expert	to	assign	POEM	scores	or	computer	analysis.	
The	time	taken	to	assign	POEM	scores	and	perform	computer	analysis	was	recorded.		
	
6.2.7.	 Ethics	approval	and	consent	to	participate	
All	videos	were	obtained	as	part	of	the	MICROSHOCK	study.	Research	Ethics	
Committee	(Yorkshire	and	Humberside	–	Leeds	West)	approval	was	granted	for	all	sites	
before	any	data	were	collected	(Ref:	14/YH/0078).	Consent	to	participate	in	the	study	was	
given	by	all	patients	except	where	they	lacked	capacity,	in	which	case	either	a	Personal	
Consultee	(close	friend	or	relative)	or	Nominated	Consultee	(Physician	looking	after	the	
patient	but	not	involved	in	the	study)	gave	consent	on	behalf	of	the	patient,	in	accordance	
with	the	approved	protocol.		
	
6.2.8.	 Data	analysis	
Inter-user	variability	for	the	ordinal	5-point	scale	was	assessed	using	the	intra-class	
correlation	coefficient	(ICC)	in	terms	of	both	consistency	(e.g.	do	participants	tend	to	score	
item	A	higher	than	item	B	but	lower	than	item	C)	and	agreement	(e.g.	do	participants	all	
tend	to	give	a	score	of	X	to	item	A	and	a	score	of	Y	to	item	B).		Values	are	presented	with	
95%	confidence	intervals	(CI).	Analysis	assumed	a	two-way	model	(where	both	the	video	
clips	and	individual	participants	are	regarded	as	random	samples	from	a	potential	larger	
pool	of	video	clips	and	participants).	Naïve	participant	scores	were	also	compared	to	expert	
scores	by	subtracting	the	true	expert	score	from	the	observed	rater	scores	and	then	
perform	a	linear	regression	on	these	‘error	scores’,	including	rater	and	video	sequence	as	
independent	predictors.			
Chapter	6	 	 Point-of-care	microcirculation	
	 147	
	 Values	from	computer	analysis	(PVD,	TVD,	PPV,	MFI,	and	MHI)	were	compared	to	
ordinal	POEM	scores	using	linear	regression.	Further	comparison	was	made	between	
computer	analysis	parameters	and	both	individual	video	scores	and	POEM	scores	as	
categorical	variables	(using	Kruskal-Wallis	analysis	followed	by	step-wise	paired	analysis	
using	Dunn’s	multiple	comparisons	test).	A	p-value	of	<	0.05	was	considered	significant.	
	
6.3.	 Results	
6.3.1.	 Study	participants	
There	were	32	study	participants,	including	12	consultants,	18	training-grade	
doctors,	and	2	intensive	care	nurses.	All	of	these	participants	worked	in	their	hospital’s	ICU.	
None	had	used	sublingual	video-microscopy	before,	and	all	were	naïve	to	IDF	video	analysis.	
All	participants	completed	the	training	and	assessment	sessions.	The	expert	user	(S.D.H.)	
who	conducted	the	offline	computer	analysis	and	POEM	scoring	has	previously	analysed	
over	1000	video-microscopy	clips.				
	
6.3.2.	 Inter-user	variability	
When	the	naïve	user	POEM	scores	were	analysed	to	determine	the	inter-user	
variability	between	clips	and	between	each	other,	the	ICC	values	for	consistency	and	
agreement	were	0.83	(95%	CI	0.626,	0.976)	and	0.815	(95%	CI	0.602,	0.974)	respectively.	
From	the	analysis	of	variance	between	users	and	expert,	there	was	greater	agreement	for	
“critically	impaired”	and	“normal”	but	higher	variability	for	the	scores	in	between;	both	item	
and	rater	were	significant	predictors	of	the	level	of	error	in	the	scores	when	compared	to	
expert	(p	<	0.001	and	p	=	0.046	respectively).	
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6.3.3.	 Human	versus	computer	analysis	of	video	clips	
When	traditional	offline	computer	analysis	parameters	were	compared	to	expert	
assigned	POEM	scores	there	was	good	correlation	with	PPV	(R2	=	0.71;	p	<	0.001),	PVD	(R2	=	
0.39;	p	<	0.05),	MFI	(R2	=	0.75;	p	<	0.001),	and	MHI	(R2	=	0.68;	p	<	0.001),	but	not	TVD	(R2	=	
0.03;	p	=	0.535)	(Figure	6.4).	
In	addition,	when	offline	computer	analysis	parameters	were	compared	to	expert	
assigned	grades	for	the	68	individual	video	clips,	these	scores	corresponded	well	to	
perfusion	(PPV	and	PVD)	and	flow	(MFI)	parameters,	but	there	was	no	statistically	
significant	relationship	to	the	pure	density	parameter	(TVD)	(Figure	6.5).		When	computer	
analysis	of	heterogeneity	(MHI)	and	flow	(MFI)	were	compared	to	POEM	scores	for	the	15	
time	points,	there	was	also	a	significant	association	(Figure	6.6).		
When	the	timings	were	compared	between	the	assignment	of	POEM	scores	and	
completion	of	computer	analysis	they	were	2	minutes	and	44	minutes	respectively	(p	<	
0.001).	
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Figure	6.4.		Relationship	between	traditional	offline	computer	analysis	and	individual	
POEM	scores.		
Dashed	lines	indicate	95%	confidence	interval	
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Figure	6.5.	Relationship	between	traditional	offline	computer	analysis	and	individual	
scores	for	video	clips	using	the	POEM	score	as	a	categorical	variable	
*p	<	0.05;	**p	<	0.01;	***p	<	0.001	
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Figure	6.6.	Relationship	between	offline	computer	analysis	of	microcirculatory	
heterogeneity	and	flow	indexes	and	POEM	scores,	with	the	POEM	score	as	a	categorical	
variable.		
*p	<	0.05;	**p	<	0.01	
	
	
	
6.4.	 Discussion		
The	current	study	reports	the	first	use	of	a	novel	5-point	grading	system	(the	POEM	
score)	for	the	hybrid	assessment	of	microcirculatory	flow	and	heterogeneity.	Naïve	users	
can	be	trained	to	assess	the	microcirculation	using	this	system,	and	have	produced	scores	
with	relative	consistency	and	agreement	even	after	just	one	teaching	session.	Furthermore,	
the	scoring	is	in	keeping	with	offline	computer	generated	analysis	of	flow,	perfusion	and	
heterogeneity	and	takes	several	minutes	rather	than	an	hour	to	perform.	It	is	a	user-
friendly,	straightforward	tool	that	may	be	used	as	a	point-of-care	test	in	the	observation	of	
patients	who	are	being	treated	for	shock.	Clinical	validation	and	further	examination	of	the	
real-time	applicability	are	required	before	the	5-point	grading	system	can	be	introduced	
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into	clinical	practice,	in	particular	in	relation	to	other	parameters	such	as	CO2	gap	and	
lactate.	The	POEM	scoring	system	has	the	potential	to	alert	the	clinician	to	lack	of	
haemodynamic	coherence,	and	also	to	the	degree	of	microcirculatory	disruption	in	terms	of	
flow	and	heterogeneity.		
The	semi-quantitative	“Boerma	Method”	of	assigning	MFI	values	during	sublingual	
video-microscopy11	has	the	potential	to	be	used	in	real-time.	Although	it	is	usually	
performed	offline	as	part	of	the	full	panel	of	agreed	parameters7,	it	has	also	been	used	at	
the	bedside	as	a	real-time	measurement	of	microcirculatory	flow	with	good	reliability	when	
compared	to	offline	computer	analysis12,	13.	The	current	study	shows	that	POEM	scores	
correspond	well	to	MFI	scores	from	the	same	video	sequences	for	both	individual	videos	
and	patient	time	points.	The	potential	advantage	of	the	POEM	scores	over	MFI	is	that	it	also	
appears	to	correspond	well	to	traditional	values	of	heterogeneity	(MHI),	flow	(PPV)	and	PVD	
(composite	flow	and	density)	rather	than	flow	alone.	The	MFI	approach	involves	
superimposing	a	quadrant	grid	over	the	video	images	and	then	grading	the	MFI	score	for	
each	quadrant	before	performing	a	calculation	to	determine	the	difference	in	minimum	and	
maximum	MFI	scores	compared	to	the	average.	By	contrast	the	POEM	score	requires	the	
user	to	identify	whether	more	than	5	vessel	segments	in	the	entire	field	have	flow	
abnormalities,	removing	the	potentially	artificial	quadrant	approach.	We	consider	that	such	
a	technique	is	easier	to	perform	for	naïve	users,	and	has	the	advantage	of	producing	a	single	
composite	ordinal	score	that	still	gives	accurate	information	about	the	state	of	overall	flow	
and	flow	heterogeneity.	
Although	heterogeneity	is	usually	presented	as	MHI	by	calculating	the	differences	in	
MFI	values,	the	POEM	score	uses	a	simplified	method	that	does	not	require	calculation,	in	
order	to	make	it	easier	to	use.	The	clinician	is	only	required	to	determine	whether	there	are	
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5	vessel	segments	different	to	the	rest	in	the	field	of	view,	regardless	of	quadrant.	Since	
POEM	scores	reflect	MHI	well,	this	method	may	not	necessarily	be	objectively	precise	but	
appears	to	be	suitable	in	determining	the	level	of	heterogeneity	for	the	purposes	of	a	5-
point	ordinal	scale	as	well	as	full	traditional	MHI	calculations.	
Recently	some	investigators	have	demonstrated	that	visual	inspection	by	clinicians	
may	have	good	agreement	with	more	detailed	offline	computer	analysis,	making	the	
prospect	of	point-of-care	microcirculatory	analysis	more	of	a	realistic	prospect14.		A	further	
study	has	demonstrated	feasibility	of	bedside	microcirculatory	monitoring	by	critical	care	
nursing	staff15.	If	a	clinician	is	to	utilise	sublingual	microcirculatory	monitoring	to	direct	
treatment	in	real-time,	the	video	microscopy	must	be	interpreted	in	a	validated,	graded,	
replicable	manner	with	minimum	inter-user	variability.	If	the	clinician	can	determine	that	
the	patient	has	lost	haemodynamic	coherence	using	a	grading	system	of	microcirculatory	
dysfunction,	then	alterations	to	therapy	might	be	made	that	otherwise	would	have	been	
guided	by	macrocirculatory	parameters	alone.	A	grading	system	of	severity	of	
microcirculatory	dysfunction	may	aid	in	diagnosis,	prognosis	and	management.		
Although	it	has	been	an	aspiration	for	some	time,	the	real-time	monitoring	of	the	
microcirculation	at	the	point-of-care	has	been	more	of	a	futuristic	prospect16,	17	rather	than	
a	present-day	clinical	tool	in	the	armoury	of	the	clinician.	It	is	timely	to	bring	the	available	
expertise	and	technology	into	clinical	practice.	Technology	has	advanced	so	that	handheld,	
ergonomic	instruments	(such	as	the	IDF	videomicroscope	(Cytocam,	Braedius	Medical	B.V.,	
Huizen,	The	Netherlands))	can	be	used	to	visualise	the	sublingual	microcirculation	with	ease	
and	speed.	There	has	been	a	decade	of	research	since	the	2006	microcirculation	consensus	
meeting7,	and	yet	microcirculatory	monitoring	has	been	confined	to	the	realm	of	research	
during	that	time.	The	microcirculation	community	eagerly	awaits	automated	computer-
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generated	analysis	so	that	the	microcirculation	can	be	assessed	without	the	requirement	for	
offline	analysis.	However,	it	is	likely	even	with	such	technology	that	a	more	simplified	
clinical	grading	system	will	be	of	maximal	utility	for	the	clinician	at	the	point-of-care.	
Essentially	the	clinician’s	two	primary	aims	when	monitoring	the	microcirculation	are	(i)	to	
determine	whether	there	is	loss	of	haemodynamic	coherence;	and	(ii)	to	determine	the	
degree	of	microcirculatory	disruption.	These	factors	have	the	potential	to	guide	therapy.		
Traditional	offline	measurements	of	microcirculatory	function	will	be	of	continued	
value	in	the	research	context	for	studies	that	utilise	microcirculatory	parameters	as	
resuscitation	outcome	measures.	They	will	also	be	important	when	testing	particular	
therapeutic	measures	following	shock,	and	in	providing	diagnostic	information	(such	as	type	
of	shock	and	classification	of	subtypes),	and	in	tailoring	therapy	to	specific	requirements.	
The	benefit	of	the	POEM	score	in	the	clinical	context	is	that	it	is	faster	to	obtain,	can	more	
easily	be	used	in	real-time,	and	has	the	potential	to	guide	and	direct	therapy	at	the	bedside.	
Rather	than	replacing	traditional	numerical	values,	the	POEM	score	is	designed	so	that	it	can	
be	used	concurrently.	One	of	the	potential	uses	of	the	POEM	score	is	as	an	early	warning	
marker	for	microcirculatory	dysfunction	and	loss	of	coherence.	More	detailed	assessment	of	
the	microcirculation	will	still	be	required	to	determine	the	precise	nature	of	
microcirculatory	dysfunction.	
	
6.4.1.	 Future	avenues	of	research	
The	POEM	score	does	not	replace	traditional	parameters	in	their	role	as	research	
endpoints.	Rather,	it	brings	the	overall	assessment	of	the	microcirculation	forward	to	the	
point-of-care,	in	order	to	act	as	guidance	of	initial	therapy.	It	is	not	currently	known	
whether	this	will	improve	outcomes	for	patients,	but	future	prospective	randomised	studies	
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may	wish	to	test	the	utilisation	of	the	POEM	score	versus	standard	practice	in	the	
management	of	patients	in	shock	(such	as	septic	or	traumatic	haemorrhagic	shock).	
Furthermore,	it	is	possible	that	the	clinician	might	direct	resuscitative	fluids	in	a	manner	
that	addresses	microcirculatory	dysfunction	when	such	a	phenomenon	is	detected	at	the	
point-of-care	(rather	than	being	falsely	reassured	by	satisfactory	global	haemodynamic	
parameters).	Recent	studies	have	reported	that	the	delivery	of	plasma	appears	to	have	
restorative	function	on	the	endothelial	glycocalyx	and	ameliorate	the	endotheliopathy	of	
trauma	18,	19.	Could	the	detection	of	microcirculatory	failure	and	subsequent	delivery	of	
plasma	in	a	circumstance	where	such	therapy	would	be	omitted	be	beneficial	to	patients?	
Such	a	question	remains	unanswered	in	a	clinical	context	and	may	be	a	promising	avenue	
for	future	research.	However,	such	research	depends	entirely	on	a	rapid	and	reproducible	
assessment	of	the	microcirculation	at	the	point-of-care	–	something	that	the	POEM	
assessment	tool	may	provide.	
The	introduction	of	user-dependency	on	a	point-of-care	test	is	not	without	
precedence;	cardiac	echo	and	ultrasonography	are	some	obvious	examples	of	techniques	
that	require	high	quality	assessment	by	expert	users	for	reliable	readings.	Trained	users	are	
accustomed	to	the	practice	of	a	fast,	efficient	assessment	of	patients	in	the	Emergency	
Department	(ED)	in	the	case	of	focused	assessment	with	sonography	in	trauma	(FAST).	
Quality	assurance	and	regular	training,	experience	and	revalidation	should	be	of	upmost	
importance	amongst	microcirculation	monitoring	users	if	their	point-of-care	assessment	
were	to	enter	the	domain	of	clinical	utility.	The	current	study	did	not	test	the	level	of	skill	
fade	or	utility	of	the	scoring	system	after	a	time	interval,	but	these	are	aspects	of	training	
and	professional	development	that	would	require	attention	if	the	POEM	score	were	to	be	
used	clinically.	Similarly,	devices	and	technology	would	need	to	come	under	the	scrutiny	of	
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clinical	point-of-care	governance	to	ensure	safety	and	consistency	in	clinical	practice.		
If	real-time	microcirculatory	assessment	is	to	be	performed	at	the	bedside,	then	
quality	assessment	of	video	clips	must	also	be	undertaken	before	an	assessment	of	flow	and	
heterogeneity	can	be	made.	The	current	study	only	utilised	videos	that	were	high	quality;	
whether	poorer	quality	videos	in	a	real-world	scenario	might	lead	to	more	variability	in	
grading	is	unknown.	The	assessment	of	quality	needs	to	be	consistent,	and	reproducible,	
and	with	little	inter-user	variability.	In	particular,	attention	should	be	paid	to	guarding	
against	pressure	artefact,	perhaps	by	ensuring	that	there	are	visible	flowing	venules	within	
the	field	of	view.			
A	decision	was	made	early	in	the	formation	of	the	POEM	score	to	not	incorporate	an	
assessment	of	vessel	density,	instead	favouring	assessments	of	flow	and	heterogeneity.	
Assessment	of	density	was	not	a	good	discriminator	between	video	clips	when	testing	the	
early	forms	of	the	scoring	system.	Early	pilot	testing	of	the	scoring	system	also	showed	that	
density	assessment	was	difficult	to	apply	in	a	manner	that	would	accurately	reflect	TVD	
values.	Nevertheless,	POEM	scores	do	correspond	well	to	PVD,	which	is	in	itself	a	mixed	
density	and	perfusion	variable.	Since	the	POEM	score	corresponds	well	to	PPV,	PVD,	MFI,	
and	MHI,	it	is	the	first	tool	to	yield	a	composite	assessment	of	flow	and	heterogeneity	and	
also	yield	potentially	meaningful	data	regarding	perfusion	and	perfused	vessel	density.				
	
6.4.2.	 Limitations	
None	of	the	POEM	study	subjects	were	physically	next	to	a	patient’s	bedside	when	
assigning	POEM	scores.	It	is	unknown	whether	this	physical	proximity	and	patient	contact	
would	influence	the	scoring	or	performance	of	the	test.	Instead,	the	study	subjects	were	
blinded	to	patient	status	in	order	to	establish	the	scoring	system	without	any	bias	that	
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clinical	exposure	might	bring.	Further	validation	at	the	patient’s	bedside	may	be	warranted	
in	future	studies	that	utilise	the	POEM	score.		
This	study	utilised	video-microscopy	clips	of	patients	with	traumatic	haemorrhagic	
shock.	Further	validation	in	other	clinical	scenarios	such	as	sepsis	and	following	major	
surgery	are	required	in	order	to	determine	whether	this	scoring	tool	has	more	generalisable	
utility.		
Although	there	is	a	good	association	between	POEM	assessments	and	PVD,	the	
POEM	scoring	system	does	not	take	into	account	pure	density	parameters	of	the	
microcirculation	(such	as	TVD).	This	may	limit	its	usefulness	in	determining	the	aetiology	of	
the	microcirculatory	derangement.	Measures	to	determine	density	parameters	must	rely	on	
alternative	techniques,	which	are	currently	not	available	at	the	point-of-care.			
	
6.5.	 Conclusion	
A	new	5-point	ordinal	scoring	system	of	microcirculatory	flow	and	heterogeneity	has	
been	tested	amongst	healthcare	professionals	at	two	large	UK	teaching	hospitals,	and	has	
relatively	high	consistency	and	agreement	even	after	just	1	hour	of	training.	POEM	scores	
take	a	matter	of	minutes	to	assign,	and	correspond	well	to	computer-analysis	variables	of	
flow,	perfusion	and	heterogeneity.	This	novel	point-of-care	microcirculatory	assessment	
tool	is	quick,	reliable,	and	gives	potentially	meaningful	clinical	parameters	that	might	guide	
resuscitation.	Prospective	randomised	trials	utilising	goal-directed	therapy	targeted	at	the	
POEM	score	are	required	to	test	its	real-life	clinical	utility.	
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What	is	the	optimal	fluid	to	resuscitate	the	
microcirculation	following	haemorrhagic	shock?	
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The	following	chapter	is	adapted	from	these	two	published	articles:	
	
Naumann	DN,	Dretzke	J,	Hutchings	S,	Midwinter	MJ.	Protocol	for	a	systematic	review	of	the	
impact	of	resuscitation	fluids	on	the	microcirculation	after	haemorrhagic	shock	in	animal	
models.	Systematic	reviews.	2015;4:135.	
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fluid	to	restore	microcirculatory	flow	dynamics	after	haemorrhagic	shock:	a	systematic	
review	of	preclinical	studies.	Shock.	2016;46(6):609-22.	
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7.1.	 Introduction	
In	the	previous	two	chapters	we	have	discussed	that	early	microcirculatory	
monitoring	can	be	safely	performed	in	the	Emergency	Department,	even	for	very	unwell	
patients,	and	that	the	microcirculation	can	be	assessed	in	real-time	rather	than	waiting	to	
perform	offline	analysis	away	from	the	patient.	If	bedside	monitoring	of	the	microcirculation	
is	performed	in	the	clinical	domain,	then	it	has	the	potential	to	guide	fluid	resuscitation	of	
patients	with	traumatic	haemorrhagic	shock.	It	is	unknown	what	type	of	fluid	is	optimal	for	
the	restoration	of	microcirculatory	flow	in	this	setting,	since	there	is	a	sparsity	of	data	from	
humans.	However,	there	are	many	pre-clinical	(animal)	studies	that	examine	the	effects	of	
different	fluids	on	the	microcirculation	after	haemorrhagic	shock.	The	following	chapter	is	a	
review	of	all	the	available	pre-clinical	literature	in	order	to	determine	which	fluid—or	which	
components	of	fluids—are	most	effective	at	restoring	the	microcirculation	following	
haemorrhagic	shock	in	animal	models.				
Alterations	in	the	microcirculation	have	been	reported	as	more	reliable	than	global	
parameters	in	predicting	clinical	outcome	following	septic	shock1	and	traumatic	
haemorrhage2.	Improved	microcirculatory	flow	during	resuscitation	is	associated	with	
reduced	organ	failure	even	when	there	is	no	difference	in	global	haemodynamic	factors3.	
Even	when	global	parameters	are	improved	following	shock,	this	may	not	be	associated	
with	improvements	in	the	microcirculation	and	tissue	perfusion4.	In	such	circumstances	
there	appears	to	be	a	clinically	meaningful	discrepancy	between	the	macro	and	
microcirculatory	behaviour.	During	normal	physiological	conditions	both	microcirculatory	
flow	and	tissue	perfusion	are	determined	by	the	circulatory	pressure	and	volume.	This	
phenomenon	is	known	as	‘haemodynamic	coherence’5.	This	coherence	may	be	lost	during	
circulatory	shock,	and	therefore	global	surrogate	markers	may	no	longer	be	relied	on	as	
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markers	of	microcirculatory	function	in	that	context	–	a	rationale	for	monitoring	of	the	
microcirculation	following	shock.	
During	resuscitation	of	patients	with	haemorrhagic	shock,	fluid	delivery	is	intended	
to	increase	oxygen	delivery	to	tissues	to	meet	demand,	repay	oxygen	debt,	eliminate	
lactate,	and	normalise	pH.	These	processes	all	occur	at	the	level	of	the	microcirculation,	
representing	a	key	anatomical	location	during	shock	and	resuscitation.	Although	pre-clinical	
studies	have	been	conducted	to	measure	global	haemodynamic	parameters	(such	as	blood	
pressure	and	heart	rate)	following	haemorrhagic	shock	and	resuscitation6,	7,	these	surrogate	
markers	of	microcirculatory	flow	may	not	be	relevant	in	the	case	of	loss	of	haemodynamic	
coherence.	Microcirculatory	flow	and	dynamics	therefore	represent	relevant	study	
endpoints	for	the	assessment	of	resuscitation	fluid	delivery	after	haemorrhagic	shock,	and	
would	be	parameters	of	importance	if	point-of-care	microcirculatory	monitoring	were	to	be	
considered.	
Current	clinical	resuscitative	practice	favours	the	utilisation	of	blood	products	(rather	
than	crystalloid	fluids)	following	haemorrhagic	shock,	but	there	are	no	randomised	clinical	
studies	that	compare	the	microcirculation	during	different	fluid	resuscitation	regimes.	In	
order	to	guide	clinical	investigation	and	form	credible	hypotheses	for	testing	in	clinical	
research,	it	is	timely	to	review	the	pre-clinical	literature	and	determine	the	current	state	of	
evidence.	No	previous	systematic	reviews	on	this	topic	were	identified	during	preliminary	
searches	on	MEDLINE	and	the	Cochrane	library.	It	was	hypothesised	that	provision	of	
haemoglobin	and	plasma,	in	particular	by	whole	blood,	may	be	superior	to	other	fluid	
characteristics	in	the	restoration	of	the	microcirculation	following	haemorrhagic	shock	
(Hypothesis	8;	Table	1.1).			
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7.1.1.	 Aim	
The	current	systematic	review	aims	to	examine	all	available	pre-clinical		
studies	of	haemorrhagic	shock	that	use	microcirculatory	parameters	as	research	endpoints	
and	compare	the	efficacy	of	at	least	one	type	of	fluid	for	resuscitation.		
	
7.2.	 Methods	
This	systematic	review	is	intended	to	address	the	impact	of	resuscitation	fluids	on	
the	behaviour	of	the	microcirculation	in	animal	models	of	haemorrhagic	shock.		
The	protocol	for	this	systematic	review	has	been	published	previously8,	and	made	freely	
available	through	Open	Access	and	registration	at	the	Collaborative	Approach	to	Meta-
Analysis	and	Review	of	Animal	Data	from	Experimental	Studies	(CAMARADES)9.	Systematic	
review	methodology	is	reported	according	to	the	Preferred	Reporting	Items	for	Systematic	
Reviews	and	Meta-Analyses	(PRISMA)	guidelines10.		
	
7.2.1	 Research	questions	
This	is	the	first	review	to	examine	the	impact	of	different	fluid	resuscitation	techniques	on	
the	physical	structure	and	function	of	the	microcirculation	in	animal	models.	The	following	
questions	will	be	addressed:	
• What	is	the	impact	of	intravascular	fluid	resuscitation	on	the	microcirculation	
following	haemorrhagic	shock,	compared	to	haemorrhagic	shock	alone?	
• Which	type	of	fluid	has	the	most	impact	on	the	microcirculation	following	
haemorrhagic	shock?	
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7.2.2.	 Study	subjects	
This	systematic	review	includes	studies	that	utilise	animal	models	of	haemorrhagic	
shock	(any	size,	age,	strain	and	species).	Any	volume	of	haemorrhage	(survivable	or	non-
survivable)	was	allowed	as	long	as	the	intention	was	to	create	a	period	of	circulatory	shock	
after	which	fluid	resuscitation	was	delivered.	Study	protocols	with	additional	elements	such	
as	trauma	were	still	eligible	for	inclusion.	Studies	that	utilised	isovolaemic	exchange	
transfusion,	ischaemia-reperfusion,	or	septic	shock	models	were	excluded	unless	they	also	
contained	a	subgroup	of	haemorrhagic	shock.	
	
7.2.3.	 Interventions	
Studies	that	used	at	least	one	type	of	fluid	intervention	for	resuscitation	following	
haemorrhage	were	eligible	for	inclusion.	There	were	multiple	interventions	of	interest,	
broadly	categorised	as:	(i)	blood	products	(e.g.	whole	blood,	packed	red	cells	(PRBCs),	
plasma);	(ii)	haemoglobin-based	oxygen	carriers	(HBOC)	(e.g.	modified	bovine	
haemoglobin);	(iii)	crystalloids	(e.g.	Ringer’s	lactate,	0.9%	or	hypertonic	saline);	and	(iv)	
colloids	(e.g.	albumin,	dextran,	starch).		
	
7.2.4.	 Comparisons	
The	studies	included	in	this	systematic	review	were	varied	in	both	methodology	and	
research	question.	Multiple	permutations	of	fluid	comparisons	were	made	(for	example	
blood	product	versus	crystalloid,	and	colloid	versus	crystalloid).	Some	studies	use	
haemorrhagic	shock	alone	as	a	control,	and	some	use	surgical	instrumentation	(sham)	as	a	
control.	These	comparisons	are	summarised	in	narrative	form.		
	
Chapter	7	 	 Fluids	to	restore	the	microcirculation	
	 166	
7.2.5.	 Outcomes	
The	outcomes	of	interest	included	any	parameter	that	was	intended	to	represent	
the	physical	microcirculatory	behaviour.	These	included:	flow	rate	(nL/s);	red	blood	cell	
velocity	(mm/s),	vessel	diameter	(μm);	Functional	capillary	density	(%);	glycocalyx	thickness	
(μm);	Shear	rate	(s-1);	proportion	of	perfused	vessels	(%);	vessel	density	(n/mm);	perfused	
vessel	density	(n/mm);	microcirculatory	flow	index;	blood	flow	intensity;	and	heterogeneity	
index.	Studies	that	only	examined	physiological	aspects	of	the	microcirculation	such	as	
lactate,	oxygen	partial	pressures,	and	delivery	of	oxygen	but	did	not	report	physical	(flow	
dynamics)	parameters11-19	were	excluded.	
	
7.2.6.	 Study	design	
Studies	were	included	if	they	were	controlled	prospective	animal	studies	with	
detailed	reporting	of	the	type	and	amount	of	fluid(s)	used	and	at	least	one	microcirculatory	
physical	parameter.	Although	randomised	studies	with	blinded	outcome	assessment	were	
considered	preferable,	prospective	studies	without	such	design	were	still	eligible	for	
inclusion.	Single	case	reports	and	letters	were	rejected.	Conference	proceedings	and	
abstracts	were	screened	for	new	data	and	adequate	methodological	detail.	They	were	only	
included	if	they	contained	new	data	(not	replicated	by	full	papers	from	the	same	authors	
and	time	period).	Uncontrolled	studies	were	recorded	but	not	included	in	the	analysis.	
	
7.2.7.	 Search	strategy	
The	following	sources	were	searched	for	primary	studies:	EMBASE	and	Medline	(via	
OVID	SP)	and	SCOPUS.	Before	starting	the	review,	scoping	searches	were	undertaken	to	
identify	any	existing	systematic	reviews	of	the	impact	of	resuscitative	fluids	on	the	
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microcirculatory	changes	during	haemorrhagic	shock	and	to	gauge	the	number	and	type	of	
relevant	primary	studies.	No	systematic	reviews	were	identified,	but	there	are	a	number	of	
pre-clinical	studies.	The	systematic	search	was	undertaken	using	a	combination	of	text	and	
MeSH	terms	relating	to	the	intervention	(e.g.	“bleed”,	“transfusion”,	“fluid	resuscitation”,	
“colloid”,	“red	blood	cells”),	to	the	condition	(e.g.	“haemorrhage”,	“trauma”,	“injury”,	
“shock”),	and	to	the	microcirculation	(e.g.	“microcirculation’,	“endothelium”,	“capillary”).	
The	search	strategies	were	broad	in	order	to	capture	any	study	that	has	explored	
resuscitation	fluids	and	microcirculatory	changes	in	the	context	of	haemorrhagic	shock,	
regardless	of	study	design,	study	subjects,	method	of	assessment,	or	outcomes	reported.	
There	were	no	language	or	date	restrictions,	or	restrictions	by	publication	type.	Citations	
were	collated	using	EndNote	reference	management	software	(V.X7,	Thomson	Reuters).	An	
example	of	a	search	strategy	used	is	shown	in	Table	7.1.	
	
7.2.8.	 Study	Selection	
All	titles	and	abstracts	were	screened	by	two	independent	reviewers,	and	full	texts	
were	obtained	for	studies	that	appeared	to	be	of	interest.	Eligible	studies	were	identified	
from	reading	the	full	texts.	References	from	full	texts	were	further	screened	for	potentially	
relevant	papers	using	pre-defined	selection	criteria.	Discrepancies	between	reviewers	were	
resolved	by	discussion	or	by	referring	to	a	third	reviewer.	
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Table	7.1.	Example	of	a	search	strategy	using	MEDLINE	
Step	 Search	term	 Results	
1	 haemorrhag$.mp.	 42370	
2	 hemorrhage.mp.	or	exp	Hemorrhage/	 317823	
3	 bleed$.mp.	 152764	
4	 trauma.mp.	or	exp	"Wounds	and	Injuries"/	 815484	
5	 shock.mp.	or	exp	Shock,	Hemorrhagic/	or	exp	Shock,	Traumatic/	or	exp	Shock/	 188261	
6	 microcirculation.mp.	or	exp	Microcirculation/	 41855	
7	 microcirculat$.mp.	[mp=title,	abstract,	original	title,	name	of	substance	word,	
subject	heading	word,	keyword	heading	word,	protocol	supplementary	concept	
word,	rare	disease	supplementary	concept	word,	unique	identifier]	
44370	
8	 capillar$.mp.	or	exp	Capillaries/	 144927	
9	 exp	Endothelium/	or	endothelium.mp.	 149398	
10	 1	or	2	or	3	or	4	or	5	 1342437	
11	 7	or	8	or	9	 308688	
12	 10	and	11	 21552	
13	 (fluid$	adj3	resuscitat$).mp.	[mp=title,	abstract,	original	title,	name	of	
substance	word,	subject	heading	word,	keyword	heading	word,	protocol	
supplementary	concept	word,	rare	disease	supplementary	concept	word,	
unique	identifier]	
4445	
14	 (fluid$	adj3	administrat$).mp.	[mp=title,	abstract,	original	title,	name	of	
substance	word,	subject	heading	word,	keyword	heading	word,	protocol	
supplementary	concept	word,	rare	disease	supplementary	concept	word,	
unique	identifier]	
3158	
15	 normal	saline.mp.	 15704	
16	 exp	Fluid	Therapy/	or	crystalloid$.mp.	 20028	
17	 (colloid$	adj3	resuscitat$).mp.	[mp=title,	abstract,	original	title,	name	of	
substance	word,	subject	heading	word,	keyword	heading	word,	protocol	
supplementary	concept	word,	rare	disease	supplementary	concept	word,	
unique	identifier]	
212	
18	 (red	blood	cell$	or	RBC	or	plasma	or	platelet$	or	whole	blood	or	blood	product$	
or	blood	component$).mp.	[mp=title,	abstract,	original	title,	name	of	substance	
word,	subject	heading	word,	keyword	heading	word,	protocol	supplementary	
concept	word,	rare	disease	supplementary	concept	word,	unique	identifier]	
1033868	
19	 exp	Blood/		 962483	
20	 18	or	19		 1806182	
21	 (resuscitat$	or	transfus$).mp.	[mp=title,	abstract,	original	title,	name	of	
substance	word,	subject	heading	word,	keyword	heading	word,	protocol	
supplementary	concept	word,	rare	disease	supplementary	concept	word,	
unique	identifier]		
182117	
22	 20	and	21		 54184	
23	 13	or	14	or	15	or	16	or	17	or	22		 91548	
24	 12	and	23		 1126	
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7.2.9.	 Data	extraction				
Data	extraction	was	performed	by	one	reviewer	(D.N.N.)	and	confirmed	by	another	
(A.B.).	Data	were	extracted	with	regards	to	study	characteristics	and	design	(author,	year,	
type	of	study,	hypothesis),	animal	model	(species,	age,	experimental	groups,	size/weight,	
housing),	number	of	animals	(haemorrhagic	shock	and	resuscitation	only),	and	haemorrhage	
protocol	(technique,	percentage	and	volume	of	bleeding,	timings,	and	target	pressures).	
Details	regarding	interventions	(type	and	timings),	and	microcirculatory	monitoring	
(technique,	anatomical	location)	were	also	extracted.	Primary	method	for	data	extraction	
was	to	take	the	numerical	values	directly	from	the	results	sections	and	tables	of	individual	
studies.	Where	only	percentages	were	reported	in	the	place	of	raw	numerical	data,	the	
numerical	values	were	calculated	based	on	the	reported	percentage	and	denominator.	
Where	a	numerical	value	is	missing	but	the	data	were	displayed	graphically,	a	digital	screen	
ruler	was	used	to	extract	the	numerical	data.		
	
7.2.10.	Quality	assessment		
Two	reviewers	(D.N.N.	and	A.B.)	assessed	the	included	studies	based	on	the	
Systematic	Review	Centre	for	Laboratory	animal	Experimentation	(SYRCLE)	risk	of	bias	
tool20.	This	tool	assesses	selection,	performance,	detection,	attrition,	and	reporting	biases.		
	
7.2.11.	Translatability	
The	validity	of	study	design	with	regards	to	translatability	to	clinical	practice	was	
examined	by	two	authors	(D.N.N.	and	A.B.)	for	each	study	based	on	the	three	domains	
described	by	Henderson	et	al:	(i)	threats	to	internal	validity;	(ii)	threats	to	construct	validity;	
and	(iii)	threats	to	external	validity21.		For	the	“threats	to	internal	validity”	domain,	there	are	
Chapter	7	 	 Fluids	to	restore	the	microcirculation	
	 170	
points	for	power	calculation,	blinding,	randomisation,	appropriate	controls,	demonstrating	
the	flow	of	animals	through	the	experiments,	and	study	of	a	dose-response	relationship.	For	
the	“construct	validity”	domain,	there	are	points	for	baseline	characteristics	of	animals,	
matching	the	animal	model	(including	age)	to	the	human	disease,	and	characterisation	of	
the	mechanistic	pathway	of	the	treatment	response.	For	the	“external	validity”	domain,	
there	are	points	for	replication	of	experiments	in	different	animals,	laboratories,	and	
models	of	the	same	disease.	The	domain	relating	to	outcome	measure	validity	was	omitted	
since	this	systematic	review	only	includes	studies	with	pre-defined	outcome	measures	
(microcirculatory	physical	parameters)	that	are	considered	valid	endpoints	of	shock	
resuscitation.			
7.3.	 Results	
7.3.1.	 Search	results	
Figure	7.1	shows	the	PRISMA	diagram	for	the	study	selection.	The	initial	search	
strategy	identified	3103	studies,	from	which	369	full	texts	were	examined.	There	were	71	
studies	that	measured	the	impact	of	resuscitation	fluids	on	the	microcirculation	in	an	animal	
model	of	haemorrhagic	shock22-92.		
	
7.3.2.	 Study	characteristics	
The	71	included	studies	were	published	between	1990	and	2015,	and	include	67	
original	articles	and	4	conference	proceedings/abstracts	with	45	individual	first	authors.	
Countries	of	origin	are	listed	as:	Austria,	Brazil,	Canada,	China,	France,	Germany,	Hungary,	
Italy,	Japan,	Spain,	Taiwan,	and	the	USA.	All	studies	were	prospective,	experimental	
controlled	studies.	Although	random	allocation	of	intervention	and	control	arms	was	
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implied	by	all	studies,	the	words	“random”	or	“randomly”	were	only	explicitly	reported	in	
52/71	(73%)	of	studies.		
	
	
Figure	7.1.	PRISMA	diagram	to	illustrate	search	results	
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7.3.3.	 Animal	characteristics		
All	studies	included	a	single	species	experimental	model.	Animal	characteristics	are	
summarised	in	Table	7.2,	and	included	62	rodent,	5	canine,	and	4	porcine	studies.	A	total	of	
1959	animals	underwent	haemorrhagic	shock	and	resuscitation	in	the	included	studies.	
There	were	55	studies	that	reported	the	sex	of	the	animals,	of	which	48	included	only	male	
animals,	4	studies	had	mixed	male	and	female	animals,	and	3	included	only	female	animals.		
	
	
Table	7.2.		Animal	characteristics	of	included	studies	
Species	 Animals		 Studies	 Weight	range	 Awake,	%	 References	
Rat	 1149	 31	 120–460	g	 0	 22-24,	35,	40-42,	46,	48,	
50,	51,	54-57,	64,	68,	
72-77,	81-83,	88-92	
Hamster	 518	 26	 40–75	g	 100	 25-34,	47,	49,	52,	60,	62,	
63,	65,	70,	71,	78-80,	
84-87	
Rabbit	 94	 3	 0.8–3.5	kg		 0	 53,	59,	61	
Pig	 74	 4	 7–45	kg	 0	 43-45,	58	
Mouse	 68	 2	 25–30	g	 0	 66,	67	
Dog	 56	 5	 22–35	kg		 0	 36-39,	69	
	 	 	 	 	 	 	
	
	
7.3.4.	 Haemorrhagic	shock	protocols	
A	haemorrhagic	shock	protocol	was	described	in	all	studies,	and	was	heterogeneous,	
as	illustrated	in	Table	7.3.	Some	studies	bled	the	animals	to	target	values	or	percentage	of	
mean	arterial	pressures,	whereas	others	bled	to	a	percentage	of	total	blood	volume	or	
weight.	The	length	of	time	of	the	“shock”	phase	was	also	variable.		
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Table	7.3.	Summary	of	haemorrhage	protocol	targets	and	timings	
	
Haemorrhage	
protocol	
N	
Target	%	
of	blood	
volume	
lost	
Target	MAP,	
mmHg	
Target	
%	of	
MAP	
Target	
mL/kg	
bled	
Period	of	
shock,	
minutes		
References	
Volume	controlled	haemorrhage	
%	of	total	blood	volume	
lost		
27	 50	(50–50)		 N/A	 N/A	 N/A	 60	(60–60)	 26-34,	53,	58,	
60,	63-65,	73-
76,	78-80,	84-
87,	91	
	
Bled	a	specific	volume	of	
blood	per	kg	
6	 N/A	 N/A	 N/A	 30	(30–
30)	
40	(30–57.5)		 43,	44,	48,	50,	
88,	89	
Pressure	controlled	haemorrhage	
Bled	to	a	target	MAP	 26	 N/A	 40	(37.5–40)		 N/A	 N/A	 60	(45–60)	 22-24,	35,	40-
42,	46,	47,	49,	
51,	54-57,	61,	
66-69,	77,	81-
83,	90,	92	
	
Bled	to	both	%	of	total	
blood	volume	and	target	
MAP		
11	 50	(40–50)	 40	(37.5–48.8)		 N/A	 N/A	 45	(36–60)		 25,	36-39,	45,	
52,	59,	62,	70,	
71	
	
Bled	to	a	%	of	MAP	 1	 N/A	 N/A	 50	 N/A	 30*	 72	
All	values	are	expressed	as	median,	with	interquartile	range	in	brackets	unless	otherwise	specified	
*This	is	a	single	value	rather	than	a	median	
	
	
7.3.5.	 Microcirculatory	monitoring	techniques	
Several	different	techniques	and	anatomical	locations	were	used	to	determine	
microcirculatory	parameters,	as	summarised	in	Table	7.4.	Five	studies41,	56,	69,	88,	89	examined	
the	microcirculation	in	multiple	regions,	and	the	remainder	studied	only	one	anatomical	
location.	One	study	conducted	haemorheological	analysis	externally	(from	blood	samples)	
without	specific	anatomical	location92.	Some	studies	used	a	combination	of	techniques	at	
the	same	anatomical	location40,	58.	Intravital	microscopy	was	the	most	common	technique	
used	for	microcirculatory	visualisation,	with	dorsal	skin	fold	and	bowel/mesentery	being	the	
most	common	anatomical	locations.	Only	five	studies	used	sidestream	dark	field	microscopy	
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(SDF)43,	44,	58,	61,	69,	which	is	considered	the	most	appropriate	technique	for	clinical	
assessment93.		
	
Table	7.4.	Anatomical	location	and	techniques	for	microcirculatory	parameter	acquisition	
	
	
7.3.6.	 Fluid	comparisons	
There	were	multiple	comparisons	made	between	fluids	in	the	included	studies,	
summarised	in	Table	7.5.	There	were	29	permutations	of	sham	(no	haemorrhage),	
haemorrhage	only,	blood	product,	HBOC,	crystalloid	and	colloid	fluid	administration.			
	 	 References		 	 	 	 	 	
Anatomical	
location	
Studies	 Intravital	
microscopy	
Laser	
speckle	
contrast	
imaging	
Sidestream	
dark	field	
microscopy	
Laser	
Doppler	
flowmetry	
probe	
Electron	
microscopy	
Orthogonal	
polarisation	
spectral	
imaging	
Dorsal	skin	
fold	
26	 25-34,	47,	
49,	52,	60,	
62,	63,	65,	
70,	71,	78-
80,	84-87	
	 	 	 	 	
Bowel	/	
mesentery	
15	 35,	41,	48,	
50,	51,	64,	
72,	91	
88,	89	 61,	69	 46	 54	 77	
Liver	 9	 22,	23,	40,	
55,	57,	68,	
81	
88,	89	 	 40	 	 	
Cremaster	 5	 66,	67,	73,	
75,	76	
	 	 	 	 	
Skeletal	
muscle	
6	 24,	41,	42,	
59	
88,	89	 	 	 	 	
Conjunctiva	 4	 36-39	 	 	 	 	 	
Sublingual	 5	 	 	 43,	44,	58	 45,	58	 	 	
Kidney	 5	 41	 88,	89	 	 46,	56	 	 	
Pancreas	 2	 82,	83	 	 	 	 	 	
Brain	 2	 	 	 	 46,	56	 	 	
Internal	
spermatic	
fascia	
1	 90	 	 	 	 	 	
Buccal	
mucosa	
1	 	 	 69	 	 	 	
Ear	
chamber	
1	 53	 	 	 	 	 	
Heart	 1	 	 	 	 46	 	 	
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Table	7.5.	Resuscitative	fluid	comparisons	in	included	studies	
	
Studies	 Sham	(no	
haemorrhage)	
Haemorrhage	
only	
Blood	
product(s)	
Oxygen	
carrier(s)	
Crystalloid(s)	 Colloid(s)	
Torres	2013	 ✔	 ✔	 ✔	 	 ✔	 ✔	
Kozar	2011	 ✔	 ✔	 ✔	 	 ✔	 	
Zhao	2009,	Wu	2015(b)	 ✔	 ✔	 	 	 ✔	 ✔	
Wu	2015(a)	 ✔	 ✔	 	 	 ✔	 	
Paxian	2003	 ✔	 	 ✔	 ✔	 ✔	 ✔	
Von	Dobschuetz	1999	 ✔	 	 ✔	 ✔	 	 ✔	
Kubulus	2009	 ✔	 	 ✔	 ✔	 	 	
Paes-da-Silva	2003	 ✔	 	 ✔	 	 ✔	 ✔	
Ni	2013,	Torres	2014	 ✔	 	 ✔	 	 ✔	 	
Torres	2015(a),	Zakaria	
2006	
✔	 	 ✔	 	 ✔	 	
Bauer	1993,	Pascual	2001,	
Vajda	2004,	Vollmar	1994	
✔	 	 	 	 ✔	 ✔	
Bauer	1995,	Cabrales	
2007(b),	Maier	2004	
✔	 	 	 	 	 ✔	
Gulati	1998	 ✔	 	 	 ✔	 ✔	 	
Pascual	2002,	Yada-Langui	
2004	
✔	 	 	 	 ✔	 	
Bi	2004	 	 ✔	 ✔	 ✔	 	 ✔	
Cabrales	2004,	Cabrales	
2005(b),	Wettstein	2006	
	 ✔	 	 	 	 ✔	
Cheung	2001,	Ortiz	2014,	
Wettstein	2004(b)	
	 	 ✔	 ✔	 	 	
Cheung	2006,	Cheung	
2007,	Kerger	1997	
	 	 ✔	 ✔	 ✔	 ✔	
Cheung	2004,	Hungerer	
2006,	Nolte	1997,	Sakai	
2002,	Wettstein	2003	
	 	 ✔	 ✔	 	 ✔	
Casali	2002,	Kao	2010,	
Torres	2015(b)	
	 	 ✔	 	 ✔	 	
Cabrales	2007(c),	Sakai	
1999,	Scalia	1990	
	 	 ✔	 	 	 ✔	
Cabrales	2007(a),	Villela	
2009	
	 	 ✔	 	 	 	
Peruski	2014	 	 	 	 ✔	 	 	
Kumar	1997	 	 	 	 ✔	 ✔	 	
Botzlar	1996	 	 	 	 ✔	 ✔	 ✔	
Cabrales	2009,	Hermann	
2007,	Palmer	2011,	
Vazquez	2011,	Wettstein	
2004(a)	
	 	 	 ✔	 	 ✔	
Kao	2011,	Villela	2011	 	 	 	 	 ✔	 	
Corso	1999,	Cryer	2005,	
Gierer	2004,	Gonzalez	
2012,	Gonzales	2016,	
Guerci	2014,	Horstick	
2002,	Komori	2005,	
Mazzoni	1990,	Vollmar	
1996	
	 	 	 	 ✔	 ✔	
Cabrales	2005(a),	Cabrales	
2008(a),	Cabrales	2008(b),	
Maier	2009,	Messmer	2012	
	 	 	 	 	 ✔	
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7.3.7.	 Risk	of	bias	
The	majority	of	studies	fulfilled	SYRCLE	criteria	to	control	for	risk	of	bias	by	
specifically	reporting	a	random	allocation	sequence	generation	for	the	different	
interventions,	and	also	reporting	similar	baseline	characteristics	(illustrated	in	Table	7.6).	No	
studies	met	all	SYRCLE	criteria.	All	studies	were	at	risk	of	selection	bias	due	to	lack	of	
reporting	of	allocation	concealment,	and	performance	bias	due	to	lack	of	reporting	of	
blinding	of	caregivers/investigators.	All	studies	were	also	at	risk	of	detection	bias	due	to	lack	
of	reporting	of	random	outcome	assessment.			
	
7.3.8.	 Translatability		
Assessment	of	the	translatability	of	the	animal	model	to	clinical	relevance	found	
some	consistently	under-reported	details,	which	threaten	the	validity	of	the	studies	in	
humans	(illustrated	in	Table	7.7).	Most	of	the	studies	did	not	describe	a	power	calculation	in	
their	methodology,	did	not	have	blinded	outcome	assessment,	and	did	not	include	a	dose-
response	relationship.	Only	one	study	reported	a	rationale	for	the	age	of	the	animals43,	and	
none	reported	their	experimental	model	had	been	tested	with	different	transgenic	strains,	
different	species,	or	in	collaboration	with	different	research	groups	(for	the	same	
experiment).		
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Table	7.6.	Assessment	of	bias	based	on	the	SYRCLE’s	risk	of	bias	tool	for	animal	studies	
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Bauer	 1993	 	 *	 	 *	 	 	 2	
Bauer	 1995	 *	 *	 	 *	 	 	 3	
Bi	 2004	 *	 *	 	 	 *	 	 3	
Botzlar	 1996	 	 *	 	 	 	 	 1	
Cabrales	 2004	 *	 *	 	 	 	 	 2	
Cabrales	 2005	(a)	 *	 *	 	 	 	 	 2	
Cabrales	 2005	(b)	 *	 *	 	 	 	 	 2	
Cabrales	 2007	(a)	 *	 *	 	 	 *	 	 3	
Cabrales		 2007	(b)	 *	 *	 	 	 *	 	 3	
Cabrales		 2007	(c)	 *	 *	 	 	 *	 	 3	
Cabrales	 2008	(a)	 *	 *	 	 	 *	 	 3	
Cabrales	 2008	(b)	 *	 *	 	 	 *	 	 3	
Cabrales		 2009	 *	 *	 	 	 *	 	 3	
Casali	 2002	 	 	 	 	 	 	 0	
Cheung	 2001	 *	 *	 	 	 *	 	 3	
Cheung	 2004	 *	 *	 	 	 	 	 2	
Cheung	 2006	 *	 *	 	 	 	 	 2	
Cheung	 2007	 *	 *	 	 	 *	 	 3	
Corso	 1999	 	 *	 	 	 	 	 1	
Cryer		 2005	 	 *	 	 	 	 	 1	
Gierer	 2004	 	 *	 	 	 	 	 1	
Gonzalez	 2012	 *	 	 	 	 	 	 1	
Gonzalez	 2016	 *	 *	 	 *	 	 	 3	
Guerci	 2014	 *	 *	 	 	 *	 	 3	
Gulati	 1998	 	 *	 	 	 	 	 1	
Hermann	 2007	 *	 *	 	 	 	 	 2	
Horstick	 2002	 *	 *	 	 	 	 	 2	
Hungerer		 2006	 *	 *	 	 	 	 	 2	
Kao		 2010	 *	 *	 	 	 *	 	 3	
Kao	 2011	 *	 	 	 	 	 	 1	
Kerger		 1997	 	 *	 	 	 *	 	 2	
Komori	 2005	 	 *	 	 	 	 	 1	
Kozar	 2011	 	 *	 	 	 	 	 1	
Kubulus	 2009	 *	 *	 	 *	 	 	 2	
Kumar	 1997	 	 *	 	 	 	 	 1	
Maier		 2004	 *	 	 	 *	 	 	 2	
Maier		 2009	 *	 *	 	 *	 	 	 3	
Mazzoni	 1990	 *	 *	 	 	 *	 	 3	
Messmer		 2012	 *	 *	 	 	 *	 	 3	
Ni		 2013	 *	 	 	 	 	 	 1	
Nolte	 1997	 *	 *	 	 	 	 	 2	
Ortiz	 2014	 *	 *	 	 	 *	 	 3	
Paes-da-Silva	 2003	 *	 *	 	 	 	 	 2	
Palmer	 2011	 *	 *	 	 	 *	 	 3	
Pascual	 2001	 *	 *	 	 *	 	 	 3	
Pascual	 2002	 *	 *	 *	 *	 	 	 4	
Paxian	 2003	 	 *	 	 	 	 	 1	
Peruski	 2014	 *	 *	 	 *	 	 	 3	
Sakai	 1999	 	 *	 *	 	 *	 	 3	
Sakai	 2002	 	 *	 *	 	 	 	 2	
Scalia	 1990	 	 *	 	 	 	 	 1	
Torres	 2013	 *	 *	 	 	 	 	 2	
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Torres	 2014	 *	 *	 	 	 *	 	 3	
Torres	 2015	(a)	 	 *	 	 	 	 	 1	
Torres	 2015	(b)	 		 *	 		 		 		 		 1	
Vajda		 2004	 *	 *	 		 		 		 		 2	
Vazquez		 2011	 *	 *	 		 		 *	 		 3	
Villela	 2009	 *	 *	 		 		 *	 		 3	
Villela	 2011	 *	 *	 		 		 *	 		 3	
Vollmar	 1994	 *	 *	 		 *	 		 		 3	
Vollmar	 1996	 *	 *	 		 		 		 		 2	
von	Dobschuetz		 1999	 *	 *	 		 		 		 		 2	
Wettstein	 2003	 *	 *	 		 		 *	 		 3	
Wettstein		 2004	(a)	 		 *	 		 		 		 		 1	
Wettstein	 2004	(b)	 *	 *	 		 		 		 		 2	
Wettstein	 2006	 		 *	 		 		 *	 		 2	
Wu	 2015	(a)	 *	 *	 		 		 		 		 2	
Wu	 2015	(b)	 *	 *	 		 		 		 		 2	
Yada-Langui	 2004	 *	 		 		 		 		 		 1	
Zakaria		 2006	 *	 *	 		 		 		 		 2	
Zhao		 2009	 *	 *	 		 		 		 		 2	
Columns	for	allocation	concealment,	caregiver	blinding,	and	random	outcome	assessment	are	not	
included,	because	no	studies	fulfilled	these	criteria	
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Table	7.7.		Assessment	of	translatability	according	to	most	frequent	recommendation	for	
pre-clinical	research	
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Bauer	 1993	 	 	 *	 	 	 	 *	 *	 	 3	
Bauer	 1995	 	 *	 *	 	 *	 	 *	 *	 	 5	
Bi	 2004	 	 *	 	 *	 	 *	 *	 *	 	 5	
Botzlar	 1996	 	 	 	 	 *	 	 *	 *	 	 3	
Cabrales	 2004	 	 *	 	 	 *	 	 *	 *	 	 4	
Cabrales	 2005	(a)	 	 *	 	 	 	 	 *	 *	 	 3	
Cabrales	 2005	(b)	 	 *	 	 	 *	 	 *	 *	 	 4	
Cabrales	 2007	(a)	 	 *	 	 *	 	 	 *	 *	 	 4	
Cabrales		 2007	(b)	 	 *	 	 *	 *	 	 *	 *	 	 5	
Cabrales		 2007	(c)	 	 *	 	 *	 	 	 *	 *	 	 4	
Cabrales	 2008	(a)	 	 *	 	 *	 *	 	 *	 *	 	 5	
Cabrales	 2008	(b)	 	 *	 	 *	 	 	 *	 *	 	 4	
Cabrales		 2009	 	 *	 	 *	 	 	 *	 *	 	 4	
Casali	 2002	 	 	 	 	 	 	 	 *	 	 1	
Cheung	 2001	 	 *	 	 *	 *	 	 *	 *	 	 5	
Cheung	 2004	 	 *	 	 	 *	 	 *	 *	 	 4	
Cheung	 2006	 	 *	 	 *	 	 	 *	 *	 	 4	
Cheung	 2007	 	 *	 	 *	 	 	 *	 *	 	 4	
Corso	 1999	 	 	 	 *	 *	 	 *	 *	 	 4	
Cryer		 2005	 	 	 	 	 	 	 *	 *	 	 2	
Gierer	 2004	 	 	 	 	 *	 	 *	 *	 	 3	
Gonzalez	 2012	 	 *	 	 	 	 	 	 	 	 1	
Gonzalez	 2016	 	 *	 *	 	 	 	 *	 *	 *	 4	
Guerci	 2014	 	 *	 	 *	 	 	 *	 *	 	 4	
Gulati	 1998	 	 	 	 	 	 *	 *	 *	 	 3	
Hermann	 2007	 	 *	 	 	 	 *	 *	 *	 	 4	
Horstick	 2002	 	 *	 	 *	 	 	 *	 *	 	 4	
Hungerer		 2006	 	 *	 	 	 	 	 *	 *	 	 3	
Kao		 2010	 	 *	 	 *	 	 	 *	 *	 	 4	
Kao	 2011	 	 *	 	 	 	 	 	 	 	 1	
Kerger		 1997	 	 	 	 *	 	 	 *	 *	 	 3	
Komori	 2005	 	 	 	 	 *	 	 *	 *	 	 3	
Kozar	 2011	 	 	 	 	 *	 	 *	 *	 	 3	
Kubulus	 2009	 	 *	 	 	 *	 	 *	 *	 	 4	
Kumar	 1997	 	 	 	 	 *	 	 *	 *	 	 3	
Maier		 2004	 	 *	 *	 	 	 *	 	 *	 	 4	
Maier		 2009	 	 *	 *	 	 	 	 *	 *	 	 4	
Mazzoni	 1990	 *	 *	 	 *	 *	 	 *	 *	 	 6	
Messmer		 2012	 *	 *	 	 *	 	 	 *	 *	 	 5	
Ni		 2013	 	 *	 	 	 *	 	 	 *	 	 3	
Nolte	 1997	 	 *	 	 	 *	 	 *	 *	 	 4	
Ortiz	 2014	 	 *	 	 *	 	 *	 *	 *	 	 5	
Paes-da-Silva	 2003	 	 *	 	 	 *	 	 *	 *	 	 4	
Palmer	 2011	 	 *	 	 *	 	 	 *	 *	 	 4	
Pascual	 2001	 	 *	 *	 	 *	 	 *	 *	 	 5	
Pascual	 2002	 	 *	 *	 	 *	 	 *	 *	 	 5	
Paxian	 2003	 	 	 	 	 *	 *	 *	 *	 	 4	
Peruski	 2014	 	 *	 *	 	 	 	 *	 *	 	 4	
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Sakai	 1999	 	 	 	 *	 	 	 *	 *	 	 3	
Sakai	 2002	 	 	 	 	 	 *	 *	 *	 	 3	
Scalia	 1990	 	 	 	 	 *	 	 *	 *	 	 3	
Torres	 2013	 	 *	 	 	 *	 	 *	 *	 	 4	
Torres	 2014	 	 *	 	 *	 *	 	 *	 *	 	 5	
Torres	 2015	(a)	 	 	 	 	 *	 	 	 	 	 1	
Torres	 2015	(b)	 	 	 	 	 	 	 *	 	 	 1	
Vajda		 2004	 	 *	 	 	 *	 	 *	 *	 	 4	
Vazquez		 2011	 	 *	 	 *	 	 	 *	 *	 	 4	
Villela	 2009	 	 *	 	 *	 	 *	 *	 *	 	 5	
Villela	 2011	 	 *	 	 *	 	 	 *	 *	 	 4	
Vollmar	 1994	 	 *	 *	 	 *	 	 *	 *	 	 5	
Vollmar	 1996	 	 *	 	 	 	 	 	 *	 	 2	
von	Dobschuetz		 1999	 	 *	 	 	 *	 	 *	 *	 	 4	
Wettstein	 2003	 	 *	 	 *	 	 	 *	 *	 	 4	
Wettstein		 2004	(a)	 	 	 	 	 	 	 *	 *	 	 2	
Wettstein	 2004	(b)	 	 *	 	 	 	 	 *	 *	 	 2	
Wettstein	 2006	 	 	 	 *	 *	 	 *	 *	 	 4	
Wu	 2015	(a)	 	 *	 	 	 *	 	 *	 *	 	 4	
Wu	 2015	(b)	 *	 *	 	 	 *	 	 *	 *	 	 5	
Yada-Langui	 2004	 	 *	 	 	 *	 	 	 *	 	 3	
Zakaria		 2006	 	 *	 	 	 *	 	 *	 *	 	 4	
Zhao		 2009	 	 *	 	 	 *	 	 *	 *	 	 4	
	
	
	
	
	
7.3.9.	 Data	synthesis	
An	assessment	of	feasibility	of	meta-analysis	was	made,	but	was	considered	to	be	
unwarranted	due	to	high	heterogeneity	of	haemorrhage	protocol	(5	permutations),	
interventions	(29	permutations),	and	endpoints	(6	permutations)	between	studies.	In	
particular,	there	were	variations	in	study	hypotheses	and	research	questions	that	rendered	
meta-analytic	synthesis	impossible.	Descriptive	narrative	is	therefore	utilised	to	synthesise	
findings	across	similar	studies.	Studies	were	summarised	according	to	study	hypothesis	and	
research	question.	The	included	studies	could	be	broadly	divided	into	5	hypotheses	as	
summarised	in	Tables	7.8	–	7.12.	These	primarily	investigated	fluids	containing	
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haemoglobin,	physical	properties	(viscosity	and	oncotic/osmotic	potential),	and	the	
restorative	and	anti-inflammatory	properties	of	the	resuscitation	fluids.	Some	studies	
reported	data	related	to	more	than	one	of	these	hypotheses.	Of	these	studies,	55/71	
(77.5%)	reported	one	fluid	being	superior	to	another,	with	the	remainder	reporting	
equivalence	between	fluids	or	only	testing	one	fluid.		
	
7.3.10.	Fluids	containing	haemoglobin	
There	were	27	studies	that	considered	resuscitation	fluids	containing	haemoglobin	
for	the	restoration	of	microcirculatory	flow	dynamics	as	summarised	in	Table	7.8.	There	
were	21	studies	that	examined	HBOC	fluids,	including	10	studies	that	tested	HBOC	versus	
both	whole	blood	and	non-haemoglobin	(Hb)	carrying	fluids;	8	studies	that	tested	HBOC	
versus	non	Hb	carrying	fluids	alone;	and	3	studies	that	tested	HBOC	versus	whole	blood	
only.	HBOC	preparations	included	bovine	haemoglobin24,	25,	34,	78,	modified	human	
haemoglobin87,	mixed	human/bovine	haemoglobin65,	diaspirin	cross-linked	haemoglobin	
(DCLHb)	46,	56,	62,	83,	o-raffinose	cross-linked	oligomerized	haemoglobin52,	and	nitric	oxide-
scavenging	recombinant	haemoglobin47.	In	the	13	studies	in	which	HBOC	fluids	were	directly	
compared	to	whole	blood,	three	HBOCs	(bovine	haemoglobin	glutamer-25063,	modified	
human	haemoglobin87,	and	DCLHb62)	were	superior	to	whole	blood	in	the	restoration	of	
microcirculatory	flow	dynamics.	All	except	one71	of	the	remaining	studies	reported	that	
HBOC	fluids	were	equivalent	to	whole	blood	in	terms	of	flow	dynamics.	HBOC	fluids	were	
superior	to	non	Hb	carrying	fluids	in	13	studies,	and	equivalent	to	non	Hb	carrying	fluids	in	5	
studies.		
Some	of	the	studies	that	tested	HBOC	fluids	also	addressed	the	potential	unwanted	
side	effects	of	HBOCs	such	as	vasoconstriction,	nitric	oxide	(NO)	scavenging	and	
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leucocyte/endothelial	interactions.	They	reported	that	HBOCs	did	not	cause	
vasoconstriction25,	did	not	increase	leucocyte/endothelial	interactions25,	49,	62,	83,	and	do	not	
have	toxic	or	lethal	effects38	when	compared	to	other	non-HBOC	fluids.	Some	preparations	
of	Hb	are	superior	to	others65,	and	lower	Hb	concentrations	appeared	to	be	superior	to	
higher	concentrations	with	regards	to	vasoconstriction34,	63.	Furthermore	specific	
modification	of	HBOCs	to	reduce	NO	scavenging	has	been	reported	as	effective47.	
Conversely,	one	study	did	report	hepatotoxic	effects	of	HBOC55.		
There	were	6	studies	that	tested	fluids	containing	Hb	that	were	not	HBOCs.	These	
included	4	studies	testing	whole	blood	versus	crystalloid35,	51,	61	or	colloid70,	and	two	studies	
examining	preparations	of	PRBCs68,	79.	These	studies	reported	that	whole	blood	was	superior	
to	crystalloid	and	colloid.	When	PRBCs	were	tested,	one	oxygen	carrying	emulsion	
(perflubron	emulsion)	was	reported	as	being	superior	to	red	cells	with	respect	to	
microcirculatory	flow	dynamics68.	Another	study	reported	that	lower	oxygen	affinity	PRBCs	
were	superior	to	higher	oxygen	affinity79.		
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Table	7.8.	Summary	of	study	findings	regarding	haemoglobin-carrying	fluids	
Study	 Animal	 Method	 Test	fluid(s)	
Control	fluid(s)	
or	sham	 Endpoint(s)	 Main	finding	
A.		Haemoglobin	based	oxygen	carriers	
Bi		
2004	
Rat	 IVM	 PEG-Hb	(3	
different	
volumes)		
Whole	blood	(2	
different	
volumes)	and	
dextran	and	HC		
Velocity,	
flow,	
diameter			
HBOC	superior	to	non	
Hb	carrying	fluid,	and	
equivalent	to	whole	
blood	
Botzlar		
1996	
Hamster		 IVM	 U-PBHb	11g/dL	
and	13g/dL	
Dextran	and	LR	 Diameter,	
FCD	
HBOC	superior	to	non	
Hb	carrying	fluid	
Cabrales	
2009	
Hamster	 IVM	 PBH	13g/dL	and	
PBH	4g/dL	
Albumin	 Velocity,	
flow,	
diameter,	
FCD	
HBOC	superior	to	non	
Hb-carrying	fluid	
Cheung		
2001	
Canine	 IVM	 Bovine	Hb	
glutamer-200		
Whole	blood	 Velocity,	
diameter	
HBOC	equivalent	to	
whole	blood	
Cheung		
2004	
Canine	 IVM	 Oxyglob	 Whole	blood	
and	6%	
hetastarch	
Velocity,	
diameter	
HBOC	equivalent	to	non	
Hb-carrying	fluid	and	
whole	blood	
Cheung		
2006	
Canine	 IVM	 Oxyglobin		 Whole	blood	
and	NS	and	6%	
hetastarch		
Velocity,	
diameter	
HBOC	equivalent	to	non	
Hb-carrying	fluid	and	
whole	blood	
Cheung		
2007	
Canine	 IVM	 Oxyglobin		 Whole	blood	
and	NS	and	6%	
hetastarch		
Velocity,	
diameter	
HBOC	equivalent	to	non	
Hb-carrying	fluid	and	
whole	blood	
Gulati		
1998	
Rat		 LDF	 DCLHb	(3	
different	
concentrations)	
LR	 Velocity,	
perfusion	
HBOC	superior	to	non	
Hb	carrying	fluid	
Hermann	
2007	
Hamster	 IVM	 Recombinant	Hb	
wild	type	and	
recombinant	Hb	
nitric-oxide	
scavenging	
6%	dextran	 Velocity,	
diameter,	
FCD	
Nitric-oxide	scavenging	
HBOC	superior	to	HBOC	
or	non	Hb	carrying	fluid	
Hungerer	
2006	
Hamster	 IVM	 DCLHb				 Whole	blood	
and	dextran	
Velocity,	
FCD	
HBOC	equivalent	to	
whole	blood	and	non	
Hb	carrying	fluid	
Kerger		
1997	
Hamster		 IVM	 Cell-free	o-
raffinose	cross-
linked	
oligomerized	Hb	
Whole	blood	
and	LR	and	
dextran	
Velocity,	
flow,	
diameter,	
FCD	
HBOC	superior	to	non	
Hb-carrying	fluid	and	
equivalent	to	whole	
blood	
Kubulus		
2009	
Rat	 IVM	 Hb	glutamer-200	 Whole	blood		 Velocity,	
flow,	
diameter,	
PVD	
HBOC	equivalent	to	
whole	blood	
Kumar		
1997	
Rat		 LDF	 DCLHb	 LR	 Velocity,	
perfusion	
HBOC	superior	to	non	
Hb	carrying	fluid	
Nolte		
1997	
Hamster	 IVM	 DCLHb		 Whole	blood	
and	dextran	
Velocity,	
diameter,	
FCD	
HBOC	superior	to	whole	
blood	and	non	Hb	
carrying	fluid	
Ortiz		
2014	
Hamster	 IVM	 Bovine	Hb	
glutamer-250	at	
4,	8,	and	12	g/dL	
Whole	blood	 Velocity,	
flow,	FCD	
HBOC	superior	to	whole	
blood;	lower	Hb	
preparations	superior	
to	higher	
Palmer		
2011	
Hamster	 IVM	 Polymerised	
human	Hb	and	
polymerised	
bovine	Hb	
HSA	 Velocity,	
flow,	FCD	
HBOC	superior	to	non	
Hb	carrying	fluid;	
bovine	preparation	of	
Hb	superior	to	human	
Sakai		
2002	
Hamster		 IVM	 Vesicle-
encapsulated	Hb	
3g/dL	and	7g/dL	
Whole	blood	
and	HSA		
Velocity,	
flow,	
diameter,	
FCD	
HBOC	superior	to	non	
Hb	carrying	fluid	but	
inferior	to	whole	blood	
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Study	 Animal	 Method	 Test	fluid(s)	
Control	fluid(s)	
or	sham	 Endpoint(s)	 Main	finding	
Vazquez		
2011	
Hamster	 IVM	 Oxyglobin		 HES				 Diameter,	
FCD	
HBOC	superior	to	non	
Hb	carrying	fluid	
von	
Dobschuetz	
1999	
Rat	 IVM	 DCLHb		 Whole	blood	
and	HES		
FCD	 HBOC	superior	to	non	
Hb	carrying	fluids	and	
equivalent	to	whole	
blood	
Wettstein	
2003	
Hamster	 IVM	 PEG-Hb		 Whole	blood	
and	HES	
Velocity,	
flow,	
diameter,	
FCD	
HBOC	superior	to	whole	
blood	and	non	Hb	
carrying	fluid	
Wettstein	
2004(a)	
Hamster		 IVM	 PEG-Alb	 PEG-Hb	(from	
earlier	
experiment)	
Velocity,	
flow	rate,	
diameter,	
FCD	
HBOC	equivalent	to	non	
Hb	carrying	fluid	
B.		Red	cells	and	whole	blood	
Casali		
2002	
Rat		 IVM	 Whole	blood	 LR	 Velocity	 Whole	blood	superior	
to	crystalloid	
Kao		
2010	
Rat	 IVM	 Whole	blood	and	
whole	blood/EPO	
NS	and	NS/EPO	 Flow,	
perfusion	
Whole	blood	superior	
to	crystalloid	
Ni		
2013	
Rabbit	 SDF	 Whole	blood	and	
LR	and	whole	
blood/LR	
Sham	 TVD,	PVD,	
PPV,	MFI	
Blood	and	crystalloid	
combined	superior	to	
either	fluid	on	its	own	
Paxian		
2003	
Rat		 IVM	 PRBC	and	
perflubron	
emulsion/HES	
and	
PRBC/perflubron	
emulsion	
LR	and	HES	and	
whole	blood	
Diameter,	
velocity,	
flow	
O2	emulsion	superior	to	
whole	blood,	red	cells,	
or	non-oxygen	carrying	
fluid	
Sakai		
1999	
Hamster		 IVM	 Whole	blood	 HSA	 Velocity,	
flow,	
diameter,	
FCD	
Whole	blood	is	superior	
to	colloid	
Villela		
2009	
Hamster	 IVM	 High	O2-affinity	
PRBC	(50mmHg)	
Low	O2-affinity	
PRBC	(10mmHg)	
Velocity,	
flow,	
diameter,	
FCD	
Lower	O2	affinity	of	red	
cells	superior	to	higher	
Techniques:	IVM:	intravital	microscopy;	LDF:	laser	doppler	flowmetry;	SDF:	sidestream	dark	field	microscopy	
Endpoints:	PVD:	perfused	vessel	density;	TVD:	total	vessel	density;	PPV:	proportion	of	perfused	vessels;	MFI:	microvascular	
flow	index;	HI:	heterogeneity	index;	FCD:	functional	capillary	density;		
Fluids:	HBOC:	haemoglobin	based	oxygen	carrier;	PRBC:	packed	red	blood	cells;	LR:	Ringer's	lactate;	NS:	normal	saline;	HTS:	
hypertonic	saline;	HSA:	human	serum	albumin;	HC:	haemorrhage	control;	HES:	hydroxyl-ethyl	starch;	PBH:	polymerized	
bovine	haemoglobin;	PEG-Alb:	polyethylene	glycol-conjugated	albumin;	PEG-Hb:	polyethylene	glycol-conjugated	
haemoglobin;	UPBHb:	ultrapurified	polymerised	bovine	haemoglobin	solution;	DCLHb:	diaspirin	cross-linked	haemoglobin;	
Hb:	haemoglobin;	EPO:	erythropoietin	
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7.3.11.		Osmotic	and	oncotic	potential	
There	were	19	studies	that	tested	the	hypothesis	that	the	osmotic/oncotic	
properties	of	a	resuscitative	fluid	are	most	important	in	the	restoration	of	the	
microcirculation	following	haemorrhage,	of	which	14	studies	reported	findings	in	keeping	
with	this	hypothesis.	These	are	summarised	in	Table	7.9.	Hypertonic-hyperosmotic	solutions	
of	saline-dextran59,	saline-HES64,	77,	81,	and	HES42,	82	were	reported	as	superior	to	isotonic	
solutions.	One	study	reported	that	hypertonic	saline/dextran	fluid	improved	
microcirculatory	parameters	better	than	whole	blood72.	One	study	reported	that	hypertonic	
saline	resuscitation	was	superior	to	isotonic	fluid	but	only	if	whole	blood	was	also	returned	
to	the	animal91.	Increase	colloid	pressure	and	volume	expansion	was	reported	as	superior	
for	microcirculatory	restoration	when	comparing	colloid	to	crystalloid	solutions53,	88,	and	
when	using	modified	colloids29.	One	study	reported	that	the	duration	of	time	of	oncotic	
force	was	important	in	restoring	the	microcirculation28,	and	another	showed	that	
hypertonic	solutions	may	restore	microcirculatory	flow	for	longer	than	isotonic	solutions41.	
One	study	reported	that	hypertonic	fluid	is	superior	due	to	its	reduced	effects	on	red	blood	
cell	deformability	when	compared	to	isotonic	fluids92.	
Five	studies	did	not	report	superiority	of	higher	osmotic/oncotic	potential	fluids;	
these	included	reports	of	equivalence23	or	inferiority50.	Although	some	studies	reported	that	
the	microcirculatory	fluid	dynamics	were	unaffected	by	higher	oncotic/osmotic	properties	
when	compared	to	isotonic	fluids,	it	was	noted	that	the	permeability	of	micro-vessels66,	67	
and	haemoglobin	oxygen	saturation58	may	be	improved	with	such	solutions	nevertheless.		
Some	studies	reported	that	the	hypertonic-hyperosmotic	nature	of	the	resuscitative	
fluids	influenced	the	behaviour	of	leucocytes	to	a	greater	effect	than	isotonic	solutions	in	
their	actions	towards	improving	the	microcirculation66,	67,	81,	as	described	later.	
Chapter	7	 	 Fluids	to	restore	the	microcirculation	
	 186	
Table	7.9.	Summary	of	study	findings	regarding	osmotic/oncotic	pressure	
Study	 Animal	 Method	 Test	fluid(s)	
Control	
fluid(s)	or	
sham	
Endpoint(s)	 Main	finding	
Bauer		
1993	
Rat	 IVM	 7.2%	HTS/Dextran	
and	7.2%HTS/10%	
HES	
LR	and	Sham	 Velocity,	flow,	
diameter			
Hypertonic	and	isotonic	
fluids	are	equivalent	
Cabrales		
2005(b)	
Hamster	 IVM	 5%	PEG-Alb	 10%	HES	and	
HC	
Velocity,	flow,	
diameter,	FCD	
Length	of	time	of	oncotic	
pressure	is	important	
Cabrales		
2008(b)	
Hamster	 IVM	 4%	PEG-Alb	 5%	HSA	and	
10%	HSA	
Velocity,	flow,	
shear	stress,	
diameter,	FCD	
Increased	plasma	
expansion	superior	with	
conjugated	molecule	
Cryer		
2005	
Rat	 IVM	 7.2%	HTS/6%	
dextran	and	
NS/dextran	
NS	 Velocity,	flow,	
diameter			
Effects	of	
hypertonic/hyperosmotic	
fluid	last	longer	than	
isotonic	
Gierer		
2004	
Rat	 IVM	 10%	HES	and	7.2%	
HTS/6%	HES	
NS	 FCD	 Hypertonic/hyperosmotic	
fluid	is	superior		
Kao		
2011	
Rat	 IVM	 7.5%	HTS	and	7.5%	
HTS/EPO	
NS	and	
NS/EPO	and	
LR	and	LR/EPO	
PVD				 Hypertonic	crystalloid	
inferior	to	isotonic	
Komori		
2005	
Rabbit	 IVM	 HES	 LR	 Velocity,	flow,	
diameter			
Hypertonic/hyperosmotic	
fluid	is	superior		
Maier		
2009	
Porcine	 LDF	and	
SDF	
Gelatine	and	7.2%	
HTS/6%	HES	
6%	HES	 Flow,	capillary	
density,	MFI	
Hypertonic	and	isotonic	
fluids	equivalent		
Mazzoni		
1990	
Rabbit	 IVM	 HTS/dextran		 LR	 Diameter	 Hypertonic/hyperosmotic	
fluid	is	superior		
Paes-da-
Silva		
2003	
Rat	 IVM	
and	LDF	
7.5%	HTS	and	5%	
BSA	and	NS/HES	
and	HTS/HES	
Whole	blood	
and	NS	
Diameter,	flow	 Hypertonic/hyperosmotic	
fluid	is	superior		
Pascual		
2001	
Mouse	 IVM	 Pentastarch	and	LR	 Sham	 Diameter,	velocity,	
shear	rate	
Hypertonic	and	isotonic	
fluids	equivalent		
Pascual		
2002	
Mouse	 IVM		 7.5%	HTS	and	LR	 Sham	 Velocity,	shear	rate,	
shear	stress	
Hypertonic	and	isotonic	
fluids	equivalent		
Scalia		
1990	
Rat	 IVM	 HTS/dextran	and	
dextran	
Whole	blood	 Diameter	 Hypertonic	fluid	superior	
to	whole	blood	
Vajda		
2004	
Rat	 OPS	 HTS/HES	 NS	 Velocity,	flow,	FCD	 Hypertonic/hyperosmotic	
fluid	is	superior		
Vollmar		
1994	
Rat	 IVM	 10%	HES	and	7.2%	
HTS/10%	HES	
LR	and	Sham	 Velocity,	perfusion	 Hypertonic/hyperosmotic	
fluid	is	superior		
Vollmar		
1996	
Rat	 IVM	
and	LDF	
10%	HES	and	7.2%	
HTS/10%	HES	
LR	 Velocity,	diameter,	
flow,	FCD	
Hypertonic/hyperosmotic	
fluid	is	superior		
Wu		
2015(b)	
Rat	 LSCI	 NS	and	HTS	and	
gelatine	and	HES	
Sham	and	HC	 Flow	 Hypertonic/hyperosmotic	
fluid	is	superior		
Zakaria		
2006	
Rat	 IVM	 Whole	blood/NS	
and	whole	
blood/HTS	and	
HTS/NS	
Sham	 Diameter,	flow	 Hypertonic/hyperosmotic	
fluid	is	superior	when	
given	with	whole	blood	
Zhao		
2009	
Rat	 IVM	 NS	and	HTS	and	
HTS/dextran					
Sham	and	HC	 Shear	rate	 Hypertonic/hyperosmotic	
fluid	improves	RBC	
deformability	
Techniques:	IVM:	intravital	microscopy;	LDF:	laser	doppler	flowmetry;	LSCI:	laser	speckle	contrast	imaging;	SDF:	sidestream	dark	
field	microscopy;	OPS:	orthogonal	polarization	spectral	imaging	
Endpoints:	MFI:	microvascular	flow	index;	FCD:	functional	capillary	density;	PVD:	perfused	vessel	density	
Fluids:	LR:	Ringer's	lactate;	NS:	normal	saline;	HTS:	hypertonic	saline;	HSA:	human	serum	albumin;	HC:	haemorrhage-only	control;	
HES:	hydroxyl-ethyl	starch:	BSA:	bovine	serum	albumin;	EPO:	erythropoietin	
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7.3.12.		Viscosity	
There	were	12	studies	which	tested	the	hypothesis	that	increased	fluid	viscosity	was	
superior	to	normal	or	reduced	viscosity	in	the	restoration	of	microcirculatory	flow	following	
haemorrhage,	as	summarised	in	Table	7.10.	Ten	of	these	studies	had	findings	in	keeping	
with	this	hypothesis.	Higher	viscosity	preparations	of	hydroxylethyl	starch	(HES)	are	
reported	as	superior	to	lower	viscosity	HES26,	33,	85.	Higher	viscosity	preparations	of	Ringers	
Lactate	(by	addition	of	0.3%	alginate)	were	superior	to	conventional	Ringers	Lactate	in	
restoring	the	microcirculation80.	Solutions	with	increased	molecular	weight	(with	higher	
viscosity)	were	show	to	be	superior	to	lower	molecular	weight	(and	therefore	lower	
viscosity)	solutions;	for	example,	using	higher	density	polymerised	human	serum	albumin	
(HSA)60	or	higher	molecular	weight	HES32.		
The	viscosity—rather	than	the	oxygen	carrying	capacity—has	been	reported	as	the	
factor	of	importance	even	when	using	oxygen-carrying	solutions27,	31.	Furthermore	increase	
in	viscosity	was	reported	as	more	important	than	the	increase	in	oncotic	pressure30.	High	
viscosity	preparations	of	pegylated	bovine	albumin	were	superior	than	the	same	
preparations	combined	with	red	blood	cells,	demonstrating	that	transfusion	haemoglobin	
triggers	might	be	lowered	if	higher	viscosity	fluids	are	used86.		
Two	studies	did	not	find	that	higher	viscosity	was	superior	to	lower;	one	of	these	
compared	higher	and	lower	viscosity	HBOCs69	and	another	higher	versus	lower	viscosity	
non-oxygen	carrying	fluids45.		
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Table	7.10.	Summary	of	study	findings	regarding	viscosity	
Study	 Animal	 Method	 Test	fluid(s)	 Control	fluid(s)	or	sham	 Endpoint(s)	 Main	finding	
Cabrales		
2004	
Hamster	 IVM	 0.7%	and	0.8%	LVM	
alginate		
5%	HES	and	HC	 Velocity,	flow,	
shear	stress,	
diameter,	FCD	
Higher	viscosity	superior	
to	lower	
Cabrales		
2005(a)	
Hamster	 IVM	 10%	HES/0.3%	
alginate	and	10%	
HES/0.6%	alginate	
10%	HES	 Velocity,	flow,	
diameter,	FCD	
Higher	viscosity	superior	
to	lower		
Cabrales		
2007(a)	
Hamster	 IVM	 OxyRBC	and	MetRBC	 Fresh	plasma	 Velocity,	flow,	
shear	stress,	
diameter,	FCD	
Higher	viscosity	superior	
to	lower,	independent	of	
O2	carrying	capacity	
Cabrales		
2007(b)	
Hamster	 IVM	 High-MW	HES	 Low-MW	HES	
and	Sham	
Velocity,	flow,	FCD	 Higher	viscosity	superior	
to	lower			
Cabrales		
2007(c)	
Hamster	 IVM	 OxyRBC	and	MetRBC	 10%	HES	 Velocity,	flow,	
shear	stress,	
diameter,	FCD	
Higher	viscosity	superior	
to	lower,	independent	of	
O2	carrying	capacity	
Cabrales		
2008(a)	
Hamster	 IVM	 6%	hetastarch	/0.4%	
alginate	
6%	hetastarch	
and	HC	
Velocity,	flow,	
shear	stress,	FCD	
Higher	viscosity	superior	
to	lower		
Guerci		
2014	
Porcine	 LDF	 HES/7%	HTS	 LR	 Perfusion	 No	difference	between	
viscosities	
Messmer		
2012		
Hamster	 IVM	 High	MW	
Polymerised	HSA	(3	
different	
concentrations)	
HSA	 Velocity,	flow,	
shear	stress,	
diameter,	FCD	
Higher	viscosity	superior	
to	lower		
Peruski		
2014	
Canine	 SDF	 HBOC-alginate	
(hyperviscous)	
Standard	HBOC	 PVD,	TVD,	MFI,	PPV	 Higher	viscosity	
equivalent	to	lower		
Villela		
2011	
Hamster	 IVM	 LR-alginate		 LR	 Velocity,	flow,	
diameter,	FCD	
Higher	viscosity	superior	
to	lower		
Wettstein		
2004(b)	
Hamster	 IVM	 PEG-BSA/PRBC	at	4	
and	8	g/dL	
PEG-BSA	 Velocity,	flow,	
diameter,	FCD	
Higher	viscosity	superior	
to	lower	and	more	
important	than	oxygen	
carrying	capacity	
Wettstein		
2006	
Hamster	 IVM	 5%	HES	and	10%	HES	
and	20%	HES	
HC					 Velocity,	flow,	FCD	 Higher	viscosity	superior	
to	lower		
	Techniques:	IVM:	intravital	microscopy;	LDF:	laser	doppler	flowmetry;	SDF:	sidestream	dark	field	microscopy	
Endpoints:	PVD:	perfused	vessel	density;	TVD:	total	vessel	density;	PPV:	proportion	of	perfused	vessels;	MFI:	microvascular	flow	
index;	HI:	heterogeneity	index;	FCD:	functional	capillary	density		
Fluids:	HBOC:	haemoglobin	based	oxygen	carrier;	PRBC:	packed	red	blood	cells;	LR:	Ringer's	lactate;	HSA:	human	serum	albumin;	
HTS:	hypertonic	saline;	MW:	molecular	weight;	HC:	haemorrhage-only	control;	HES:	hydroxyl-ethyl	starch;	OxyRBC:	oxygen-
carrying	red	blood	cells;	MetRBC:	methemoglobin	red	blood	cells;	PEG-BSA:	pegylated	bovine	albumin;	LVM:	low	viscosity	high-
mannuronic	acid	
7.3.13.		Attenuation	of	inflammation	
There	were	9	studies	that	considered	the	anti-inflammatory	properties	of	
resuscitation	fluids,	as	summarised	in	Table	7.11.	Using	albumin	as	a	resuscitative	fluid	has	
been	reported	to	both	improve	the	microcirculatory	parameters	as	well	as	reducing	the	
inflammatory	response48.	A	number	of	studies	have	proposed	that	small	volume	
resuscitation	with	hypertonic-hyperosmotic	solutions	may	affect	the	flow	behaviour	of	
leucocytes	and	reduce	their	stagnation40,	margination22,	rolling67	and	adhesion	to	the	
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endothelium81,	as	well	as	attenuating	the	number	of	endothelium-leukocyte	interactions23,	
66,	90.	Reduction	of	leucocyte	adhesion	has	also	been	reported	when	using	gelatin	serum	
protein	solutions	as	a	resuscitative	fluid57.		
	
	
Table	7.11.	Summary	of	study	findings	regarding	attenuation	of	inflammation	
	
7.3.14.		Restorative	properties	
There	were	5	recent	studies	from	the	USA	that	tested	the	hypothesis	that	
endothelial	glycocalyx	is	shed	following	haemorrhagic	shock,	and	may	be	restored	by	
components	of	plasma	(but	not	crystalloid),	restoring	the	microcirculatory	dysfunction.	All	
Study	 Animal	 Method	 Test	fluid(s)	
Control	
fluid(s)	or	
sham	
Endpoint(s)	 Main	finding	
Bauer		
1993	
Rat	 IVM	 7.2%	HTS-Dextran	
and	7.2%	
HTS/10%	HES	
LR	and	Sham	 Velocity,	flow,	
diameter	
Modified	fluid	can	reduce	
leucocyte	adhesion	and	
restore	microcirculatory	flow	
Bauer		
1995	
Rat	 IVM	 HES-
desferoxamine	
conjugate	
HES	and	
Sham	
Velocity,	flow	 Modified	fluid	to	scavenge	free	
radicals	can	reduce	leucocyte	
adhesion	and	restore	
microcirculatory	flow	
Corso		
1999	
Rat	 IVM	and	
LDF	
6%	dextran	and	
7.2%	HTS/10%	
dextran	
LR	 Velocity,	flow,	
shear	stress	
Hypertonic	fluid	no	difference	
in	flow	but	attenuates	
leukocyte	adhesion		
Horstick		
2002	
Rat	 IVM	 20%	albumin	 NS	 Velocity,	
shear	rate	
Albumin	has	anti-inflammatory	
properties		
Maier		
2004	
Rat	 IVM	 Gelatin	and	
5%HSA	and	SPS	
Sham	 Diameter,	
velocity,	flow	
Serum	protein	solution	can	
reduce	inflammation	
Pascual		
2001	
Mouse		 IVM	 Pentastarch	and	
LR	
Sham	 Diameter,	
velocity,	shear	
rate	
Hypertonic	fluid	attenuates	
leukocyte	adhesion		
Pascual		
2002	
Mouse	 IVM		 7.5%	HTS	and	LR	 Sham	 Velocity,	
shear	rate,	
shear	stress	
Hypertonic	fluid	attenuates	
leukocyte	adhesion		
Vollmar		
1994	
Rat	 IVM	 10%	HES	and	7.2%	
HTS/10%	HES	
LR	and	Sham	 velocity,	
perfusion	
Hypertonic	fluid	attenuates	
leukocyte	adhesion		
Yada-Langui	
2004	
Rat	 IVM	 HTS	 LR	 Velocity,	
shear	rate	
Hypertonic	fluid	attenuates	
leukocyte	adhesion		
Techniques:	IVM:	intravital	microscopy;	LDF:	laser	doppler	flowmetry;		
Fluids:	LR:	Ringer's	lactate;	NS:	normal	saline;	HTS:	hypertonic	saline;	HES:	hydroxyl-ethyl	starch;	SPS:	serum	protein	solution;	HSA:	
human	serum	albumin	
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studies	reported	that	their	results	were	in	keeping	with	that	hypothesis	as	summarised	in	
Table	7.12	54,	73-76.	
	
	
Table	7.12.	Summary	of	study	findings	regarding	restorative	properties	of	the	fluid	
	
	
	
7.3.15.	Notable	exclusions	
Some	studies	were	ineligible	for	inclusion	due	to	lack	of	comparator.	This	was	either	
due	to	the	same	fluid	being	given	in	different	volumes94	or	no	control95.	Some	study	
protocols	varied	the	amount	of	haemorrhage	rather	than	resuscitation	fluid96,	97.		
Isovolaemic	exchange	transfusion98-100,	haemodilution101,	and	ischaemia-reperfusion102-105	
protocols	were	excluded.	Small	volume	acute	blood	loss	without	haemorrhagic	shock106,	107	
were	also	excluded.	
	 There	were	multiple	studies	that	used	drug	delivery	as	interventions	(rather	than	
purely	comparing	different	fluids),	including	additives108-111,	noradrenaline112,	polydatin113,	
nitric	oxide114	and	naloxone115.	
Study	 Animal	 Method	 Test	fluid(s)	 Control	fluid(s)	or	sham	 Endpoint(s)	 Main	finding	
Kozar		
2011	
Rat	 Electron	
microscopy	
Fresh	plasma	 LR	and	Sham	and	
HC	
Glycocalyx	
thickness	
Plasma	can	restore	
the	endothelial	
glycocalyx		
Torres		
2013	
Rat	 IVM	 FFP	 LR	and	HES	and	
HC	and	sham	
Velocity,	diameter	 Plasma	can	restore	
the	endothelial	
glycocalyx		
Torres		
2014	
Rat	 IVM		 1:1	PRBC/LR	and	
1:1	washed	
PRBC/LR	and	
whole	blood	
LR	and	Sham	 Glycocalyx	
thickness,	flow	
Constituents	of	
plasma	can	restore	
the	endothelial	
glycocalyx		
Torres		
2015(a)	
Rat	 IVM	 FFP	 NS	and	3%	HTS	
and	Sham	
Glycocalyx	
thickness	
Plasma	can	restore	
the	endothelial	
glycocalyx		
Torres		
2015(b)	
Rat	 IVM	 FFP	 NS	 Glycocalyx	
thickness,	flow	
Plasma	can	restore	
the	endothelial	
glycocalyx	and	flow	
Techniques:	IVM:	intravital	microscopy	
Fluids:	PRBC:	packed	red	blood	cells;	LR:	Ringer's	lactate;	NS:	normal	saline;	HTS:	hypertonic	saline;	HC:	haemorrhage-only	control;	
HES:	hydroxyl-ethyl	starch;	FFP:	fresh	frozen	plasma	
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Although	of	interest	in	the	basic	science	of	endothelial	behaviour,	in	vitro	studies116	
and	those	that	measured	endothelial	relaxation117,	118	and	activity119	were	excluded.	
Similarly,	conformational	changes	in	red	blood	cells	(such	as	deformability	and	fragility99,	
106),	and	the	modulation	of	the	inflammatory	components	of	haemorrhagic	shock120	and	
leucocyte	behaviour48,	81	were	ineligible	for	inclusion.		
Studies	that	only	reported	perfusion	endpoints	(such	as	delivery	of	oxygen)	rather	
than	any	microcirculatory	flow	dynamics	were	also	excluded17,	18.			
	
7.4.	 Discussion	
According	to	the	pre-clinical	available	evidence,	the	most	favourable	properties	of	
resuscitative	fluids	for	the	restoration	of	the	microcirculatory	flow	dynamics	are:	(i)	the	
presence	of	a	haemoglobin	preparation	(HBOC	being	mostly	equivalent	to	whole	blood);	(ii)	
higher	viscosity;	(iii)	higher	oncotic/osmotic	potential,	and	(iv)	having	the	physical	and	
constituent	properties	that	enable	attenuation	of	endothelial-leucocyte	interactions,	
reduced	inflammation	and	endothelial	permeability.	The	evidence	for	these	properties	
comes	from	71	published	pre-clinical	studies	that	have	each	tested	the	basic	scientific	
questions	regarding	physical	properties	of	resuscitation	fluids,	as	well	as	the	influence	of	
their	constituents.	Since	none	have	tested	all	of	these	properties	in	a	single	experiment,	it	is	
only	by	summation	and	consideration	of	all	available	evidence	that	translatable	research	
questions	might	be	considered	for	the	clinical	context.		
After	catastrophic	haemorrhage	whole	blood	is	not	usually	readily	available,	and	
fractionated	parts	of	blood	such	as	PRBCs,	FFP,	and	platelets	are	precious	resources.	
Furthermore,	the	most	appropriate	ratios	of	these	fractions	is	a	matter	of	controversy121.	
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Availability	is	also	not	the	only	limitation,	since	whole	blood	or	components	may	not	be	the	
ideal	fluids	to	deliver	following	haemorrhagic	shock;	some	of	these	pre-clinical	studies	have	
demonstrated	superiority	of	other	fluid	strategies	to	delivery	of	whole	blood.	Regardless	of	
the	type	of	fluid	delivered	in	the	emergency	scenario,	the	priority	is	to	restore	tissue	
perfusion	by	enabling	the	transport	of	oxygen	at	the	microcirculatory	surface.	This	goal	
requires	consideration	of	which	characteristics	of	the	resuscitative	fluid	are	most	important	
for	that	task.	Not	only	should	the	fluid	restore	the	microcirculatory	flow	dynamics,	but	may	
also	contribute	to	the	mitigation	and	repair	of	endothelial	injury	that	has	occurred	following	
haemorrhage.	Restoration	of	the	endothelium	and	endothelial	glycocalyx	and	prevention	of	
leucocyte-endothelial	interactions	may	be	key	for	longer-term	outcomes,	but	such	a	
question	has	not	been	answered	in	animal	models.	All	of	the	individual	fluid	characteristics	
reported	here	provide	a	sound	basis	for	further	clinical	research.		
The	design	of	an	‘ideal’	fluid	for	resuscitation	after	haemorrhagic	shock	appears	to	
depend	on	several	factors	of	importance.	The	careful	balance	of	osmotic	potential	and	
viscosity	in	resuscitative	fluids	appears	to	allow	the	fluid	to	inhibit	endothelial	cell	swelling,	
minimise	shear	stress,	and	keep	the	individual	microcirculatory	segments	open	long	enough	
to	allow	the	exchange	of	oxygen	between	the	circulation	and	the	end	tissues.	Some	studies	
in	this	review	have	reported	that	Hb	preparations	and	red	cells	improve	the	microcirculatory	
function	by	their	osmotic	and	viscous	effect	on	microcirculatory	flow	dynamics	rather	than	
their	oxygen	carrying	capacity.	Reduction	in	cell	swelling	and	maladaptive	endothelial-
leucocyte	interactions	might	lead	to	reduction	in	shunting	of	flow	and	subsequent	systemic	
inflammatory	response.	The	fluid	itself	has	potential	to	deposit	glycoproteins	and	essential	
components	of	the	endothelial	glycocalyx	that	may	enable	the	microcirculation	to	improve	
its	function.	Although	HBOCs	are	thought	to	interfere	with	the	endothelium	derived	relaxing	
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factor	and	NO	system	and	increase	vasoconstriction,	unwanted	oxidative	reactions,	and	
endothelial-leucocyte	interactions,	the	studies	included	in	this	review	appear	to	report	that	
appropriate	modification	of	HBOCs	can	reduce	such	unwanted	effects.		
As	well	as	the	usual	limitations	in	translatability	that	arise	when	attempting	to	apply	
results	of	animal	studies	to	the	clinical	context,	the	studies	included	in	this	review	were	all	
at	risk	of	threats	to	their	validity	according	to	the	most	widely	common	recommendations	
for	animal	studies21.	The	majority	of	studies	were	undertaken	with	rodent	models	rather	
than	large	animals,	which	may	provide	further	issues	for	translatability;	testing	the	same	
research	question	from	a	rodent	study	in	a	large	animal	study	may	result	in	a	different	
answer122.	Furthermore,	all	studies	had	a	potential	risk	of	bias	according	to	the	SYRCLE	tool;	
indeed,	the	majority	of	studies	were	only	assessed	as	positive	in	3	or	fewer	domains	(out	of	
a	possible	10).	In	particular,	the	general	lack	of	blinding	of	investigators	and	outcome	
assessments	mandate	a	cautious	approach	to	their	interpretation.	It	is	not	known	whether	
these	studies	failed	to	fulfil	all	domains	of	the	assessment	tools	due	to	methodological	
deficiencies	or	whether	they	simply	did	not	report	the	relevant	details.	If	further	animal	
studies	are	to	be	conducted	in	this	field,	we	would	recommend	that	the	experimental	
protocols	and	reporting	technique	are	designed	according	to	the	SYRCLE	tool	domains	of	
importance.	This	tool	is	based	on	the	Cochrane	Collaboration’s	Risk	tool	for	assessing	bias	in	
randomised	controlled	trials,	and	should	therefore	be	the	gold	standard	for	animal	studies	
that	hope	to	establish	clinically	sound	hypotheses123.	It	is	also	important	to	note	that	a	
limited	number	of	studies	used	sublingual	video-microscopy,	which	is	the	most	appropriate	
technique	for	human	translatability,	as	discussed	in	previous	chapters.		
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7.4.1.	 Limitations	
Meta-analytical	tests	could	not	be	undertaken	for	the	studies	included	in	this	review	
since	there	were	too	many	permutations	of	animal	model,	intervention,	and	outcome	
measure	to	provide	consistent	grouping	of	studies.	Such	a	feasibility	assessment	was	pre-
defined	in	the	original	review	protocol.	Statistical	heterogeneity	could	not	be	assessed	and	
funnel	plots	could	not	be	used	to	assess	publication	bias.	This	is	a	notable	limitation	since	
significant	results	are	more	likely	to	be	published124,	and	it	is	likely	that	unpublished	and	
unavailable	studies	have	not	been	included	in	the	current	systematic	review.	Nevertheless,	
this	systematic	review	summarises	the	available	published	literature	with	regards	to	
haemorrhagic	shock	resuscitation	in	pre-clinical	models,	and	provides	a	basis	on	which	to	
test	hypotheses	in	the	clinical	context.		
	 There	are	some	clinically	relevant	omissions	in	the	pre-clinical	literature	with	regards	
to	haemorrhagic	shock	resuscitation	and	the	microcirculation.	For	example,	there	were	no	
studies	that	tested	platelets	as	a	resuscitation	fluid.	When	plasma	was	delivered	and	shown	
to	be	superior,	the	exact	constituent	components	of	benefit	have	not	been	identified.	There	
were	also	no	clinically	relevant	long-term	outcomes	analysed.	The	experimental	protocols	
were	not	intended	to	assess	clinically	relevant	outcomes	such	as	24-hour	or	survival	to	
discharge,	organ	failure,	or	complications	of	treatment.	Such	questions	could	only	be	
reliably	tested	in	the	clinical	context.		
	
7.5.	 Conclusion	
Based	on	the	available	pre-clinical	evidence,	the	ideal	resuscitation	fluid	for	
restoration	of	microcirculatory	flow	following	haemorrhagic	shock	is	likely	to	contain	a	
preparation	of	haemoglobin,	favour	higher	oncotic/osmotic	potential	and	viscosity,	protect	
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and	reconstitute	the	endothelium,	and	attenuate	inflammation.	The	latter	two	of	these	are	
in	keeping	with	the	findings	in	Part	1	of	this	thesis,	where	endotheliopathy	was	reported	as	
a	significant	pathological	element	in	the	early	phase	following	trauma.	The	hypotheses	here	
are	derived	from	an	extensive	series	of	pre-clinical	studies	that	have	tested	the	basic	
biological	questions	regarding	the	physical	properties	of	a	wide	range	of	fluids.	Because	of	
the	potential	risk	of	translatability,	further	evaluation	in	clinical	studies	are	warranted	in	
order	to	determine	the	‘ideal’	resuscitative	fluid	to	restore	the	microcirculation	in	humans.	
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8.1.			Summary	of	findings	
In	Part	1	of	this	thesis	I	have	presented	some	novel	findings	based	on	5	hypotheses	
(Table	1.1),	regarding	the	endothelium	and	microcirculation	in	the	context	of	trauma	and	
haemorrhagic	shock.	The	first	of	these	findings	is	that	there	is	an	association	between	the	
endotheliopathy	of	trauma	and	poor	microcirculatory	flow	following	haemorrhagic	trauma,	
which	is	most	prominent	in	the	first	hours	after	injury1.	Secondly,	endotheliopathy	occurs	
just	minutes	after	trauma,	and	is	associated	with	multiple	organ	dysfunction	syndrome2.	
Thirdly,	these	pathological	processes	are	associated	with	the	presence	of	cell-free	DNA	
within	the	circulation,	which	may	play	a	role	in	the	mechanisms	of	microcirculatory	
impairment	following	trauma	and	haemorrhagic	shock3.	Taken	together,	these	findings	may	
partly	contribute	to	the	growing	narrative	of	the	early	pathological	response	to	trauma,	
particularly	in	the	first	minutes	and	hours	after	injury	(Figure	8.1).						
	
Figure	8.1.	Schematic	diagram	of	the	mechanistic	findings	in	Part	1	
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In	Part	2	of	this	thesis,	I	have	presented	some	data	regarding	the	clinical	context	in	
which	the	microcirculatory	derangements	described	in	Part	1	might	be	important,	by	
addressing	a	further	3	broad	hypotheses	(Table	1.1).	I	have	presented	that	microcirculatory	
flow	can	be	assessed	safely	soon	after	arrival	in	the	Emergency	Department4,	and	that	the	
flow	and	heterogeneity	might	be	quantified	at	the	point-of-care5.	It	might	therefore	be	
proposed	that	microcirculatory	monitoring	be	performed	earlier,	and	be	integrated	into	the	
clinical	management	pathway	if	justified	by	further	investigation	(Figure	8.2).		
	
	
Figure	8.2.	Schematic	diagram	of	(a)	the	traditional	approach	to	microcirculatory	
monitoring,	and	(b)	what	might	be	proposed	based	on	the	findings	within	this	thesis.		
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In	anticipation	that	microcirculatory	monitoring	may	one	day	be	used	within	the	
realm	of	clinical	practice,	I	have	further	presented	a	synthesis	all	of	the	available	pre-clinical	
literature	regarding	fluids	and	restoration	of	microcirculatory	flow6,7.	From	these	pre-clinical	
studies,	it	appears	that	the	optimal	fluid	for	this	aim	would	contain	a	preparation	of	
haemoglobin,	favour	higher	oncotic	potential,	higher	viscosity,	and	mitigate	the	
inflammation	and	endotheliopathy	of	trauma.	Further	clinical	investigations	are	required	in	
order	to	determine	whether	the	hypotheses	generated	from	these	pre-clinical	studies	can	
be	supported	in	clinical	practice,	and	may	be	guided	by	the	findings	presented.			
	
8.2.	 Avenues	for	future	research	
	
	 In	the	process	of	investigating	the	hypotheses	within	this	thesis,	several	more	have	
been	generated	that	require	further	clinical	studies	in	order	to	address.	Some	research	
questions	warrant	further	discussion,	and	will	be	briefly	summarised	here.		
	
8.2.1	 Does	endotheliopathy	of	trauma	cause	microcirculatory	dysfunction,	or	vice	versa?	
	 In	Chapters	2	–	4,	we	were	able	to	see	associations	between	cfDNA,	
endotheliopathy,	and	microcirculatory	flow	disruption1-3.	Unfortunately,	within	the	
limitations	of	observational	clinical	studies,	the	precise	causality	could	not	be	demonstrated.	
A	linear	narrative	from	point	of	injury	that	includes	a	timeline	of	these	phenomena	cannot	
be	proven	with	the	current	data,	since	there	was	no	definitive	evidence	of	cause-and-effect.	
Indeed,	it	is	likely	that	a	continuous	timeline	from	one	phenomenon	to	another	is	an	over-
simplification,	since	cfDNA,	endotheliopathy,	and	microcirculatory	failure	are	just	a	few	
elements	in	a	far	greater	and	interconnected	network	of	pathological	processes,	that	
includes	coagulopathy8,	inflammatory	dysfunction,	genomic	activation,	and	subsequent	
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organ	failure9,10.	From	the	data	presented,	a	hypothesis	might	be	proposed	that	injury	leads	
to	the	release	of	cfDNA	as	one	type	of	damage-associated	molecular	pattern	(DAMP),	which	
exacerbates	endotheliopathy,	leading	to	microcirculatory	flow	disruption.	Together,	these	
processes	may	each	make	the	others	worse,	and	may	increase	the	likelihood	of	
coagulopathy8,	inflammatory	dysfunction,	and	increase	the	risk	of	subsequent	organ	failure	
and	death	(Figure	8.3).	The	finding	that	the	microcirculatory	flow	dynamics	mostly	improve	
over	time	for	all	patients,	even	when	biomarkers	of	endotheliopathy	may	remain	elevated	
(Chapter	2)1	remains	unexplained.	It	may	suggest	that	current	ICU	resuscitation	techniques	
are	aimed	at	the	restoration	of	flow	and	perfusion,	but	not	endotheliopathy—which	may	be	
responsible	for	poorer	outcomes,	even	when	flow	is	restored.	Whether	ICU	treatment	
directed	at	both	restoration	of	the	endothelium	and	perfusion	and	flow	would	improve	
patient	outcomes	is	unknown.				
	
	
Figure	8.3.	Schematic	illustration	of	a	hypothesis	for	the	sequence	of	events	after	trauma.		
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	 It	is	also	important	to	note	that	any	proposed	sequence	of	events	would	not	exist	in	
isolation,	but	must	be	taken	in	the	context	of	the	many	other	elements	within	the	
physiological	response	to	trauma.	Finding	the	answers	to	questions	regarding	timescales	
may	be	important	when	planning	treatments	that	might	address	each	pathological	factor.	
The	discovery	that	endotheliopathy	occurs	within	minutes	of	injury	may	have	implications	
for	pre-hospital	resuscitative	care,	with	a	potential	new	therapeutic	target:	the	preservation	
and	reconstitution	of	the	endothelial	glycocalyx.	This	may	be	particularly	important	in	the	
context	that	coagulopathy	of	trauma	may	also	be	a	pre-hospital	phenomenon11.			
	
8.2.2		 Why	are	early	pathological	processes	associated	with	organ	failure	days	later?	
	 In	Chapter	3,	the	failure	to	restore	the	endothelium	within	the	first	hours	of	injury	
was	associated	with	organ	failure	some	days	later2.	In	Chapter	4,	raised	cfDNA	was	
associated	with	poorer	clinical	outcomes	days	later3.	The	full	narrative	that	connects	these	
early	phenomena	with	later	clinical	outcomes	is	not	fully	understood.	It	may	be	the	case	
that	these	early	insults	to	the	physiology	may	have	lasting	effects	on	organs,	and	that	failure	
to	“restore”	homeostasis	may	increase	the	likelihood	of	this	occurrence.	This	hypothesis	
would	be	supported	by	data	shown	in	Chapter	3,	where	patients	who	developed	MODS	
were	less	likely	to	have	restoration	of	the	endothelium	than	those	who	did	not2.	A	return	to	
normal	levels	of	endothelial	biomarkers	on	arrival	in	hospital	was	associated	with	lower	
levels	of	organ	failure.	The	exact	physiological,	biochemical,	and	anatomical	effects	of	early	
endotheliopathy	and	microcirculatory	dysfunction	require	further	investigation.	A	better	
understanding	of	homeostatic	mechanisms	would	allow	insights	into	the	pathophysiology	
and	the	potential	therapeutic	opportunities.	
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8.2.3	 Would	point-of-care	tests	for	cfDNA	or	endotheliopathy	be	useful	in	clinical	
practice?		
	 We	have	seen	in	Chapters	2	–	4	that	both	cfDNA	and	endothelial	biomarkers	might	
be	used	to	predict	clinical	outcomes.	Such	data	may	have	the	potential	to	guide	decisions	
such	as	early	triage,	or	requirement	for	surgery	or	intensive	care.	For	example,	could	the	
presence	of	endotheliopathy	or	raised	cfDNA	be	combined	with	other	physiological	
parameters	in	order	to	improve	the	sensitivity	and	specificity	of	pre-hospital	triage	systems,	
or	the	requirement	for	massive	transfusion?	Point-of-care	lactate	devices	have	already	been	
used	within	the	pre-hospital	environment12,	and	in-hospital	lactate	values	from	arterial	
blood	gas	are	commonplace	during	trauma	care,	but	there	are	no	point-of-care	tests	for	
endotheliopathy	in	clinical	practice.	A	rapid	technique	for	cfDNA	quantification	has	been	
described13,	but	this	has	not	yet	entered	clinical	practice.	A	recent	systematic	review	
reported	a	low	level	of	accuracy	for	current	pre-hospital	triage	systems14.	Could	the	addition	
of	further	biochemical	data	within	the	pre-hospital	period	improve	these	systems?		As	well	
as	for	triage	and	prognosis,	it	is	possible	that	they	may	also	have	some	potential	in	guiding	
treatment.	For	example,	would	early	detection	of	endotheliopathy	in	the	pre-hospital	
environment	favour	a	plasma-first	resuscitation	strategy,	in	order	to	restore	the	endothelial	
glycocalyx?	Such	a	question	would	require	prospective	investigation.					
	
8.2.4.		 Could	cfDNA	levels	be	used	as	a	biomarker	of	injury	severity?	
	 There	have	been	some	criticisms	of	the	utility	and	accuracy	of	the	Injury	Severity	
Score	(ISS),	and	several	variations	have	been	proposed15,16.	Furthermore,	anatomical	injury	
severity	scoring	systems	are	vulnerable	to	inter-user	variability17.	These	scoring	systems	
attempt	to	quantify	the	injury	burden	by	adding	together	scores	from	individual	anatomical	
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areas.	Rather	than	calculating	arbitrary	scores	on	an	ordinal	scale,	it	is	possible	that	the	
concentration	of	cfDNA	within	the	circulation	could	be	a	biomarker	of	injury	burden.	
Although	this	has	not	been	thoroughly	investigated,	it	is	an	appealing	hypothesis,	because	it	
may	offer	an	objective,	continuous	variable	that	quantifies	the	full	burden	of	visible	and	
hidden	tissue	injury.	The	exact	quantities	of	tissue	or	cellular	sources	of	cfDNA	would	need	
to	be	determined.	Further	large-scale	investigations	are	required	to	compare	cfDNA	levels	
to	other	forms	of	injury	severity	scoring	systems,	as	well	as	with	clinical	outcomes.		
	
8.2.5.	 Can	bedside	microcirculatory	monitoring	be	used	for	goal-directed	therapy	for	
shocked	patients?	
	 Handheld	video-microscopy	or	the	detection	of	microcirculatory	flow	disruption	has	
been	used	for	research	purposes	for	decades,	but	has	not	yet	entered	mainstream	clinical	
practice.	Two	of	the	factors	preventing	clinical	use	are	(a)	the	lengthy	and	offline	computer	
analysis;	and	(b)	doubts	about	the	feasibility	of	using	this	technology	at	the	point-of-care,	
for	critically	unwell	patients.	These	two	concerns	have	partly	been	addressed	within	
Chapters	5	and	64,5.	I	have	demonstrated	that	the	technique	can	be	used	safely	within	the	
ED,	even	for	patients	with	haemorrhagic	shock,	and	that	it	is	still	possible	to	capture	high	
quality	videos	for	these	patients.	Whether	access	to	these	extra	data	at	the	bedside	might	
affect	clinical	practice	or	guide	resuscitation	is	unknown,	since	no	interventional	trial	has	
been	conducted.	Although	clinicians	might	be	able	to	grade	the	microcirculation	as	
accurately	as	offline	analysis	(Chapter	6),	this	may	not	be	as	accurate	as	traditional	offline	
analysis,	especially	when	it	comes	to	density	parameters.	This	technique	has	also	not	yet	
been	tested	in	real-time	at	the	patient	bedside,	and	its	clinical	utility	is	unknown.	The	next	
step	would	be	to	design	a	study	that	utilised	the	findings	in	both	Chapters	5	and	6,	so	that	
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clinicians	might	assess	the	microcirculation	at	the	bedside	for	critically	unwell	patients.	At	
time	of	writing,	I	am	an	investigator	in	an	ethically	approved	study	that	has	been	designed	
to	do	exactly	this	(Real	time	clinical	validation	of	the	Point-of-Care	Microcirculation	tool	at	
the	bedside;	REC	reference	17/SC/0274).	Furthermore,	a	prospective	randomised	controlled	
trial	with	bedside	handheld	video-microscopy	compared	to	normal	care	might	test	the	
utility	of	these	extra	data	for	goal-directed	therapy.		
	
8.2.6.	 Which	therapeutic	strategies	are	superior	for	the	restoration	of	the	
microcirculation?		
	 Although	some	hypotheses	were	generated	for	this	question	in	Chapter	7	using	a	
systematic	review	of	all	pre-clinical	literature6,	the	answer	for	humans	is	unknown.	There	is	
uncertainty	regarding	the	optimal	ratios	of	blood	products	that	might	be	ideal	following	
trauma	and	haemorrhage18,	and	whether	there	is	a	place	for	crystalloid	or	colloid	fluids	in	
trauma	care.	More	recently,	whole	blood	transfusion	has	been	reported	to	be	associated	
with	greater	survival	than	fractionated	components19.	Furthermore,	there	is	some	pre-
clinical	evidence	of	a	wide	range	of	non-fluid	therapies	that	might	restore	the	
microcirculation,	such	as	sulodexide20,	tranexamic	acid21,	and polyethylene	oxide22.	If	
randomised	controlled	trials	are	undertaken	in	the	future	to	compare	resuscitation	
strategies	(such	as	component	therapy	versus	whole	blood	for	damage	control	
resuscitation),	data	regarding	microcirculatory	flow	would	be	of	value,	especially	if	those	
data	were	to	be	associated	with	clinical	outcomes.		
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